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ABSTRACT 
The endocannabinoid system is a complex homeostatic signaling system controlled 
through the actions of two G-protein coupled receptors, cannabinoid receptor 1 (CB1) and 
cannabinoid receptor 2 (CB2). Significant neuronal expression and distribution of CB1 throughout 
the brain establishes its function as a major synaptic signaling receptor, and in regards to the 
actions of Cannabis sativa, it is the primary mediator of the psychotropic effects of marijuana. 
Conversely, CB2 expression is confined to microglial cells in the brain and predominantly 
peripheral immune cells. The expression of CB2 provides a pharmacological basis for the well-
documented immunomodulatory effects of cannabis, providing a potential therapeutic target for 
the treatment of diseases involving immune function. Through careful isolation and 
characterization, the active constituents of cannabis were eventually revealed as a unique class of 
natural products, the cannabinoids, the most prolific of which is (-)-Δ9-tetrahydrocannabinol. 
This aim of this dissertation research is to utilize a natural product cannabinoid as a starting 
point in the development of synthetic cannabinoid receptor ligands. The discovery of the THC 
analog (-)-Δ9-10a-α-hydroxytetrahydrocannabinol (10a-OH THC) provided a molecular 
framework from which a benzofuran scaffold was hypothesized to provide opportunities to include 
most of the pharmacophoric elements of 10a-OH THC. Target molecules were designed to 
maximally explore the chemical space of this new scaffold to elucidate a structure activity 
relationship, culminating in the discovery of an analog with 78.4 nM affinity and over 100-fold 
selectivity for the CB2 receptor. The synthetic analogs described herein serve as lead molecules 
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for further synthesis and optimization of cannabinoid receptor activity, potentially contributing 
interesting new drug leads for CB2 receptor targeting therapeutics. 
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CHAPTER 1   
INTRODUCTION: DISCOVERY, PHARMACOLOGY AND MEDICINAL 
CHEMISTRY OF CANNABINOIDS    
1.1 History of Cannabis Sativa 
Cannabis sativa has one of the longest histories of plants used for medicinal and 
recreational uses by humans. Cannabis, commonly known as marijuana, has been used throughout 
human history to treat a wide variety of ailments, with some of the earliest known references dating 
back to 2600 BC in ancient Chinese texts prescribing its use for relieving pain and cramping. While 
the medicinal and psychoactive properties of cannabis were well known for thousands of years, it 
was not until the late nineteenth century that cannabis fell under scientific scrutiny to understand 
the underlying mechanisms of these actions. The first scientific report in the Western world on the 
medicinal use of cannabis came from an Irish physician, Sir William B. O’Shaughnessy, who noted 
in 1843 that hemp “possesses, in small doses, an extraordinary power of stimulating the digestive 
organs, exciting the cerebral system, of acting also on the generative apparatus.”1 This report also 
noted the ability of hemp oil to alleviate pain, both rheumatic and otherwise in origin, and perhaps 
most remarkably noted the effects of hemp oil in reducing seizures in infants, a use now being 
heavily explored for medical marijuana and therapeutic use of cannabinoids. 
 With the rise of natural products research and the isolation of alkaloids like morphine and 
cocaine, from the opium poppy and coca plant, respectively, cannabis was thought to possess 
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similar chemical constituents. Much of the early research conducted on cannabis and hemp oil 
centered on the search for alkaloids and other amine natural products, and attempts to develop 
colorimetric tests for cannabinoids.2 The search for psychoactive compounds in cannabis, 
however, lead not to a mixture of alkaloids, but the discovery of new terpenes. Most isolation 
experiments followed a similar procedure for nearly one hundred years; hemp oil would be 
extracted with organic solvents, filtered, followed by removal of the solvent and fractional 
distillation of the resulting residue.3 This residue, referred to as “red oil,” possessed biological 
activity similar to that of the plant material, and when further fractionally distilled would yield an 
active fraction at 180–190 ºC (1 mm), called “purified red oil.” It was this purified red oil that was 
used in most chemical studies from the 1840s until the 1940s, when the adoption of 
chromatographic methods became more prevalent. The first secondary metabolite of cannabis 
isolated was cannabinol, in 1896 from purified red oil derived from hemp by Wood, Spivey, and 
Easterfield.4 Their work was unable to be repeated until 1933 when Robert Cahn reported a partial 
structure of cannabinol; the structure was fully elucidated by two groups in 1940 (Figure 1.1).5–7  
 
Figure 1.1. Structures of cannabinol, Δ9-THC, and cannabidiol 
 
It was initially thought that cannabinol was the active constituent of cannabis, but these 
early reports, likely obtained using impure cannabinol extracts, were proved erroneous in the 
1930s.3,8 From 1940 until the 1960s, several other non-cannabinoid natural products in cannabis 
were isolated, as well as cannabidiol (CBD).9 The active component of cannabis was finally 
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discovered in 1964 by Raphael Mechoulam and Yehiel Gaoni, with the report of the structure and 
partial synthesis of (–)-9-tetrahydrocannabinol (THC).10 The discovery of new compounds in 
cannabis has continued, with over 100 phytocannabinoids reported to date.    
 
1.2 Phytocannabinoids    
Phytocannabinoids are found throughout all major morphologies of cannabis. 
Cannabinoids are mixed polyketides derived from malonyl-CoA, hexanoyl-CoA units prenylated 
with geranyl phosphate.11–13 This biosynthetic pathway, shown in Figure 1.2 with the synthesis of 
CBD, THC, and CBN, produces several classes of phytocannabinoids. 
 
Figure 1.2. Phytocannabinoid biosynthesis 
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Of the 100+ phytocannabinoids isolated and characterized, THC and CBD, depicted in 
Figure 1.1, have received the most attention in both basic science and clinical research. THC is 
marketed as dronabinol (Marinol®), and is currently approved for the treatment of anorexia in 
AIDS patients and chemotherapy induced nausea and vomiting (CINV).14 CBD has not been 
approved by the US FDA, but clinical trials are underway exploring the use of CBD, branded as 
Epidiolex®, in the treatment of epilepsy and Dravet Syndrome, a severe seizure disorder in 
children.15,16 Despite the long-standing traditional medicinal uses of cannabis, and the culmination 
of scientific evidence leading to FDA approval of THC, the mechanism of action of cannabinoids 
in humans remained a conundrum until recently. The cannabinoid (CB) receptors remained elusive 
for 30 years after the discovery of THC. Both CBD and THC exert their therapeutic effects through 
the CB receptors, in addition to GPR55, 5-HT3A ligand-gated ion channel, TRPA1 cation channel 
and TRPV2 cation channel.17–20 The pharmacology of CBD, is not entirely understood with respect 
to the treatment of seizures; CBD has been shown to block both CB receptors, activate several 
transient receptor potential (TRP) cation channels, and activate the 5-HT1A receptor.
18,19,21    
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1.2.1 Cannabinoid (CB) Receptors and the Endocannabinoid System    
The G-protein coupled receptor (GPCR) superfamily of genes encodes for 800 GPCRs. This 
superfamily of genes is further divided into five major families: Glutamate, Rhodopsin, Adhesion, 
Frizzled/Taste2, and Secretin.22 The largest of these is the Rhodopsin family, containing 672 
GPCR genes, approximately 300 of which encode known GPCRs, with the remainder classified 
as orphan receptors whose structure, endogenous ligand(s) and function remain unknown.23–25 
GPCRs are characterized by having a transmembrane domain unit with seven alpha-helices 
(Figure 1.3), coupled to a “G-protein” consisting of three subunit proteins: Gα, β, and γ. Upon 
binding of an agonist ligand to the transmembrane domain, the G-protein subunits catalyze 
downstream functions by coupling to another cellular protein (e.g. adenylyl cyclase, protein 
kinases, etc).26 Because of their significant role in human cellular functions, drugs targeting 
GPCRs make up 30–40% of all drugs on the market.27 
 
Figure 1.3. Structural schematic of CB receptors. This research was originally published in The 
Journal of Biological Chemistry. David Shire, et al. Structural Features of the Central Cannabinoid 
CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A. Journal of 
Biological Chemistry. 1996; 271:6941–6946. © the American Society for Biochemistry and 
Molecular Biology. 28   
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The CB receptors are members of the Rhodopsin-like family of GPCRs. The first evidence 
of a CB receptor surfaced in 1984 with Howlett et al. demonstrating that select cannabinoids 
decreased cyclic adenosine monophosphate (cAMP) conecentrations in neuroblastoma cells.29,30 
Further work in 1986 showed that cannabinoids induce a decrease in cAMP production, and this 
effect was eliminated by exposing cells to pertussis toxin, a known Gαi (commonly referred to 
simply as the Gi protein) protein inhibitor, which strongly suggested the presence of a cannabinoid 
binding GPCR.31 In 1988 the same group characterized a CB specific receptor in rat brain, and in 
1990 the CB1 receptor was finally cloned from a cDNA library from rat cerebral cortex tissue.32 
The same year that CB1 was discovered, tissue distribution studies showed that CB1 was one of 
the most abundantly expressed receptors in the brain, nearly equivalent to the expression of 
glutamate and GABA receptors.33,34 The correlation between CB1 localization in the brain and the 
known pharmacological effects of cannabinoid agonists was made immediately clear; CB1 
expression in the basal ganglia and cerebellum associated with the effects on gait, and expression 
in the cerebral cortex and hippocampus with the effects on cognition and memory. More recent 
studies have found CB1 expression in the spleen and tonsils, gastrointestinal tract, uterus, prostate, 
vascular smooth muscle cells, and adrenal glands.35 
 
While the CB1 receptor was commonly referred to as the “cannabinoid receptor” this 
receptor did not account for the well-documented immunomodulatory effects of cannabis. The 
search for an explanation led to the discovery of the CB2 receptor in a human promyelocytic 
leukemia cell line in 1993.34,36 The human CB1 and CB2 receptors share 48% sequence identity 
and is also coupled to Gi protein; neither CB1 or CB2 have been crystallized to date.37 The 
pharmacology of the CB2 receptor has a long, complicated history since its discovery, with 
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numerous contradicting reports and flawed methodologies, leading some to call CB2 ‘a receptor 
with an identity crisis.’38 The CB2 receptor, unlike CB1, is not highly expressed in the CNS. For 
several years after its discovery CB2 was known as the peripheral cannabinoid receptor, owing to 
its high expression levels in the spleen and immune cells and relative absence from the brain.39 
This was proven incorrect, however, with CB2 protein expression in microglial cells in the brain 
and reports of CB2 expression in neurons. CB2 expression in the brain correlates with 
neuroinflammation, with one study in 2005 showing a 200-fold upregulation of CB2 receptors in 
microglial cells in an in-vitro autoimmune encephalomyelitis model.40  
These and many other results, however, have been called into question, as anti-CB2 
antibodies used in these immunohistochemical methods have been demonstrated to have non-
specific binding with other proteins.41,42 The immunomodulatory role of CB2 has remained 
unchallenged, and CB2 has been heavily implicated in neurodegenerative diseases such as 
Huntington’s and Alzheimer’s diseases.43,44 Increased expression of CB2 in the brain was 
confirmed with CB2-selective Positron Emission Tomography (PET) tracers in Alzheimer’s mice 
models; this increased expression was concomitant with the formation of amyloid-beta plaques, 
suggesting a potential utility for CB2 PET tracers as diagnostic for the onset of neuroinflammation. 
Activation of either CB1 and CB2 produces a dose-dependent decrease in cellular cAMP 
levels, and modulation of intracellular Ca2+ and K+ levels.45 Stimulation of CB receptors results in 
activation of the p42/44 mitogen-activated protein kinases (MAPK), otherwise known as the 
extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), respectively.46 Signal 
transduction studies have linked this CB1/2 mediation of ERK1/2 to downstream regulation of 
genes controlling cytokine synthesis, transcription regulation and cell differentiation (Figure 
1.4).47,48 
8 
 
Figure 1.4. Neuronal cannabinoid signaling. Activation of a cannabinoid receptor with an 
agonist causes several downstream effects: inhibition of adenylcyclase and inwardly rectifying 
calcium channels, and activation of potassium channels as well as the mitogen activated protein 
kinase pathway. Activation of MAPK modulates gene expression, depending on downstream 
signaling, cell types, etc. Gene expression can also be modulate as a downstream effect of adenylyl 
cyclase inhibition through the activation of protein kinase A. MAPK = mitogen activated protein 
kinases, AC = adenylyl cyclase, cAMP = cyclic adenosine monophosphate, PKA = protein kinase 
A. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery, 
copyright 200449     
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1.2.2 Endocannabinoid System 
While the discovery (and the naming) of the CB receptors was driven by a desire to 
understand the pharmacological effects of cannabis, both receptors are involved in extensive 
signaling pathways known as the endocannabinoid system. The presence of cannabinoid GPCRs 
suggested the existence of endogenous ligands, and as most phytocannabinoids are highly 
lipophilic, it was assumed that these ligands would likely be lipids. 
 
Figure 1.5. Structures and CB receptor affinities of major endocannabinoids. 
 
 The identification of anandamide (AEA) by the Mechoulam group in 1992 confirmed its 
role as an endogenous ligand for the cannabinoid receptors, with a Ki of 61.0 nM at CB1 and 1930 
nM at CB2.50,51 AEA produces similar effects to that of the exogenous phytocannabinoids, with 
administration to rodents of AEA inducing hypothermia, analgesia, catalepsy, and appetite 
stimulation.52,53 Furthermore, its tissue distribution is highly similar to that of CB1: the highest 
levels of AEA are found in the hippocampus and cerebellum, and to a lesser degree in the spleen 
and heart tissue.54 Although AEA was the first endogenous cannabinoid ligand discovered, its 
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importance in the endocannabinoid system has been diminished by the discovery of additional 
ligands, namely 2-arachidonoylglycerol (2-AG), with Ki values of 472 ± 55 nM at CB1 and 1400 
±172 nM for CB2, O-arachidonoyl ethanolamine, with Ki values of 1900 nM at CB1 and 1400 nM 
at CB2, and 2-arachidonoyl glyceral ether with Ki values of 21.2 nM at CB1 and 480 nM at CB2 
(Figure 1.5).55-58 Although initially considered an insignificant component of the endocannabinoid 
system, the role of 2-AG has evolved to that of one of the more important signaling molecules in 
the brain. 2-AG has been linked to the modulation of feeding, hypotension, neuroprotection and 
cell proliferation, and other interesting physiological processes.59-62  
 
Figure 1.6. Synaptic endocannabinoid signaling. Dashed arrows indicate inactivation of 
endocannabinoid. AA, arachidonic acid; DAGs, diacylglycerols; ER, endoplasmic reticulum; 
MAPK, mitogen-activated protein kinases; PIP2, phosphoinositide bisphosphate; PKA, protein 
kinase A; PLCβ, phospholipase Cβ; PPARs, peroxisome proliferator-activated receptors; TRPs, 
transient receptor potential channels; VGCCs, voltage-gated calcium channels. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, copyright 2014.43 
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 Endocannabinoid signaling typically occurs in retrograde fashion: from post- to pre-
synaptic neurons (Figure 1.6). Due to the highly hydrophobic nature of endocannabinoids like 2-
AG, it was initially thought that endocannabinoids were synthesized in the same cell in which 
receptor binding occurs. This was supported by the observation that endocannabinoids could 
approach a receptor by moving laterally through the cell membrane, through post-synaptic non-
retrograde signaling.63 However, the identification of AEA in interstitial fluid and cell incubation 
media suggested additionally that AEA, and likely other endocannabinoids, can travel across a 
synapse by either passive diffusion or active transport mechanisms, although a specific mechanism 
has yet to be resolved.64,65  
In retrograde signaling endocannabinoids cause a variety of downstream effects. 
Presynaptic CB1 activation causes two major neurotransmitter inhibition mechanisms: short-term 
and long-term plasticity.66 In short-term plasticity, elevation of the intracellular Ca2+ levels by 
postsynaptic depolarization stimulates the production of 2-AG, which diffuses across the neuronal 
synapse to CB1 receptors on the presynaptic neuron.67-69 Activation of CB1 causes inhibition of 
Ca2+ influx via voltage-gated Ca2+ channels and subsequent downregulation of neurotransmitter 
release. Long-term plasticity, while initiating in a similar fashion, involves the suppression of 
neurotransmitter release via the downregulation of cAMP production and protein kinase A 
inhibition. 
Once released, endocannabinoids are rapidly deactivated by two enzymes: fatty acid amide 
hydrolase 1 (FAAH) and monoacylglycerol lipase (MAGL).43 The distribution of these enzymes 
provides some evidence as to the signaling mechanisms carried out by the endocannabinoid 
system, as FAAH is located post-synaptically and MAGL pre-synaptically.  
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 The role the CB2 receptor in the endocannabinoid system is less well defined than CB1. 
The involvement of CB2 in the endocannabinoid signaling system has been relegated to that of an 
immunomodulatory mediator. Like CB1, CB2 also decreases the production of cAMP, although 
to a lesser degree, and unlike CB1 it has not been found to be coupled to G proteins other than Gi, 
somewhat limiting its inhibitory effect on Ca2+ and K+ channels.37 Also unique to the activation of 
CB2 receptors is an initial decrease in cAMP production, followed by a sustained increase up to 
10-fold in T-cell cAMP levels, which can lead to suppression of T-cell signaling manifesting 
phenotypically as an immunosuppressant effect.70 Immunohistochemical and mRNA analysis 
show CB2 localization to occur primarily in microglial cells in the brain, and neutrophils, 
macrophages, monocytes and lymphocytes peripherally, with significantly increased expression 
under inflammatory conditions.40,71,72 Increased endocannabinoid production in immune cells has 
been linked to pro-inflammatory stimuli and hematopoietic stem cell differentiation.73,74    
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1.3 Synthetic Classical Cannabinoids 
 
 
Figure 1.7. SAR of Classical Cannabinoids (left) Major pharmacophores of classical 
cannabinoids, and common regions of functionalization and analog synthesis; (right) 
Dibenzopyran numbering of Δ9-THC. 
 
Since the initial discovery of THC and other related cannabinoids, numerous modifications 
and analogs were synthesized in an attempt to define the structure activity relationship (SAR) of 
THC at both CB1 and CB2. 9-THC contains five major structural features, depicted in Figure 
1.7: the C3 side chain, phenolic hydroxyl, and three rings: the aromatic A ring, pyran ring B, and 
cyclohexenyl ring C. While not present in any natural cannabinoids, some important synthetic 
analogs replace the pyran ring B with a substituted aliphatic chain, and as such the “southern 
aliphatic region” is included as a major structure feature of classical cannabinoids.  
Many of the earliest SAR studies on classical cannabinoids involved modifications to the 
C3 side chain. While most analogs contain saturated straight or branched alkyl chains, a number 
of C3 side chains incorporating unsaturated alkyl chains, heteroatoms and functional groups such 
as esters, carboxylic acids, ethers, nitriles, and heterocycles were reported, with varying effects on 
CB1 and CB2 potency and selectivity.     
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1.3.1 C3 Alkyl Derivatives 
 The length of the C3 side chain of THC directly correlates to CB1 and CB2 binding affinity; 
an increase in chain length leads to an increase in binding affinity at both receptors (Figure 1.8). 
CB binding affinity data for methyl or ethyl substituted THC analogs has not been published, 
however a study conducted in 2011 examined the functional activity of these THC analogs 
demonstrating receptor affinity decreasing in a linear fashion with decreasing chain length.75 
Interestingly, this study found an inverse relationship between chain length and TRPA1 channel 
activity; a one carbon chain was found to be a potent TRPA1 agonist, this effect decreasing with 
additional carbons on the chain. This may be a contributing factor to the biological significance of 
cannabinoids like propyl substituted Δ9-tetrahydrocannabiviran, which does not activate either CB 
receptor yet retains numerous biological effects. 
 
Figure 1.8. Relationship between alkyl chain length and CB receptor binding affinity 
 
 Utilizing the C3 alkyl chain as a point of diversification in classical cannabinoids has 
remained a staple of cannabinoid research since the discovery of Δ9-THC. Numerous analogs 
containing a variety of carbon chains and rings with and without heteroatom incorporation, 
provided a well-defined and predictable SAR profile for this portion of the THC scaffold.  
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
1.  
 
9-THC 
9-
THC 
40.7±1.7 36±10 
Partial 
Agonist 
76,77 
2.  
 
-THC 
-
THC 
44±12 44±17  78 
3.  
 
9-THC      
4.  
 
9-THC      
5.  
 
9-THC 
9-
THCV 
75.4 62.8 Mixed 79 
6.  
 
-THC 
JWH-
130 
65±13   80 
7.  
 
-THC 
JWH-
124 
41±3.8   80 
8.  
 
-THC 
JWH-
091 
22±3.9   80 
9.  
 
-THC 
JWH-
138 
8.5±1.4   80 
10.  
 
-THC  20±4   81 
11.  
 
-THC  7.6±0.6   81 
12.  
 
-THC  11±1   81 
13.  
 
-THC  19±5   81 
14.  
 
-THC  53±1   81 
15.  
 
-THC 
JWH-
359 
38±3   81 
16.  
 
-THC  141±52   81 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
17.  
 
-THC  0.51±0.02   82 
18.  
 
-THC  2.0±0.3   82 
19.  
 
-THC  1.4±0.2   82 
20.  
 
-THC  2.0±0.8   82 
21.  
 
-THC  9.5±2.9   82 
22.  
 
-THC  1.3±0.2   82 
23.  
 
-THC  18±2   82 
24.  
 
-THC  32±5   82 
25.  
 
-THC  75±9   82 
26.  
 
-THC  38±5   82 
27.  
 
-THC  19±1   82 
28.  
 
-THC  0.46±0.04   83 
29.  
 
-THC  0.81±0.08   83 
30.  
 
-THC  0.84±0.21   83 
31.  
 
-THC  0.60±0.15   83 
        
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
32.  
 
-THC  14±1.8   84 
33.  
 
-THC  14±0.9   84 
34.  
 
-THC  10.9±1.7   84 
35.  
 
-THC
JWH-
133 
3.9±0.9   84 
36.  
 
-THC  2.7±1.2   84 
37.  
 
-THC  0.83 0.49  84 
38.  
 
-THC  0.09±0.1   84 
39.  
 
-THC  1.6±0.4   84 
40.  
 
-THC  6.1±1.8   84 
41.  
 
-THC  25.8±5.8   84 
42.  
 
-THC  126±18   84 
43.  
 
-THC O-964 0.65±.012 3.1±0.13 Agonist 85 
44.   -THC
O-1317 0.86±0.09  Agonist 80 
45.  
 
-THC O-584 4.9±2.0  
Partial 
Agonist 
80,86 
46.   -THC
O-1020 9.0±1.3  Agonist 80 
47.  
 
-THC O-1052 19±1.3  Agonist 80 
48.  
 
-THC O-1004 367±23   80 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
 
 
      
49.  
 
-THC  703±98   87 
50.  
 
-THC  402.4 161.5  88 
51.  
 
-THC AM855 22.3 58.6  88 
52.  
 
-THC  542.1 455.6  88 
53.  
 
-THC  126.0±22   89 
Table 1.1. C3 alkyl analogs of Δ8 and Δ9 THC 
 
 Of the major pharmacophores defined for classical cannabinoid SAR, the C-3 side chain 
seems to have the largest influence on binding affinity for the CB receptors. Table 1.1 illustrates 
a homolog series of 8 and 9-THC analogs with various saturated aliphatic substitutions. Entries 
1 and 2, 9-THC and Δ8-THC respectively, are nearly equipotent at both CB receptors, displaying 
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partial-agonist functional activity. As such, Δ9 and Δ8-THC are interchangeable in most SAR 
studies. Examining various alkyl chain lengths (entries 2-9), there is a definite requirement for at 
least 3 carbons, with 5 to 8 carbon length chains being optimal. 79,80 Binding affinity at CB1 
receptors is further enhanced by the addition of methyl groups on the alkyl chain, preferably at the 
1’ and 2’ positions. A systematic study of methylated Δ8-THC analogs (entries 10-16) revealed 1’ 
and 2’ substitutions to be optimal, with a slight decrease in affinity in 3’- methyl analogs 14-15 
and a sharp decrease in 4’-methyl analog 16, with little difference in affinity observed between the 
R and S isomers.81 Given the near doubling of receptor affinity by the 7-carbon chain analog 8, a 
similar study of compounds with a 7-carbon alkyl chain, entries 17-27, showed a similar trend, 
although less pronounced than the 5-carbon chain analogs.82 Again, there were minimal 
differences between R and S isomers, with binding affinity optimal at the 1’ and 2’ positions in 17-
20, slowly decreasing as the methyl substitutions is moved down the alkyl chain (entries 21-27). 
Expanding on this trend, 1’,2’-dimethylheptyl analogs 28-31 possessed sub-nanomolar binding 
affinity, with essentially no difference in activity observed between the four diastereromers.83 A 
series of 1’,1’-dimethylalkyl analogs (entries 32-42) with chains lengths of 2-12 carbons displayed 
a similar trend to that of the unsubstituted homolog series (entries 2-9), with optimal binding 
affinity for CB1 achieved between 5-9 carbons.84 The 1’,1’-dimethyl substitution clearly has a 
significant effect on the affinity however, as none of the entries in this series with, with the 
exception of the 12-carbon chain analog 42, had binding affinities greater than 100 nM. The 1’,1’-
dimethylalkyl substituted analogs have typically been preferred over the 1’,2’-dimethylakyl 
congeners, since the latter possesses two stereogenic centers which add unnecessary complexity 
in synthesis with the potential for formation of diastereomeric mixtures.  
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 Introducing unsaturation on the alkyl chain does not significantly modulate CB1 receptor 
binding, with activity retained between homologs of the same chain length [e.g., compare the 
unsaturated 8-carbon analogs 45 – 47 (ki = 4.9±2.0 nM, 9.0±1.3± nM and 19±1.3) to the saturated 
8-carbon analog 9 (ki = 8.5±1.4 nM)].
80 Similar to the unsaturated series, chain length has a 
significant influence on affinity, with the terminal acetylene 4-carbon analog 48 showing modest 
affinity at CB1 (ki = 367±23 nM). 
 A series of rotationally restricted Δ8-THC analogs, entries 49-52, narrows the possible 
conformers the alkyl chain can adopt. Entry 49, reported by Huffman et al. incorporates the typical 
5-carbon chain with a six-membered ring bridging the aryl C-2 and alkyl C2’, exhibited low 
affinity for the CB1 receptor.87 This is reinforced by a series of compounds (entries 50-52), 
reported by Makriyannis et al, in which the seven carbon homolog 50 displayed equally poor 
affinity for both CB1 and CB2.88 Shifting the alkyl chain to the adjacent carbon on the alkyl chain 
restores the affinity to 22.3 nM and 58.6 nM for CB1 and CB2, respectively. The significant loss 
in affinity for 49, 50 and 52 suggest the lateral orientation of the alkyl chain is not the relevant 
conformer for receptor binding, rather the conformer 51 with the chain orienting “downward,” 
away from phenol. It is unlikely that the ring in 50 and 51 is occupying space required by either 
receptor, as the 2-iodo substituted 53 retains modest affinity at CB1; the C4-C2’ ring of 54 however 
follows a similar pattern of other C4 substituted analogs with significant loss of affinity, suggesting 
this space is required in the CB1 receptor for binding.90 Substitution with an adamantyl group in 
place of the alkyl chain also retained potency at both CB1 and CB2, suggesting that favorable 
hydrophobic interactions can be made with the receptor in the C1’ and C2’ positions on the chain.91  
 These aliphatic side chain analogs offer several conclusions that can be inferred in regards 
to CB receptor binding requirements. A 5 to 8 carbon length alkyl chain is optimal, with binding 
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affinity decreasing when shorter and longer alkyl chains are incorporated. Restricting the 
flexibility of the alkyl chain lends some insight into the optimal conformation for receptor binding. 
Firstly, introducing methyl substitutions in various positions on the chain adds steric congestion 
that restricts the number of possible rotamers, in addition to providing hydrophobic bulk that may 
be interacting with the receptors. Branching close to the aromatic ring provides a minimum 10-
fold increase in affinity for CB1 (17 and 18 vs 8), with affinity diminishing as the methyl group is 
moved down the chain further from the aryl ring (19-27), and the best affinity is achieved with 
1’,2’- and 1’,1’-dimethyl substitutions. Secondly, restricting rotation by introducing double and 
triple bonds on the chain follows a similar pattern: cis-double bonds and triple bonds in the C1’ 
position (43 ki = 0.65 nM, 44 ki = 0.86 nM) have no change in receptor binding, with affinity 
decreasing as the triple bond is moved down the chain to the C2’ position (45 ki = 4.9 nM), C3’ 
(46 ki = 9.0 nM) and C4’ positions (47 ki = 19 nM). Thirdly, restricting the C1’ and C2’ carbons 
in a ring results in the chain orienting in a linear (50 ki = 402.4 nM) or “downward” fashion (51 ki 
= 22.3 nM), illustrated in Figure 1.9.  
 
Figure 1.9. Rotational conformers of 3-heptyl-Δ8-THC. Studies of rotationally restricted alkyl 
chains determined the optimal conformation of the chain is oriented “downward” away from the 
phenol, rather than linearly away from the phenyl ring. 
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 The optimal rotational isomer of Δ8-THC substituted with a saturated alkyl chain seems to 
be that of the chain oriented downward from the phenol, rather than the traditionally depicted linear 
conformer. By deselecting the number of possible rotamers of the chain, the energetic “cost” of 
binding to the receptor is decreased, reflected by the enhanced affinity of these analogs at both the 
CB1 and CB2 receptor. This was contradictory to computational studies of these compounds, as 
the minimized energy orientation of this chain is the linear conformation. Analogs containing 
substitutions that favor the alkyl chain adopting this downward conformation show increased 
binding affinity, making substitution near the phenyl ring a common strategy for the synthesis of 
high affinity classical cannabinoids. 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
54.  
 
-THC
AMG-
41 
0.44±0.07 0.86±0.16  92 
55.  
 
-THC  1.5±0.2 11.5±3.4  93 
56.  
 
-THC
AMG-
36 
0.45±0.07 1.92±0.4  94 
57.  
 
-THC  18.4±2.1 23.5±4.1  93 
58.  
 
-THC  13.6±2.4 143±31.5  93 
59.  
 
-THC  3.9±0.5 4.9±0.7  93 
60.  
 
-THC  0.32±0.08 0.52±0.17  85 
61.  
 
-THC  0.52±0.11 0.22±0.06  94 
62.  
 
-THC  32.3±4.0 19.7±2.7  94 
63.  
 
-THC  56.9±6.8 257±41  94 
Table 1.2. C3 analogs of Δ8 and Δ9 THC, continued 
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To investigate the SAR requirements of C1’ substitutions on the side chain, several series 
of compounds containing aliphatic rings and heterocycles were synthesized, illustrated in Table 
1.2. Transforming the 1’,1’-geminal dimethyl substitution into a compact cyclopropyl ring further 
enhances activity at both receptors.92 Expanding the ring size to 4, 5, and 6 carbons modulates the 
activity as a function of the lowest energy conformation of the alkyl chain, as well as the presence 
of hydrophobic bulk potentially creating steric clashes with the putative binding site in the 
receptor. Quantitative Structure-Activity Relationship (QSAR) studies confirm that the 
cyclopropyl and cyclopentyl rings force the chain into a similar favorable orientations, with the 
cyclobutyl and cyclohexyl substituted chains adopting less favorable conformations for optimal 
receptor binding.95 This orientation, with the alkyl chain oriented perpendicular to the aromatic 
ring of the THC scaffold appears to be the optimal conformer for receptor binding.  
In addition to the alkyl chain conformation, the increased affinity of these compounds also 
suggests the presence of a hydrophobic binding subsite near the phenyl ring in both CB1 and CB2. 
Both receptors appear to be indifferent to heteroatoms at this position, illustrated by the high 
affinity of analogs 60–62; however, CB2 has a preference for smaller rings, as larger substitutions 
such as the cyclohexyl analog 58 and bulky benzodithiolane 63 show decreased affinity for CB2 
but not CB1. 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
64.  
 
-THC AM735 8.9±1.0 7.4±0.8  96 
65.  
 
-THC AM731 60.2±0.8 6.1±0.6  96 
66.  
 
-THC AM411 6.80 52.0 Agonist 91 
67.  
 
-THC AM744 34.9 14.0 Agonist 91 
68.  
 
-THC AM757 79.7 76.0 Agonist 91 
69.  
 
-THC  95.5±16.7 71.8±12.2  97 
70.  
 
-THC  11.7±1.6 9.4±1.5  97 
71.  
 
-THC KM-233 12.3±0.6 0.9±0.1  98 
72.  
 
-THC  76.1±1.5 12.4±0.2  98 
73.  
 
-THC  18.8±1.4 1.7±0.2  98 
74.  
 
-THC  5.03±0.4 1.5±0.2  98 
75.  
 
-THC  3.1±0.4 0.9±0.1  98 
76.  
 
-THC  5.3±0.9 0.9±0.02  98 
Table 1.3. C3 analogs of Δ8 and Δ9 THC, continued 
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The replacement of the alkyl chain with various ring structures results in a variety of effects 
on receptor binding (Table 1.3). To explore the necessity of hydrophobic bulk near the phenolic 
ring, a series of saturated alkyl ring analogs were synthesized and evaluated. Bulky bornyl and 
adamantyl derivatives 64-67 display interesting profiles depending on the substitution pattern of 
the rings. An epimer change from bornyl substituted 64 and isobornyl 65 results in 10-fold 
selectivity for CB2, and the location of the link between the adamantyl and phenolic rings results 
in either CB1 preference for 66 or CB2 for 67. The differences in binding affinity of these 
compounds can be explained, at least in part, by conformational analysis of each compound. The 
allowable conformational space of 65 and 67 both occupy a larger volume than that of their 
respective isomers 64 and 66, suggesting such compounds are better accommodated by the CB2 
receptor. This hypothesis is further reinforced by the loss selectivity by the more flexible analog 
68, which is capable of accessing both conformational spaces.91,96,99  
Using more planar phenyl rings, analogs 69–75 display modest activity at both receptors. 
Replacing the alkyl chain in Δ8-THC with an aromatic ring (69) leads to a reduction in affinity, 
and expansion of the ring to a naphthyl analog 70 enhanced affinity. Reincorporating the gem-
dimethyl linker in 71–75 restores activity to low nanomolar affinity; substituting the phenyl ring 
in the para-position requires a bulky, non-polar group, with affinity increasing from para-fluoro 
analog 72 to p-methyl 75. Moving these groups to the meta-position negates any loss in receptor 
activity by substitution, as illustrated by meta-fluoro analog 76.  
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
77.  
 
-THC  10.8±1.8   89 
78.  
 
-THC  81±3.5   89 
79.  
 
-THC  1.27±0.13   100 
80.  
 
-THC O-774 0.6±0.05 2.94±1.40 Agonist 101,102 
81.  
 
-THC O-607 222±66.3 4.00±1.35 Agonist 102 
82.  
 
-THC
O-
1125 
0.86±0.06 1.98±0.26 Agonist 101,103 
83.  
 
-THC  1.2±0.2 3.23±0.29  101,102 
84.  
 
-THC  6.0±0.65 11±0.91  104 
85.  
 
-THC  112±14 389±46  104 
86.  
 
-THC  1.3±0.12 0.57±0.04  104 
87.  
 
-THC O-704 3.0±2.0 1.14±0.54 Agonist 101,102 
88.  
 
-THC  2.8±0.35 1.0±0.16  104 
89.  
 
-THC
O-
2545 
1.3±0.17 0.12±0.01  104 
Table 1.4. C3 analogs of Δ8 and Δ9 THC, continued 
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The addition of heteroatom substitutions on the terminal position of the alkyl chain 
provides analogs that display increases in binding affinity as well as enhanced polarity (Table 1.4). 
The use of halogens and nitrile pseudohalogens on the terminal position of the alkyl chain for both 
the pentyl (77) and dimethyl-heptyl (79) analogs provides an increase in binding affinity over their 
hydrocarbon homologs, while substitution with smaller halogens such as fluorine (78) cause a loss 
of affinity at CB1. One postulation on this change between fluorine and bromine is that the 5’-
bromide chain (77) is closer to length of a 7-carbon chain, with the bromine essentially serving as 
a bioisostere for two carbons.105 The addition of a more polar carboxyl group (81) causes a 
significant loss in CB1 affinity to 222±63 nM while retaining CB2 affinity at 4.00±1.35 nM. Using 
substituted carboxamide groups (82-86), with the exception of 85, shows similarly high affinities 
for both receptors. Removing the carboxamide linker and directly coupling a heterocycle to the 
alkyl chain is not detrimental to binding affinity, as seen in morpholine 87 and imidazole 88. These 
analogs provide a welcomed decrease in lipophilicity, as the vast majority of classical cannabinoid 
analogs are insoluble in water, severely hampering their potential utility as therapeutic candidates. 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
90.  
 
-THC  27.1±4.5 51.5±11.2 Agonist 106 
91.  
 
-THC  0.3±0.1 1.7±0.4 Agonist 106 
92.  
 
-THC  0.7±0.2 3.0±0.7 Agonist 106 
93.  
 
-THC  0.8±0.3 0.7±0.2  107 
94.  
 
-THC  0.5±0.2 1.4±0.7  107 
95.  
 
-THC  3.4±1.1 1.3±0.3  107 
Table 1.5. C3 analogs of Δ8 and Δ9 THC, continued 
 
 In another effort to improve the pharmacokinetics and bioavailability of classical type 
cannabinoids, Makriyannis et al. synthesized a series of side chain analogs containing a labile 
ester, in order to increase polarity and solubility and to extend the half-life in vivo (Table 1.5). 
Installing an ester in the 2’ position on the side chain afforded analogs with enhanced binding 
affinities at both CB1 and CB2. Carboxyester 90, while retaining nanomolar activity at both 
receptors suffered from an extremely short half-life of 0.7 minutes in mouse plasma.106 Adding the 
usual 1’,1’-dimethyl substitution in 91 increased the half-life substantially to 120 minutes, with a 
90-fold and 30-fold increase in affinity at CB1 and CB2, respectively. Analogs containing a 
cyclobutyl ring exhibited improved half-lives to 263 minutes with no binding affinity cost at either 
receptor. Introducing steric hindrance near the ester carbonyl demonstrated a clear strategy for 
increasing the half-life for analogs 93–95 through inhibition of ester hydrolysis.    
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1.3.2 C1 Phenol Analogs 
Another major point of structure modification on the THC scaffold is the C1 phenol (Table 
1.6). Analogs lacking the phenolic hydroxy group or those that have been modified with minor 
changes to the phenolic group can result in drastic changes in the pharmacological activity of these 
compounds. It was quickly realized that etherification or removal of the phenol generated 
compounds that displayed significant selectivity for CB2. For example, the deoxy-Δ8-THC analog 
96 is >300 fold selective for CB2; addition of the 1’,1’-demethyl group in analog 97 results in a 
slight decrease in selectivity to 200 fold. Conversion of the phenol to a methyl ester in analog 98 
results in approximately 800-fold selectivity for CB2 over CB1. 
#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
96.  
 
-THC
JWH-
056 
>10,000 32±9.0  78 
97.  
 
-THC
JWH-
133 
677±132 3.4±1.0  78 
98.  
 
-THC
L-
759,633 
15,850 20±12.4  108 
99.  
 
-THC  - -  109 
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100.  
 
 
-THC  ≈Δ8-THC -  109 
Table 1.6. C1 analogs of Δ8 and Δ9 THC 
Analogs 99 and 100 represent two compounds that demand additional comment. It was discovered 
that forcing the orientation of the phenol oxygen lone pair toward the cyclohexene ring resulted in 
analogs with optimal CB receptor activity.109 Both of these compounds were tested before the 
discovery of the CB receptors making in vitro analysis unavailable (and not been determined 
since), however intraperitoneal injection of these compounds in animal assays showed similar 
potency to Δ8-THC for 100, and almost no activity for 99. The presumption for some time was 
that the free phenol served as an important hydrogen bond donor, but the reanalysis of these 
compounds showed that while this may be true for CB1, there is no necessity for hydrogen bonding 
in this position for CB2. Computational modeling studies suggested the diminished selectivity of 
the deoxy-analogs compared to the methoxy analogs could be a result of inverted binding to the 
receptor, where the pyran oxygen can serve as a hydrogen bond acceptor in the CB1 receptor.110    
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1.3.3 C9/C11 analogs 
#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
101.  
 
  1.82±0.11 0.58±0.30  108 
102.  
 

L-
759,656 
>20,000 19.4±3.8  108 
103.  
 

Nabilone 
(Cesamet) 
2.19±0.89 1.84±0.42 Agonist 108 
104.  
 
  621±215 132±44  108 
105.  
 
 HU-210 0.73±0.11 0.22±0.18  77 
106.  
 
 

JWH-
051 
1.2±0.1 0.032±9.0  110 
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#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
107.  
 
  2.24±0.05 2.61±0.36  108 
108.  
 
 CT-3 32.3±3.70 170.5±7.8  111 
109.  
 
  23.9 40.5  112 
110.  
 
  146.3 671.8  112 
111.  
 
 Δ6a-THC 29±12 18±12  113 
Table 1.7. C9/C11 analogs of Δ8 and Δ9 THC 
The C11 methyl group is another major pharmacophore at which minor structural changes 
can significantly modulate receptor binding (Table 1.7). Substitutions at this position do not confer 
selectivity when compared to analogs modified at the C1 phenol, however binding affinity can be 
great enhanced. Methylene analogs 101 and 102 retain similar affinities to their respective 
homologs 37 and 98, with slighter higher CB2 selectivity for 102 (1000-fold) compared to 98. 
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Conversion of the methylene group to a carbonyl almost completely eliminates this selectivity in 
104. Nabilone, 103, is one of two marketed cannabinoid therapeutics, approved by the US FDA in 
1985 as an antiemetic. Hydroxylation of the C11 methyl group is a major metabolite of THC, 
which retains activity at both receptors at sub-nanomolar affinities. This analog, 105, better known 
as HU-210 has been widely used in cannabinoid pharmacology studies. Removal of the phenol in 
106 confers a slight selectivity for CB2, but this is mitigated by the presence of the C11 hydroxy 
group. Aldehyde 107 and carboxylic acid 108 are also major metabolites of THC, which maintain 
modest affinity at the CB receptors. The decreased selectivity of the oxygen substituted analogs 
103–108 compared to their more selective homologs was the subject of a computational study 
which suggested the phenolic hydroxyl group was necessary for CB1 binding by hydrogen bonding 
with lysine-192, and the introduction of polar group on the C-11 position may satisfy this 
requirement.114 The removal of the unsaturation at C9 introduces another stereogenic center, which 
can dramatically affect receptor binding. Hydroxy analogs 109 and 110 show remarkably diverse 
activities; the R-diastereomer 109 is 6-fold and 17-fold more potent at CB1 and CB2, respectively, 
compared to S-diastereomer 110. This effect does not appear to be guided by hydrogen bonding 
interactions with either receptor, as the (R)-methyl analog 111 binds with higher affinity at both 
receptors. Compound 111 is also the only reported Δ6-THC analog.    
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1.3.4 Miscellaneous Analogs 
#  Cannabinoid Name 
CB1 
Ki (nM) 
CB2 
Ki (nM) 
Functional Ref 
112.  
 

(-)-CP 
47,497 
21±0.56    
113.  
 

(-) CP-
55,940 
0.58±0.07 0.69±0.02 
Full 
Agonist 
77 
Table 1.8. Miscellaneous analogs of Δ8 and Δ9 THC 
Early SAR studies revealed that the pyran ring was not a requirement for cannabinergic 
activity in animal assays. Subsequent work on the core structure of 112 identify what is arguably 
one of the most important synthetic cannabinoids ever discovered, CP 55,940; its radiolabeled 
[3H]-CP-55,940 isotope has been one of the most widely employed reference ligands used in 
pharmacology studies (Table 1.8). The use of radiolabeled 112 revealed the presence of CB1 
receptor in rat brain, and it has been used as a standard in nearly every CB receptor assay 
developed.     
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1.4 Non-Classical Cannabinoids 
1.4.1 CB1 Selective 
While classical cannabinoid development has remained a staple of compound synthesis, 
compounds adopting alternative scaffolds have become prominent. The lipophilicity of most 
classical cannabinoids has hampered their development into viable drugs, so efforts to increase the 
polarity and water solubility of new cannabinoid ligands has been an area of major focus.  
 
Figure 1.10. Representative non-classical CB1 ligands. The first non-classical cannabinoid 
scaffold discovery were the n-alkyl indoles, exemplified by WIN 55,212-2 and JWH-018, both 
non-selective CB1 and CB2 agonists. SR141716, a member of the diarylpyrazole class was the 
first CB1 inverse agonist discovered.  
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 Pravadoline (WIN 48,098) was a cyclooxygenase (COX) inhibitor developed by Sterling-
Winthrop in the 1980s, but its antinociceptive activity was significantly higher than other known 
COX inhibitors, despite its lower effect on prostaglandin synthesis compared to known non-
steroidal anti-inflammatory drugs (NSAIDs).115 With animal assay results similar to known 
cannabinoids, the possibility was raised that the antinociceptive activity was derived not from 
COX binding, but from CB receptor activity. Structural optimization of Pravadoline yielded one 
of the first non-classical cannabinoids, WIN 55,212-2.116 Like CP-55,940, WIN 55,212-2 is a CB 
receptor agonist widely used in cannabinoid receptor assays as a reference compound. Since the 
discovery of WIN 55,212-2, numerous other potent, non-classical cannabinoids were synthesized; 
two other notable compounds in this class are depicted in Figure 1.10. The (aminoalkyl)indole 
JWH-018 is nearly equipotent at both cannabinoid receptors, with slight selective toward 
CB2.117,118 In recent years, JWH-018 has gained notoriety for its illicit use in herbal blends known 
as “Spice.” 119,120 Diarylpyrazole derivative SR141716 was first described as a CB1 receptor 
antagonist, but further studies found it to be a CB1 inverse agonist. SR141716, also known as 
Rimonabant, was briefly approved and marketed as Acomplia by Sanofi in Europe as an 
antiobesity treatment from July 2006 to October 2008, when significant side effects such as 
suicidal thoughts and depression forced its withdrawal from the market.121    
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1.4.2 CB2 selective 
 
Figure 1.11.  CB2 selective agonists. PRS-211,375 and GW-842,166X were both investigated in 
clinical trials for the treatment of pain; both failed for lack of efficacy and side effects. S-777,469 
completed Phase II trials, but no results have been reported and development has presumed halted. 
 
 CB2 selective agonists have been explored for a number of therapeutic indications, most 
commonly as analgesic and anti-inflammatory compounds (Figure 1.11). Cannabinor, formerly 
known as PRS-211,375, was tested in humans for the treatment of several modes of pain; it 
ultimately failed due to a lack of efficacy in a Phase IIb study in the treatment of pain follow third-
molar tooth extraction.122 Cannabinor may have also suffered from modulation of bladder activity, 
as animal studies have demonstrated a cannabinoid receptor-linked effect increasing urination 
frequency.123,124  GW-842,166X was also explored for the treatment of third-molar tooth extraction 
and osteoarthritis, but failed in Phase II trials due to lack of efficacy.125,126 S-777,469 completed 
Phase II trials for atopic dermatitis in 2011, but no clinical data or future plans for clinical testing 
of this compound have been released, indicating its development may have been halted. 127-129 
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After several failed clinical trials, the possibility that years of immunostaining results were 
inaccurate, and halted CB2 research programs, the progress of CB2-targeted therapeutics was 
seemingly at an impasse. Research efforts into therapeutic potential of CB2 selective agonists have 
recently focused on improving selectivity by several orders of magnitude. Although many of the 
conventional CB2 agonists were as much as 500-fold selective, this may not be effective in vivo, 
causing CB1 activation at higher doses.130 While comparison of their respective binding affinities 
may characterize compounds these compounds as highly selective, the overall expression levels 
of the cannabinoids receptors in humans are not equivalent. In many disease states, overall CB1 
expression can be significantly higher than CB2, causing activation of both receptors.131 High 
dosages used in human studies likely precipitated effects of CB1 and CB2 activation. Many 
preclinical animal models may also not be effective in studying CB2 selective activation because 
of interspecies differences in CB2 receptor expression and signaling.132 
Since late 2014, several landmark improvements in the pharmacological tools used to study 
the CB2 receptor have been reported. Transgenic mice expressing a CB2-GFP reporter have 
allowed for highly specific and accurate studies of CB2 expression, especially in light of the 
specificity problems with most anti-CB2 antibodies.133 Many advances have been made in the 
development of CB2 selective compounds. New scaffolds have been employed in the synthesis of 
compounds that display selectivity at high as 35,000 fold, significantly greater than previously 
reported compounds (Figure 1.12).    
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Figure 1.12. CB2 selective ligands reported in 2014 and 2015  
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Triazolopyrimidine 112 is CB2 agonist developed by Roche, which displayed a 1,250-fold 
selectivity over CB1 and demonstrated a protective effect in inflammatory kidney damage 
models.134 Benzimidazole containing scaffolds have also been reported, with RQ-00202730 
showing over 4,000-fold selectivity for CB2 and a dose-dependent analgesic effect in rats.135 Both 
of these compounds displayed favorable pharmacokinetic parameters, and were completely devoid 
of in vivo activity traditionally associated with CB1 activity. Naphthyridin-2(1H)-one 113 
possesses CB2 affinity in the picomolar range, with over 15,000-fold selectivity.136 This compound 
was one of many in a series employing this scaffold that allows for the control of functional activity 
depending on substitution patterns. Pyridine analog RSR-056 and 4-oxo-quinoline analog RS-028 
are >4,000 fold and >12,500 fold selective for CB2 over CB1, respectively, and have been used as 
11C PET tracers in rat and mouse models.137,138 Proline analogs 114 and 115 developed by 
Boehringer Ingelheim Pharmaceuticals, are two of the most selective compounds reported to date 
with greater than 35,700-fold selectivity and 29,300-fold selectivity, respectively.139 Both of these 
demonstrated a dose-dependent reversal of hyperalgesia in a rat diabetic neuropathy model. 
 While 2015 has been a landmark year for advances in the medicinal chemistry of selective 
cannabinoid ligands, the development of novel scaffolds has proved a necessity in order to advance 
the therapeutic potential targeting the CB2 receptor.      
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CHAPTER 2  
DESIGN AND SYNTHESIS OF A BENZOFURAN CANNABINOID SCAFFOLD 
2.1 Compound Design 
This dissertation research began with the discovery of a novel cannabinoid by researchers 
at the University of Mississippi Natural Products Center, namely (–)-α-10a-hydroxy-Δ9-
tetrahydrocannabinol (10a-OH THC), depicted in Figure 2.1. Cannabinoid receptor binding 
studies revealed this THC analog has high affinity for both receptors: 1.867 nM at CB1, and 31.93 
nM at CB2 (unpublished work). 
 
Figure 2.1. Structures of (–)-10aα-hydroxytetrahydrocannabinol (10a-OH THC) and (–)-Δ9-
tetrahydrocannabinol (THC) 
 
This THC analog was a unique finding, as this was the first reported cannabinoid mono-
substituted on the 10a-position. The closest structural analog to this compound is (–)-cannabitriol 
(Figure 2.1) and its stereoisomers. From a medicinal chemistry perspective, 10a-OH-THC 
presented an additional clue on the classical cannabinoid scaffold that could potentially be useful 
for the development of novel cannabinoid ligands. In an effort to exploit this structural feature we 
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set out to develop new compounds which retained the important pharmacophores of classical 
cannabinoids with the addition of the 10a-hydroxy group.  
The evaluation of the classical cannabinoid structure activity relationships (SAR) data 
provided insight for the development of a new scaffold. Focusing on CB2 selective analogs 
highlighted several important SAR elements, namely etherification of the phenol significantly 
decreases CB1 affinity without effecting CB2 binding, a variety of ring sizes and substitutions in 
place of the “Northern” cyclohexene ring are tolerated at both receptors, and the “Southern” 
dimethyl pyran ring is not required for binding at CB1 or CB2 (Figure 2.2). 
 
Figure 2.2. SAR elements of classical cannabinoids 
 
From this data it was hypothesized that a 3-hydroxybenzofuran scaffold would provide 
opportunities for substitutions at key positions to include most of the pharmacophoric elements 
present in classical cannabinoids. Comparing minimized energy structures of this scaffold against 
10a-OH THC, shown in Figure 2.3 (Chem3D 15.0, Perkin-Elmer), provides support for this 
approach. In these simulations, structures were subjected to MM2 force field energy minimization 
calculations provided in the software.140 After obtaining the minimized energy conformations for 
each molecule, the alkyl chains were truncated to methyl groups since the conformations of these 
chains were not identical for both molecules. The flexibility of these chains would suggest the 
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same conformational space should be accessible in both 10a-THC and our scaffold, provided the 
phenyl rings were aligned in a similar fashion. 
2.1.1 Scaffold Considerations 
 
Figure 2.3. Computational superimposition of 10a-OH THC and 3-hydroxybenzofuran. 3D 
Overlay of 3-hydroxybenzofuran scaffold and 10a-OH THC minimized energy structures in 
Chem3D 15.0 (Perkin-Elmer). Structures of those used in this simulation are shown left in 
corresponding colors. 
 
This simulation provided a comparative analysis of an accessible conformation for these 
compounds, highlighting similarities in the important pharmacophores of each molecule. The 3-
hydroxy group and furan oxygen of the benzofuran scaffold overlapped with the 10a-hydroxy 
group and phenol of 10a-OH THC, respectively. This suggests that the 3-hydroxybenzofuran 
scaffold may be capable of forming the same critical interactions with CB receptors for binding. 
Substitution on the phenyl ring and C2 position would present points of diversification to build a 
library of analogs. The THC C3 substitutions discussed in Chapter 1 can be employed as 
substitutions on the benzofuran phenyl ring, and the C2 position can be easily altered to enhance 
receptor binding.   
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Figure 2.4. Elimination of 2,3-dihydrobenzofuran-3-ol to benzofuran 
 
 The creation of a viable synthetic route for a 2,3-dihydrobenzofuran-3-ol scaffold proved 
problematic. Literature reports revealed an inherent instability, favoring elimination of the hydroxy 
group to form the aromatic benzofuran (Figure 2.4).141,142 
 
Figure 2.5. Tautomerization of 3-hydroxybenzofuran 
 
Alternatively, 2-substituted 3-hydroxybenzofurans were examined, however literature 
examples demonstrated that compounds containing these motifs have a high propensity to undergo 
keto-enol tautomerization, with the keto tautomer predominating (Figure 2.5). In a kinetics study 
monitoring reactions dynamics using 1H-NMR, 3-hydroxybenzofuran was only briefly observed 
following hydrolysis of the TMS-protected enol with deuterium chloride (Figure 2.6).143,144  
 
Figure 2.6. Synthesis of 3-hydroxybenzofuran via silyl ether deprotection  
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Figure 2.7. Proposed hydroxyaurone scaffold.  
 
 To prevent elimination and tautomerization, incorporating an exo-olefin linker in place of 
the methylene group seemed to be a reasonable strategy (Figure 2.7). Fortunately, this structure 
was reported in the literature, although most frequently as an intermediate in the synthesis of other 
target compounds.145-149 The previous computational technique was also used in the analysis of 
this structure in Figure 2.8. 
 
Figure 2.8. Computational superimposition of 10a-OH THC and benzofuran scaffolds. 
Overlay of the hydroxyaurone scaffold (purple), (–)-10a-α-hydroxytetrahydrocannabinol (orange) 
and 2,3-dihydrobenzofuran-3-ol scaffold in green.  
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 In comparison with 2,3-dihydrobenzofuran-3-ol, the hydroxyaurone structure was nearly 
homologous with respect to the orientation of the 3-hydroxy groups. However, including a 2-
benzyl substitution revealed a significant deviation from 10a-OH THC for the new scaffold. The 
inclusion of a C2 sp3 carbon linker in 2,3-dihydrobenzofuran-3-ol allowed the benzyl substitution 
to occupy conformational space similar to the cyclohexene ring of THC. The hydroxyaurone, with 
an exo-olefin C2 linker in the (Z)-configuration would prevent this rotation. Preparation of the (E)-
isomer could potentially mitigate this issue, however (E)-aurones are unstable and isomerize upon 
exposure to light (Figure 2.9).150 
 
 
Figure 2.9. (E)-aurone isomerization 
 
Although this represented a potential flaw in our compound design, other classical 
cannabinoids with bulky esters at the C1 phenol or C11 position had been previously found to 
retain cannabinoid receptor activity, supporting the notion that this orientation of the phenyl ring 
in the hydroxyaurone scaffold may not be problematic.104    
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2.2 Chemistry 
 At the outset of this project we focused our attention on utilizing established protocols 
reported for the synthesis of aurones. This class of natural product flavonoids are typically found 
in brightly colored plants as a primary pigment, seen especially in yellow flowers.151 There are 
two major synthetic routes employed in aurone synthesis, shown in Figure 2.10 The focal point 
of the first method involves a metal catalyzed cyclization reaction to form the benzofuran ring, 
followed by an oxidation, while the second pathway centers on an aldol condensation with 3-
coumaranone and benzaldehyde.152-156 
 
Figure 2.10. Retrosynthesis of the hydroxyaurone scaffold. The synthesis could proceed via the 
top pathway, dependent on a cyclization step to produce a common precursor, or the bottom 
pathway, which could use aldol couplings to produce analogs. Each pathway allows for the rapid 
synthesis of analogs by functionalization on one side of the scaffold. 
 
 One of the primary objectives of this project is to produce a large number of analogs in 
order to begin developing a structure activity relationship, and accomplishing this in a reasonable 
timeline demanded our synthetic route prioritize rapid library synthesis from a common precursor.  
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Figure 2.11. Major scaffold SAR elements 
 
 Using lead compound 2.4 as a representative example, our synthesis was designed to 
facilitate diversification of two portions of the scaffold: “the western half” (alkyl chain) and the 
“eastern half” (phenyl ring). Ideally, the common precursor for diversification would be the 
coumaranone core, with the final synthetic steps invoking the addition of an alkyl chain followed 
by condensation with a substituted benzaldehyde to produce the final products, however an 
immediate concern surfaced. The vast majority of saturated alkyl-aryl coupling reactions require 
the use of alkylzinc or alkylmagnesium reagents, that are incompatible with the carbonyl 
containing coumaranone.157 
 
Figure 2.12. Synthetic strategy for alkyl analog synthesis 
 
Of the two synthetic pathways illustrated in Figure 2.10, each allowed for the addition of 
either a substituted benzaldehyde or the alkyl chain in the final step, with other group installed in 
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the early stages of the synthesis. For example, Figure 2.12 shows that by employing the cyclization 
chemistry, the “eastern” phenyl ring would be installed in the first stage of the synthesis, with the 
“western” alkyl chain coupled in the final step. Conversely, the aldol approach in Figure 2.13 
completes the western alkyl substitution in the first step.  
 
 
Figure 2.13. Synthetic strategy for phenyl analog synthesis 
 
Reiterating the SAR of classical cannabinoids, an important point of functionalization for 
analog synthesis is the C3 alkyl chain, which can significantly modulate CB1 and CB2 receptor 
affinity. Therefore, it was logical to optimize the “western half” of the scaffold first, given the 
potential influence of this group on receptor affinity.   
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2.2.1 Transition Metal Catalyzed Cyclization Synthesis 
 
 
Scheme 2.1. Cyclization synthesis of lead compound 2.4. Reagents and Conditions: a) 
methylmagnesium chloride, phenyl acetylene, THF, 0ºC, 2 hours; b) PdCl2, KCl, morpholine, 
MeOH, 40ºC, 12 hours; (c) 5% Fe(acac)3, pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 
minutes. 
 
 Hydroxyaurone 2.4 was chosen initially as a viable target molecule for synthetic route 
evaluation (Scheme 2.1). Alkynylation of commercially available 4-chlorosalicylaldehyde 2.1 
with phenylacetylene afforded the desired propargyl alcohol 2.2 in excellent yields. 
Methylmagnesium chloride was used in this reaction as a base to generate 
phenylacetylenylmagnesium chloride in situ, avoiding lithium-halogen exchange common with 
organolithium bases.158 Cyclization of 2.2 was initially attempted with palladium (II) chloride as 
a catalyst but did not yield 2.3, rather, the 6-endo-dig chromanone product in low yields (Figure 
2.14).159 This step was repeated using other catalysts, including silver (I) nitrate and copper (I) 
iodide, both without success.146–148,160  
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Catalyst Yield 2.3 Yield 2.5 
(a) PdCl2, KCl 0% 10% 
(b) AgNO3 0% 0% 
(c) CuI, PPh3 0% 0% 
(d) AuCl, K2CO3 93% 0% 
 
Figure 2.14. Catalyst screening for cyclization chemistry. Reagents and conditions: (a) PdCl2, 
KCl, morpholine, methanol, 40ºC, 12 hours; (b) AgNO3, DMF, 60ºC, 6 hours; (c) CuI, PPh3, 
CsCO3, methanol, 40ºC, 12 hours; (d) AuCl, K2CO3, acetonitrile, 25ºC, 12 hours. 
 
 Fortunately, gold (I) chloride was recently reported to function as an excellent catalyst in 
the synthesis of aurones, and in our hands, reaction of 2.2 with gold (I) chloride under standard 
conditions selectively afforded the desired 5-exo-dig product 2.3 in excellent yields.145 However, 
subsequent replicates of this reaction resulted in a significant drop in product purity and yield, 
revealed by product analysis using thin-layer chromatography (TLC) (Figure 2.15). While minor 
product quantities were identified in the reaction mixture, isolation of 2.3 proved exceedingly 
difficult. This sudden decrease in reaction efficiency was without any obvious explanation, and 
the multifactorial nature of this problem necessitated careful analysis of the starting materials and 
reagents in this reaction. Degradation of the starting material was deemed unlikely after reanalysis 
of the purity of 2.2, as these reactions were performed using the same batch. Newly acquired 
quantities of gold (I) chloride and the use of anhydrous acetonitrile in the reaction did not solve 
the problem. 
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Figure 2.15. Gold (I) cyclization complications. (left) TLC analysis of 1st and 4th runs, 
highlighting differences in product purity and yield. (right) Gold (0) band in the reaction flask after 
4th replicate. 
 
While the original report of this gold catalyzed reaction used acetonitrile as a solvent, other 
reports successfully employed methanol, dichloromethane or toluene, however these alternative 
solvents provided no appreciable quantities of 2.3.161–163 Of these failed replicates, perhaps the 
most perplexing occurrence was the presence of metallic, presumably gold (0) on the surface of 
the round-bottomed flask. This suggested a change in oxidation state of the gold catalyst, not 
indicated by the proposed mechanism illustrated in Figure 2.16. It is conceivable that these gold 
(0) deposits were a result of the disproportionation of gold (I) to gold (III) and gold (0), however 
this process is infrequently reported in the literature, and rarely within the context of gold catalyzed 
organic reactions.164 Furthermore, the in situ generation of gold (III) is not viewed as problematic 
throughout the literature, and may in fact serve as the active catalyst in many reactions.165,166  
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Figure 2.16. Mechanistic insights of gold (I) chemistry. (left) Proposed mechanism for AuCl 
catalyzed cyclization. (right) Mechanism of gold (I) disproportionation reaction proposed by 
Gammons et al.167 
 
The original report of this cyclization, however, screened gold (III) chloride as a catalyst, 
resulting degradation products. Furthermore, Gammons et al. reported in Geochimica et 
Cosmochinica Acta that the disproportionation of gold (I) is significantly accelerated in the 
glassware with cracks and/or scratches, shown in Figure 2.l6.167 This was especially enlightening, 
as the same round bottomed flask was used in each replicate in an effort to decrease the possible 
variables contributing to the outcome of this reaction. After each replicate, the round bottomed 
flask was vigorously scrubbed with brushes and spatulas to remove the residual gold from the glass 
walls. Ironically, these actions likely enhanced the disproportionation reaction, increasing the gold 
(III) catalyzed degradation of 2.2. The use of new, scratch-free round bottom glassware remedied 
the aforementioned reaction problems, affording 2.3 in 90% yield. 
With this issue resolved, our attention returned to coupling the desired C-alkyl side chain to 
the benzofuran ring using an iron-catalyzed cross coupling reaction between alkyl and aryl 
halides.168 It was critical to protect the hydroxy group (compound 2.7), since formation of 
55 
magnesium hydroxide salts was observed in the iron coupling reaction of aryl chloride 2.3 using 
Fe(acac)3 as the catalyst. 
 
Scheme 2.2. Protection of 2.3 and iron coupling. Reagents and conditions: (a) 5% Fe(acac)3, 
pentylmagnesium bromide, THF/NMP (10:1), 0ºC, 5 minutes; (b) Imidazole, TBSCl, CH2Cl2, 25 
ºC, 2 hours; (c) 5 TBAF, THF, 0ºC 
 
Iron catalyzed cross-coupling of 2.7 provided the product 2.8, albeit in very low yields. This 
problem was anticipated, as the original report of this iron-coupling reaction reported low yields 
for electron-rich aryl chlorides, and circumvented this problem with the use of aryl triflates.169-171 
The original literature reports also found success using simpler starting materials such as methyl 
4-chlorobenzoate and 4-chlorobenzonitrile, and other chlorinated phenyl rings with deactivating 
groups such as trifluoromethyl groups and sulfonates. With the exception of esters, activating 
groups such as methoxy groups, methyl and other alkyl and aryl groups, failed to react as aryl 
chlorides but were successful when aryl triflates were employed.168 Given the lack of deactivating 
groups on compound 2.7, synthesis of the compound with a triflate in place of the aryl chloride 
was required. 
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Scheme 2.3. Synthesis of triflate precursor 2.12. Reagents and conditions: (a) 
trifluoromethanesulfonic anhydride, 2,6-lutidine, 0ºC, 1 hour; (b) methylmagnesium chloride, 
phenylacetylene, THF, 0ºC, 2 hours; (c) 10% AuCl, K2CO3, acetonitrile, 25ºC, 12 hours. 
 
Fortunately, synthesis of aryl triflate precursors required no major changes our synthetic 
route. Utilizing 3-hydroxysalicyladehyde 2.9 as a starting material, reaction with triflic anhydride 
afforded product 2.10.172 Hydrogen bonding between the aldehyde and phenol in 2.9 allowed for 
the selective formation of 2.10. The remainder of the synthesis proceeded similarly when 
compared to using the aryl chloride; nucleophilic addition of phenylacetylene afforded 2.11, 
followed by gold (I) catalyzed cyclization to form the coupling partner 2.12. 
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Scheme 2.4. Protection of 2.12 and iron cross coupling. Reagents and conditions: (a) 5% 
Fe(acac)3, pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 minutes; (b) imidazole, TBSCl, 
CH2Cl2, 25ºC, 2 hours; (c) 5% Fe(acac)3, pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 
minutes. (d) 20% Fe(dbm)3, pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 minutes. 
 
Reattempting the iron-catalyzed coupling reaction, Fe(acac)3 catalyzed coupling with 
unprotected 2.12 resulted in only trace amounts of product, detectable by mass spectrometry and 
thin-layer chromatography. Considering that almost all literature references reported 
approximately 70% product yields with diverse substrates, it was obvious that the free hydroxy 
group was interfering with this reaction. Reaction with the tert-butyldimethylsilyl ether 2.13 gave 
much higher yields of the desired product 2.8. 
Optimization of the reaction conditions improved product yield with increased Fe(acac)3 
loadings, however these increases ceased beyond 100 mol% catalyst loading. Further yield 
improvement was observed with the use of Fe(dbm)3 as a catalyst (figure 2.17), possibly a result 
of its higher stability in solution compared to Fe(acac)3, however the lack of an established 
mechanism for the iron (III) coupling makes this result difficult to interpret.173   
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Catalyst Yield 2.8 
5% Fe(acac)3 20% 
20% Fe(acac)3 45% 
100% Fe(acac)3 57% 
5% Fe(dbm)3 82% 
20% Fe(dbm)3 95% 
  
Figure 2.17. Optimization of iron (III) catalyzed cross coupling.  
 
With deprotection of the silyl ether remaining, 2.8 was subjected to numerous reaction 
conditions to remove the TBS protecting group (scheme 2.5). Treatment of 2.8 with 
tetrabutylammonium fluoride or hydrogen fluoride-pyridine led to a mixture of products, with 
fluoride addition product 2.14 identified as the only product on mass spectrometry (MS ES+ m/z 
= 319.43 [M+Na]+). The inherent problems with this synthetic route warranted an alternate 
synthesis. 
 
Scheme 2.5. Deprotection of 2.8. Reagents and conditions: (a) TBAF, THF, 0ºC 1 hour, or 
HF·pyridine, THF, 0ºC, 1 hour;    
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2.2.2 Synthesis of an Aldol Condensation Precursor 
To obviate the problems associated with the original route, a new scheme for the synthesis of 
2.4 was devised. Abandoning the cyclization pathway for the synthesis of a hydroxyaurone, this 
new scheme would allow for analog synthesis using an aldol reaction as a key step (Scheme 2.6). 
 
Scheme 2.6. New synthesis for 6-pentylcoumaranone. Reagents and conditions: (a) CH2N2, 
ether, 0ºC, 1.5 hours; (b) imidazole, TBSCl, CH2Cl2, 25ºC, 2 hours, (c) 5% Fe(acac)3, 
pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 minutes; (d) KF, tert-butyl bromoacetate, 
DMF, 25ºC, 6 hours; (e) KOtBu, THF, 0ºC, 2 hours; (f) 10% NaOH, 1,4-dioxane, 100ºC, 12 hours. 
(g) 2N HCl, 100ºC, 12 hours.  
 
The conversion of 4-chlorosalicyladehyde (2.15) to methyl ester 2.16 using diazomethane 
proceeded in near quantitative yields, followed by protection of the phenol as a TBS-ether (2.17), 
used as a substrate in the iron-catalyzed coupling reaction with pentylmagnesium bromide. 
Interestingly, the use of Fe(dbm)3 as a catalyst gave significantly lower yields than Fe(acac)3. The 
TBS ether 2.18 was converted to the ether 2.19 in a one pot deprotection-substitution reaction with 
potassium fluoride and tert-butyl bromoacetate.174 The enolate of 2.19 generated with potassium 
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tert-butoxide cyclized to the exo-tert-butyl ester product 2.20. The remainder of the synthesis, 
seemingly straightforward, was hindered by subpar yields. The carboxylic acid 2.21 was obtained 
in low yields from hydrolysis with sodium hydroxide in 1,4-dioxane. Several attempts to optimize 
this reaction included the use of potassium hydroxide or lithium hydroxide in both aqueous and 
anhydrous conditions, without any improvement in yield. Nonetheless, proceeding with the 
acquired 2.21, the decarboxylated product 2.22 proved exceedingly difficult to obtain. Refluxing 
2.21 in 2N hydrochloride acid failed to provide 2.22; alternative conditions attempted included 
treatment of 2.21 with 6N hydrochloric acid, 2N sulfuric acid, or trifluoroacetic acid in water. The 
lack of product formation may be a result of the propensity of the final product to undergo an 
intermolecular aldol reaction; although 2.23 was not isolated in appreciable quantities (Scheme 
2.7). This product 2.23 was observed on mass spectrometry (MS ES+ m/z = 429 [M+Na]+), along 
with unreacted carboxylic acid 2.21. 
 
Scheme 2.7. Intermolecular aldol reaction of 2.22. Reagents and conditions used included 2N, 
6N, HCl, 2N H2SO4, TFA in water; all reactions were run at reflux for at least 6 hours; no product 
besides dimer 2.23 was observed.  
 
Confronted with a synthetic pathway plagued with reactivity issues, a new scheme for 
producing coumaranone 2.22 for aldol couplings was explored. The apparent instability of 
compound 2.22 under highly acidic or basic conditions would require that any reaction forming 
this structure could not include a decarboxylation step. Therefore, the 5-membered ring of the 
coumaranone would need to be constructed through cyclization with a phenol, or obtained from 
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the use of commercially available substituted coumaranones that may facilitate the addition of an 
alkyl chain. 
 
Scheme 2.8. Alternate synthesis of 6-pentylcoumaranone. Reagents and conditions: (a) 
trifluoromethanesulfonic anhydride, 30% K3PO4, toluene, 0ºC, 1 hour; (b) 5% Fe(acac)3, 
pentylmagnesium chloride, THF/NMP (10:1), 0ºC, 15 minutes; (c) HClO4-SiO2 (0.5 mol-% 
HClO4), trimethyl orthoformate, methanol:H2O 1:1, 25ºC, 1 hour;  
(d) p-toluenesulfonic acid, ethylene glycol, toluene, Δ, 12 hours or 1% tetrabutylammonium 
tribromide, ethylene glycol, methanol, 25ºC, 4 hours; (e) NaHMDS, TBSCl, THF, -78ºC  25ºC, 
2 hours. 
 
 Several alternative routes to the 6-pentyl-3-coumaranone 2.22 were explored using 
commercially available 6-hydroxy-3-coumaranone 2.24 (Scheme 2.8). This pathway hinged upon 
the success of the iron-catalyzed coupling reaction, which would offer a two-step synthesis to 2.22 
Conversion of 2.24 to the triflate using previously established conditions afforded product 2.25 in 
a 96% yield. Comparatively, the reactivity of the Grignard reagent with the iron (III) complex is 
much higher than with the ester, thereby allowing this reaction to proceed in the presence of this 
functional group.175 It is noteworthy that the significantly higher electrophilic character of the 
ketone 2.25 prevents its conversion to 2.22 via iron (III) coupling. Furthermore, the 
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tautomerization of 2.25 prevents both ketal protection of the carbonyl and silyl ether protection of 
the enol.176-178 
It was thus apparent that the pentyl chain could not be coupled with a penultimate precursor 
of compound 2.22 or a final compound, as shown in Figure 2.18. Requiring a deactivated or 
protected coupling partner in the iron-catalyzed coupling hindered the development of a viable 
synthesis with this chemistry. Therefore, a method opting to use the addition of an alkyl 
nucleophile to a substituted benzaldehyde to provide the desired pentyl chain was adopted.  
 
Figure 2.18. Failure points of attempted syntheses. Pathways that failed as a result of iron (III) 
couplings are shown in red. The green pathway hinged on the unsuccessful deprotection of a silyl 
ether. The blue pathway required a decarboxylation step which afforded no product. The 
commonality of each of these pathways was the presence of either the hydroxyfuran ring or 
furanone ring. The new synthesis, would define the alkyl substitution in the first step followed by 
synthesis of the 5-membered furan ring, preventing the functional group incompatibilities present 
in each of the previous syntheses. 
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Scheme 2.9. 6-pentylcoumaranone synthesis. Reagents and conditions: (a) n-BuLi, THF, 0ºC, 1 
hour, 90%; (b) cat. HClO4, Pd/C, H2, methanol, 25ºC, 2 hours, 85%; (c) AlCl3, BCl3, 
chloroacetonitrile, CH2Cl2, 25ºC, 12 hours, 89%; (d) K2CO3, DMF, 25ºC, 1 hour, 98%.  
 
Starting with commercially available 3-hydroxybenzofuran (2.29), nucleophilic addition of  
n-butyllithium to the aryl aldehyde afforded the desired addition product (2.30) in high yields 
(Scheme 2.9). Elimination of the secondary alcohol with catalytic perchloric acid and in situ 
hydrogenation of the resulting styrene gave 3-pentyphenol 2.31 in excellent yields. Friedel-Crafts 
acylation of 2.31 with chloroacetonitrile under Sugasawa conditions, using boron-trichloride to 
direct the acylation ortho to the phenol, afforded the alpha-chloro ketone 2.32179 The substitution 
pattern on the aromatic ring of 2.32 was confirmed by the observation of two doublets and one 
singlet upon evaluation of the 1H-NMR spectrum. Cyclization of 2.32 was accomplished using 
potassium carbonate to afford 2.22 in near quantitative yields. The advantages of this synthetic 
pathway were numerous: firstly, the coumaranone 2.22 was synthesized in 4 steps with an overall 
yield of 66%. Secondly, the only product which required column chromatography purification was 
the Sugasawa acylation product 2.31, and thirdly, analogs of 2.22 with different alkyl substitutions 
could be synthesized using the same process with alternate nucleophiles or starting materials, such 
as salicylaldehyde.      
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CHAPTER 3  
SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS AND STRUCTURE 
ACTIVITY RELATIONSHIP ELUCIDATION 
3.1 Strategies for Final Compound Synthesis 
With the establishment of an efficient synthetic method for 2.22, we turned our attention to 
the synthesis of lead compound 2.6 and analogs. It was envisioned that this compound could be 
obtained through the use of an aldol condensation followed by selective 1,2-reduction of the 
resultant ketone.  
 
Scheme 3.1. Synthesis of final compounds. Reagents and conditions: (a) glacial acetic acid, 25ºC, 
1 hour; (b) NaBH4, CeCl3·7 H2O, methanol, 25ºC, 20 minutes. 
 
Indeed, this proved to be a facile synthesis, affording aurone 3.1 in excellent yields utilizing 
an acid-catalyzed aldol condensation reaction with benzaldehyde. Chemoselective 1,2-reduction 
of α,β-unsaturated carbonyls can be achieved with a number of reagents, including sodium 
borohydride and cerium chloride,180 sodium monoacetoxyborohydride181, diisobutylaluminum 
hydride (DIBAL),182 9-borabicyclo[3.3.1]nonane (9-BBN),183 and iridium catalysts.184 Reduction 
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of 3.1 using sodium borohydride and cerium chloride, the Luche reduction, provided an expedient 
synthesis of 2.6, affording the product in 87% yield. With our lead compound for biological 
analysis in hand, we next turned to synthesizing specific analogs.  
 
Scheme 3.2. Synthesis of p-acetimido aurone 3.2. Reagents and conditions: (a) glacial acetic 
acid, 25ºC, 1 hour. 
 
Using commercially available substituted benzaldehydes, the same chemistry was applied 
toward the synthesis of analogs of 2.6 (Scheme 3.2). However, the presence of several functional 
groups, namely those capable of supporting resonance structures, complicated product isolation. 
This problem is best exemplified by the synthesis para-acetimido analog 3.2. Using the acid-
catalyzed aldol condensation reaction provided only trace amounts of product, despite complete 
consumption of the starting material (TLC monitoring of the reaction). Analysis of the reaction 
progress using MS indicated formation of product, in agreement with the presence of a lower Rf 
spot on TLC, as expected for this product. The work-up of this reaction was instructive, as 
differences from the initial run with benzaldehyde were encountered. Unlike compound 3.1 which 
afforded a yellow solution during reaction work up, neutralization of the reaction with sodium 
bicarbonate provided a strong red color. The yellow color returned upon acidification of this 
solution, which suggested the occurrence of acid-base chemistry during workup. 
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Scheme 3.3. Keto-enol tautomerization of 3.2. 
 
Given the significant conjugation of 3.2 it was hypothesized that while the product was 
obtained, its isolation proved elusive due to its propensity to tautomerize and form a water soluble 
tautomer. To mitigate this issue, changes in the method of this aldol condensation were needed to 
circumvent the need for an acid-base workup. 
 
Scheme 3.4. EDDA catalyzed aldol reaction. Reagents and conditions: (a) EDDA,  
4-acetimidobenzaldehyde, acetonitrile, reflux (microwave), 6 minutes, 58.2%; 
 
The synthesis of aurones using the aldol condensation reaction as a key step in the presence 
of ethylenediamine acetate (EDDA) under sonication was used a model reaction. In our hands, we 
were unable to replicate this reaction under sonication conditions, but were successful using 
microwave irradiation.154 The reaction was performed using a household microwave (1250W), 
which presented a few challenges. Firstly, household microwaves operate at only a single wattage, 
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unlike most scientific microwave reactors, and in an attempt to prevent the reaction from 
overheating and evaporating the solvent, reactions were performed at 60% power. This does not 
change the wattage, but pulses the magnetron producing microwave radiation so that it represents 
60% of the run time specified. Secondly, microwave radiation is not uniform throughout the 
interior of the chamber, so the reactions were spun on the plate inside the microwave throughout 
the duration of the run. Thirdly, as more analogs were produced, it was noted that benzaldehydes 
with polar substitutions, such as p-methoxy, required longer run times in the microwave, typically 
around six to ten minutes, whereas non-polar benzaldehydes like 4-chlorobenzaldehyde were 
completed within three minutes. This required careful monitoring of the reaction by TLC, and at 
times additional solvent was necessary to continue the reaction if it required longer heating times, 
as these reactions were conducted in open vials. Additionally, the use of a household microwave 
was enormously cost effective compared to a Biotage Initiator reactor ($0.01 vial vs $5.62 Biotage 
reaction vessel). Aqueous workup was not required prior to purification, as the crude reaction 
mixtures are typically viscous oils; simple dilution with ethyl acetate and direct loading onto a 
silica gel column was required for purification. This protocol resulted in significantly higher yields, 
e.g., the synthesis of 3.2 with acetic acid resulted in a trace quantities of product, compared to 58% 
yield under microwave conditions.  
 
Scheme 3.5. Luche reduction rearrangement. Reagents and conditions: (a) NaBH4, CeCl3·7 
H2O, methanol, 25ºC, 20 minutes 
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The product from the Luche reduction of 3.3 (Scheme 3.5) resulted in a mixture of the desired 
allyl alcohol and a rearrangement product, presumably from the nucleophilic addition of methanol 
to the exo-methylene of 3.4 via an SN2’ mechanism (Scheme 3.6). A literature search for precedent 
of this rearrangement provided a single reference detailing the same product forming from a 
similarly conjugated substrate.185 
 
Scheme 3.6. Proposed SN2’ mechanism of Luche reduction rearrangement 
 
Mechanistically, the Lewis acid properties of cerium chloride were likely facilitating the 
resultant secondary alcohol serving as a leaving group, with methanol adding to the exo-
methylene. Further evidence of this was provided by using ethanol in place of methanol and 
ethanol addition product 3.6 was obtained in a similar fashion (Scheme 3.7). 
 
Scheme 3.7. Rearrangement in ethanol. Reagents and conditions: (a) NaBH4, CeCl3·7 H2O, 
ethanol, 25ºC, 20 minutes 
 
It was evident removal cerium chloride or the protic solvent would be necessary, and thus 
alternative reaction conditions were attempted shown in Figure 3.1. Reduction with DIBAL and 
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9-BBN afforded the allyl alcohol as the major product, with significant quantities of unreacted 
starting material remaining. Sodium mono and tri-acetoxy borohydride, and sodium 
cyanoborohydride also afforded a similar mixture of starting material and allyl alcohol product, 
albeit at lower yields. 
 
 
 
Yield 3.3 Conditions Yield 3.4 Yield 3.5/3.6 
0% NaBH4, CeCl3 MeOH 20-50% 50-80% (3.5) 
~20% DIBAL, THF, -78º182 80% 0% 
46% 9-BBN, THF183 54% 0% 
96% NaBH(OAc)3, EtOH 4% 0% (3.6) 
61% NaBH3(OAc), EtOH
181 39% 0% (3.6) 
93% NaBH3CN, THF 7% 0% 
86% NaBH4, CeCl3, THF 14% 0% 
0% NaBH4, CeCl3 EtOH 20-90% 10-80% (3.6) 
 
Figure 3.1. Optimization of reduction reaction conditions. Reactions were conducted at room 
temperature with commercially available reagents unless otherwise noted. NaBH3(OAc) was 
prepared in situ by reaction of NaBH4 with 1 equivalent of acetic acid.  
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Ultimately, as a matter of practicality, the Luche reduction with ethanol as a solvent provided 
the most efficient route to compound 3.4. A mixture of the rearranged product 3.6 and allyl alcohol 
3.5 was significantly easier to separate via column chromatography than a mixture of starting 
material 3.4 and allyl alcohol 3.5, owing to similar Rf values. Comparatively, the reduction rate 
was slower in ethanol, allowing the reaction to be quenched before significant quantities of 
rearrangement product could form. This method was broadly applicable to a variety of substrates, 
allowing the synthesis of analogs to proceed. 
 
3.2 Analog Synthesis 
3.2.1 Unsubstituted C6 Analogs 
 
 
Scheme 3.8. Synthesis of analogs 3.8a-g and 3.9 b-d. Reagents and conditions: (a) EDDA, R-
benzaldehyde, acetonitrile, reflux (microwave), 3-5 minutes; (b) NaBH4, CeCl3·7 H2O, ethanol, 
25ºC, 20 minutes. 
 
An initial series of analogs lacking a C6 alkyl chain was synthesized to probe the necessity of 
this group for CB receptor binding. The majority of analogs depicted in Scheme 3.8 were obtained 
in high yields, with the exception of those containing strong electron withdrawing groups in para 
or ortho positions. Aldol coupling of 3.7 with p-nitrobenzaldehyde, for example, resulted in a 14% 
yield, with the reduction affording only trace quantities of 3.9f.  
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Scheme 3.9. Failed compounds. Reagents and conditions: (a) EDDA, R-benzaldehyde, 
acetonitrile, reflux (microwave), 3-5 minutes; (b) NaBH4, CeCl3·7 H2O, ethanol, 25ºC, 20 minutes. 
 
 This series of compounds were submitted for biological analysis in radioligand 
displacement assays for both CB1 and CB2. As depicted in Figure 3.2, none of these compounds 
demonstrated any measure of affinity or selectivity for CB1 or CB2. This was anticipated, given 
the near ubiquitous presence of a saturated alkyl chain in classical cannabinoids, both synthetic 
and phytochemical in origin. Several of the carbonyl intermediates were screened as well, with 
none revealing any affinity for either receptor. The p-methoxy and p-nitro derivaties 3.7d and 3.7f, 
respectively, showed activity in the initial screen, but was later confirmed to be a result of the 
strong yellow color produced by solutions of these compounds. Strongly fluorescent compounds 
inflating scintillation counts is a known phenomenon, as scintillation counting does not directly 
measure beta-particle emission, but rather photon emission from phosphors following their energy 
absorption of beta-particles.186 Compounds 3.7d and 3.7f, being particularly prone to 
tautomerization, can exhibit fluorescence in solution, unsurprising when considering their 
homology to natural product aurones exhibiting chromophoric properties.187 
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Compound 
Concentration 
Tested 
CB1 % 
Displacement 
CB2 % 
Displacement 
3.8a 10 μM 12.6 23.0 
3.8b 10 μM 11.3 28.5 
3.8c 10 μM 38.3 60.0 
3.8d 10 μM 58.0* 83.7* 
3.8e 10 μM 32.7 31.8 
3.8f 10 μM 81.2* 71.4* 
3.8g 10 μM 2.8 5.9 
3.9b 10 μM 11.0 12.0 
3.9c 10 μM 22.6 19.5 
3.9d 10 μM 24.7 27.0 
* = These compounds were highly fluorescent, inflating scintillation counts. In further analysis these compounds 
failed to demonstrate any receptor affinity.  
 
Figure 3.2. CB receptor activity of analogs without an alkyl substitution.   
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3.2.2 C6 Alkyl Analogs 
While the results from the initial series of compounds devoid of an alkyl chain were 
negative, their lack of affinity lent some support to the underlying hypothesis for our compound 
design, as high affinity for the CB receptors would have suggested an alternative binding mode of 
these compounds compared to that of the classical cannabinoids. With these results in hand, we 
turned to synthesizing compounds with the traditional pentyl chain, varying substitutions on the 
coupled phenyl ring (Scheme 3.10).  
 
Scheme 3.10. Synthesis of 6-pentyl analog series. Reagents and conditions: (a) EDDA, 
benzaldehyde, acetonitrile, reflux (microwave) for 3-6 minutes; (b) NaBH4, CeCl3·7 H2O, 
methanol, 25ºC, 5-20 minutes. 
 
 The majority of compounds were obtained as benzyl alcohols 3.11a-j, however as 
previously demonstrated, reduction of para-acetimido analog 3.10j resulted in the formation of 
the ethanol addition product 3.12j. Although this compound did not follow our original compound 
design, it was submitted for cannabinoid receptor screens to probe the influence of substitutions 
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on the exo-methylene group. The substitutions on the coupled benzaldehyde were chosen to 
maximize the SAR guidance from biological results.  
Several compounds synthesized provided additional hydrogen bond acceptors and donors 
and allowed for the further refinement of the SAR. The para-fluoro derivative could provide 
specific evidence for hydrogen bonding interactions. Other analogs synthesized were selected to 
maximize chemical space around the aryl ring for SAR profiling (Figure 3.3).  
 
Figure 3.3. Alkylated series of final compounds. 
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Compound 
Concentration 
Tested 
CB1 % 
Displacement 
CB2 % 
Displacement 
3.11a 
10 μM 43.8 74.8 
0.5 μM 25.9 1.2 
3.11b 
10 μM 66.1 98.1 
0.5 μM 4.7 4.1 
3.11c 
10 μM NT NT 
0.5 μM - 9.9 
3.11d 
10 μM 64.6 41.3 
0.5 μM - - 
3.11e 
10 μM 87.2 78.8 
0.5 μM 4.6 - 
3.11f 
10 μM 51.6 54.6 
0.5 μM 26.0 - 
3.11g 
10 μM 73.2 84.8 
0.5 μM 17.1 8.2 
3.11h 
10 μM 44.8 55.9 
0.5 μM - - 
3.11i 
10 μM 73.2 52.9 
0.5 μM 15.0 26.4 
3.11j 
10 μM 43.0 62.4 
0.5 μM - - 
3.12j 
10 μM 94.5 96.7 
0.5 μM 31.9 57.7 
NT = not tested, - = 0% displacement 
Table 3.1. Screening results for compounds 3.11a-3.11j, 3.12j.  
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The screening data from this series of pentyl-chain aryl-substituted analogs provided some 
interesting SAR insights (Table 3.1). Almost without exception, compounds containing a 
hydrogen bonding group in the para position all displayed the highest radioligand displacement, 
and to our delight, several compounds showed slight selectivity toward the CB2 receptor. Fluoro 
compound 3.11b nearly completely displaced 3H-CP 55,940 at CB2 at 10 μM concentrations, 
compared to 66.1% displacement at CB1, a trend also observed with compounds 3.11a, 3.11g, and 
3.11j. Interestingly, meta-methoxy derivative 3.11d and the disubstituted analog 3.11e displayed 
a slight preference for CB1, in addition to the 4-methylthiazole analog 3.11i. Bromo analog 3.11f 
showed non-selective displacement of approximately 50% at both receptors. These data suggest 
meta-substitution on the coupled phenyl ring may increase CB1 binding potentially at the expense 
of CB2 affinity, and as such we focused on producing additional para-substituted analogs. Perhaps 
most perplexing, however, is the rearrangement product 3.12j. Reduction of the para-acetimido 
carbonyl afforded the ethanol addition product over the allyl alcohol 3.11j at a ratio of 10:1, so 
both products were submitted for receptor screening assays. This compound breaks significantly 
from the predicted mode of binding discussed in chapter 2, and displayed the highest displacement 
at 500 nM by a significant margin, with 31.9% at CB1 and 57.7% at CB2, the best profile for all 
compounds tested. Given the high displacement of the ethanol rearrangement product 3.12j, we 
no longer attempted to circumvent the synthesis of the ethanol addition products, opting to halt the 
reduction at a point when both products were observed on TLC at an approximate 1:1 ratio. Thus 
far, the results of cannabinoid receptor screening were encouraging, affording several compounds 
which bind the cannabinoid receptors with varying degrees of selectivity. To further probe the 
structure activity relationship of this scaffold, additional analogs were synthesized. 
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3.2.3 C7 Alkyl and C6 Ether Analogs 
 
Scheme 3.11. Synthesis of 7-pentylcourmaranone. Reagents and conditions: (a) n-BuLi, THF, 
0ºC, 1 hour, 88%; (b) cat. HClO4, Pd/C, H2, methanol, 25ºC, 2 hours, 87%; (c) AlCl3, BCl3, 
chloroacetonitrile, CH2Cl2, 25ºC, 12 hours, 84%; (d) K2CO3, DMF, 25ºC, 1 hour, 97%. 
 
In addition to the solvent addition products, we also wanted to examine the effect of moving 
the alkyl chain on receptor affinity. Using the same chemistry as that of 6-pentylcoumaranone, 7-
pentylcoumaranone was synthesized with an overall yield of 62.4% in 4 steps using 
salicylaldehyde as a starting material (Scheme 3.11). Compound 3.17 was then subjected to aldol 
couplings with a variety of aldehydes to produce another series of analogs.  
 
Scheme 3.12. Synthesis of 3.19. Reagents and conditions: (a) NaH, 1-bromobutane, DMF, 25ºC, 
16 hours, 61%.  
 
An additional analog series was synthesized incorporating an ether linkage in the alkyl 
chain (Scheme 3.12). Compound 3.19 was synthesized in 1 step from commercially available 6-
hydroxycoumaranone 3.18, by reaction of sodium hydride with 1-bromobutane to yield the ether 
product. This route may also be used to produce analogs with varying alkyl ether substitutions. 
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Scheme 3.13. Synthesis of third analog series. 2.22, 3.17 and 3.19 were used as starting materials 
and coupled with several substituted aldehydes. Reagents and conditions: (a) EDDA, 
benzaldehyde, acetonitrile, reflux (microwave) for 3-6 minutes; (b) NaBH4, CeCl3·7 H2O, 
methanol or ethanol, 25ºC, 5-20 minutes. 
 
 
Figure 3.4. Third series of final compounds. 
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Compound 
Concentration 
Tested 
CB1 % 
Displacement 
CB2 % 
Displacement 
3.21a 
10 μM 29.0 75.5 
2.5 μM 44.0 60.4 
0.5 μM 34.0 30.7 
3.21b 
10 μM 61.6 91.9 
2.5 μM 48.9 84.4 
0.5 μM 44.6 58.9 
3.21c 
10 μM 61.3 79.8 
2.5 μM 49.8 84.4 
0.5 μM 35.6 37.9 
3.21d 
10 μM 71.9 79.6 
2.5 μM 57.0 78.9 
0.5 μM 36.8 56.2 
3.21e 
10 μM 57.1 68.9 
2.5 μM 38.0 48.8 
0.5 μM 37.7 32.0 
3.21f 
10 μM 59.0 83.4 
2.5 μM 44.9 62.2 
0.5 μM 37.7 26.3 
3.21g 
10 μM - 20.1 
2.5 μM 13.0 15.2 
0.5 μM 15.2 15.8 
3.21h 
10 μM 24.3 43.3 
2.5 μM 17.6 30.5 
0.5 μM 14.8 14.0 
 
Table 3.2. Screening results of compounds 3.21a-3.21h. All compounds were screened as 
racemic mixtures at concentrations of 10 μM, 2.5 μM, and 0.5 μM. - = 0% displacement. 
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The third series of compounds, depicted in Figure 3.3, (synthesis illustrated in Scheme 
3.13)  were also screened at 2.5 μM in addition to 10 μM and 0.5 μM to better quantify and evaluate 
receptor binding (Table 3.2). Although the p-fluoro allyl alcohol product was the desired outcome 
from reduction of 3.20a, the ethanol addition product 3.21a was obtained selectively after only 60 
seconds. Nonetheless, this compound was submitted for comparison to its allyl alcohol homolog 
3.11b. Compound 3.21a showed specific binding at CB2, but insignificant displacement at CB1 
at 10 μM. Acetimido analog 3.21b showed nearly identical displacement to its homolog 3.12j at 
58.9% and 57.7%, at CB2, respectively. Although the ether linkage did not confer any benefit in 
CB2 binding or selectivity, it did provide a much welcomed decrease in cLogP from 5.87 to 4.76. 
Reduction of para-acetimido ketone 3.10j in methanol afforded the methanol rearrangement 
product 3.21c, which showed slightly decreased radioligand displacement compared. Exploring 
other para-substitutions, methoxy compounds 3.21d and 3.21e followed a similar trend to that of 
acetimido compounds, in which the ethanol rearrangment displayed much higher receptor binding 
compared to the allyl alcohol.  
 Another series of compounds (3.21f-h), represented by compounds in which the alkyl chain 
was moved ortho to the benzofuran oxygen displayed significantly decreased affinity in all 
analogs. In accordance with previous results, the para-acetimido 7-pentyl homologs 3.21f and 
3.21g displayed slight CB2 selectivity, with increased displacement with ethanol addition product 
3.21f. Shifting the alkyl chain was clearly detrimental, exemplified by 26.3% displacement at CB2 
at 500 nM by 3.21f contrasted with 57.7% by 6-pentyl homolog 3.12j. Thus far, the most 
encouraging results were derived from 3.21b-d, and as such were subjected to determination of 
binding affinities at both CB receptors to better characterize the activity of these compounds. 
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Compound ki CB1 (nM) ki CB2 (nM) CB2/CB1 
3.21b 438.2±141 113.3±12.2 3.87 
3.21c 365.9±166 395.9±45.5 0.92 
3.21d 618.9±254 320.7±27.9 1.93 
 
Figure 3.5. Inhibition constants for 3.21b-d at CB1 and CB2. Compound 3.21d was found to 
be nearly equipotent and both receptors, with mid-nanomolar affinity, whereas compounds 3.21b 
and 3.21c were found to have nanomolar affinity for both receptors with 3.87 and 1.93-fold 
selectivity for CB2 over CB1, respectively. 
 
 These data provided significant insights into the SAR of these rearranged compounds. 
Firstly, para-methoxy analog 3.21d displayed approximately 2-fold selectivity for CB2 over CB1, 
with a binding affinity of 320.7±27.9 nM at CB2 (Figure 3.5). Compared with compound 3.21b 
which showed an approximate 4-fold selectivity for CB2 over CB1 with a binding affinity of 
113.3±12.2 nM. This is starkly contrasted with compound 3.21c, the methanol addition acetimido 
analog, with displayed no selectivity and diminished affinity for both receptors. The acetimido 
substitution provides the highest binding affinity at both receptors, and the ether linkage in 
compound 3.21b may in fact provide a modest increase in binding affinity, contradicting the 
screening data. Perhaps most striking however, is the complete lack of selectivity in methanol 
addition compound 3.21c compared to ethanol addition 3.21b and 3.21d. It is conceivable that the 
size of this group on the addition products may be imparting receptor selectivity.  
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3.2.4 Rearranged C6 Alkyl and Naphthyl Analogs 
 To test these hypotheses, an additional series of analogs with specific substitutions on the 
exo-methylene position was warranted. Fluoro substituted analogs were prioritized instead of those 
containing acetimido group due to low yields in the synthesis of these compounds. The fluoro 
analogs have showed modest activity in previous CB receptor screens, and the synthesis of fluoro 
analogs was much more efficient. 
 
 
Scheme 3.14. Synthesis of analogs 3.22-3.25. Reagents and conditions: (a) EDDA, 4-
fluorobenzaldehyde, acetonitrile, reflux (microwave) for 4 minutes, 71.8%; (b) NaBH4, CeCl3·7 
H2O, methanol, 25ºC, 2 minutes, 69.7%; (c) NaBH4, CeCl3·7 H2O, ethanol, 25ºC, 2 minutes 
74.8%; (d) glacial acetic acid, bromine, 25ºC, 1 hour, 86.9%. (e) 6N HCl, THF, 25 ºC, 1 hour, 
55.8%;  
 
 Synthesis of the para-fluoro ketone 3.10b with the previously used method of the EDDA 
catalyzed aldol condensation reaction provided a key intermediate (Scheme 3.14). Reduction of 
the carbonyl under Luche conditions in methanol afforded the methanol addition product 3.22. A 
substitution reaction was performed in acidic conditions to afford the hydroxy analog 3.25. 
Reduction of the ketone 3.10b in ethanol afforded product 3.23 in high yields. In an attempt to 
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brominate this product, 3.23 was reacted with bromine in glacial acetic acid, however, no 
bromination products were obtained, and instead acetate 3.24 was isolated in excellent yields. 
Notably, this reaction does not proceed in the absence of bromine, suggesting 3.24 is formed 
through a bromine mediated dealkylation reaction.  
 
Figure 3.6. Computational superimposition of 3.11b and RS-028. RS-028 is displayed in 
magenta, and 3.11b in cyan. Energy minimization of the RS-028 resulted in the chain adopting a 
different conformation than that of 3.11b, so it was truncated to a methyl group after energy 
minimization calculations. Given the that this is a rotatable bond, it is reasonable to presume the 
chain of RS-028 could adopt the same conformation of 3.11b. Figure was produced using Chem3D 
(Perkin-Elmer) and PyMol. 
 
 Another analog investigated originated from comparison of the CB2 selective compound 
RS-028 with 3.11b (Figure 3.6). Computational alignment of the benzofuran ring of 3.11b with 
the 4-oxo-tetrahydroquinoline of RS-028 resulted reasonable superimposition, with the carbonyl 
and amide of RS-028 and the allylic hydroxy and benzofuran oxygen of 3.11b, respectively. The 
hydrophobic groups of both compounds also superimpose. This raised the possibility that these 
two compounds, while structurally diverse, may be adopting a similar binding mode at the CB 
receptors. Compound 3.11b, however, was lacking the additional ring of RS-028, which if added 
to our scaffold may provide a significant increase in CB2 selectivity.  
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 It was anticipated the desired naphthyl analogs were accessible through 3-hydroxy-1-
naphthaldehyde, utilizing the previously established synthetic procedure for 2.22. Bromination of 
commercially available 1-naphthylamine (3.26) afforded 3.27, which was subjected to 
diazotisation with sodium nitrite to form diazo compound 3.28 (Scheme 3.15).188,189 
Unfortunately, reduction of this compound with sodium borohydride did not afford significant 
quantities of 3.29, and the instability of diazo compound 3.28 made characterization and 
purification a challenge. 
 
Scheme 3.15. Synthesis of 3-hydroxy-1-naphthaldehyde. Reagents and conditions: (a) glacial 
acetic acid, bromine, 0ºC  60ºC, 30 minutes, proceeded with purification or characterization; (b) 
sodium nitrite, glacial acetic acid, propionic acid, 0ºC, 10 minutes, proceeded with purification or 
characterization; (c) sodium borohydride, ethanol, 0ºC, 3 hours, 18.7%; (d), N-formylpiperidine, 
NaH, n-BuLi, ethyl ether, 25ºC. 
 
Fortunately, a recent report provided a more efficient procedure for the synthesis 3-
pentylnaphthol (Scheme 3.16).190 Starting with commercially available phenylacetyl chloride 
(3.31), tandem Friedel-Crafts acylation with 1-heptyne afforded 4-pentyl-2-naphthol 3.32. 
Proceeding in similar fashion using established chemistry, Sugasawa acylation of 3.32 to form the 
alpha-chloroketone 3.33 and cyclization with potassium carbonate afforded the 
naphthylcoumaranone prescursor 3.34 in excellent yields.  
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Scheme 3.16. Synthesis of naphthyl final compound 3.36. Reagents and conditions: (a) AlCl3, 
1-heptyne, 0ºC25ºC, 2 hours, 90%; (b) BCl3, AlCl3, chloroacetonitrile, DCM, , 0ºC25ºC, 16 
hours, 73%; (c) .K2CO3, DMF, 25ºC, 2 hours, 87%. (d) EDDA, 4-fluorobenzaldehyde, acetonitrile, 
reflux (microwave) for 10 minutes, 36.0%; (e) NaBH4, CeCl3·7 H2O, ethanol, 25ºC, 20 minutes 
30.5%. 
 
 With precursor 3.34 in hand, the final naphthyl derivative 3.36 was obtained in moderate 
yields following standard aldol/reduction protocols. An additional analog with the naphthyl ring 
system moved to the coupled side chain was also synthesized. Using 7-pentylcoumaranone 2.22, 
final compound 3.38 was synthesized in two steps (Scheme 3.17). The allyl alcohol product was 
not isolated from the reduction step. 
 
 
Scheme 3.17. Synthesis of naphthyl analog 3.38. Reagents and conditions: (a) EDDA,  
2-methoxynaphthaldehyde, acetonitrile, reflux (microwave), 7 minutes, 84.0%; (b) NaBH4, 
CeCl3·7 H2O, ethanol, 25ºC, 20 minutes 19.7%.  
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Compound 
Concentration 
Tested 
CB1 % 
Displacement 
CB2 % 
Displacement 
3.22 
10 μM 84.8 87.4 
2.5 μM 72.1 53.8 
0.5 μM 35.1 23.3 
3.23 
10 μM 59.5 82.1 
2.5 μM 51.2 78.2 
0.5 μM 24.3 39.6 
3.24 
10 μM 79.7 90.1 
2.5 μM 62.4 61.9 
0.5 μM 42.2 46.7 
3.25 
10 μM 75.5 86.4 
2.5 μM 19.9 46.4 
0.5 μM 1.6 10.8 
3.36 
10 μM 84.8 85.4 
2.5 μM 70.7 77.8 
0.5 μM 1.1 30.7 
3.38 
10 μM 50.7 83.8 
2.5 μM 19.4 64.4 
0.5 μM 9.2 49.3 
Figure 3.7. Screening results for compounds 3.22-3.25, 3.36 and 3.38.  
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Compound ki CB1 (nM) ki CB2 (nM) CB2/CB1 
3.22 200.7 ± 84.4 323.7 ± 95.7 0.62 
3.23 740.0 ± 328.9 296.1 ± 114.0 2.50 
3.24 565.6 ± 188.5 461.7 ± 118.8 1.23 
3.25 3,768 ± 1890 990.0 ± 176.3 3.81 
3.36 505.1 ± 205.2 229.8 ± 27.4 2.20 
3.38 2,206 ± 1223 78.36 ± 18.63 28.15 
 
Table 3.3. CB2 binding affinities for 3.22-3.25, 3.36, and 3.38. Determination of CB1 binding 
affinities is currently pending at the time of this writing.  
 
 The CB receptor activities of these compounds reveal important SAR trends (Figure 3.7, 
Table 3.3). Compounds 3.22-3.25 are particularly informative as to the relationship between the 
exo-methylene substitution and receptor binding. Similar to compounds 3.21b and 3.21c, the 
methoxy rearrangement compound 3.22 maintains moderate affinity for CB2 at 323.7 nM, with 
the screening results indicating non-selective binding at both CB receptors. The replacement of 
this methoxy group with the slightly larger ethoxy induces modest CB2 selectivity, with a ki of 
296.1 nM at CB2 and a ki of 740 nM at CB1. Interestingly, acetate containing 3.24 has lower 
affinity for CB2 at 461.7 nM, and potentially a similar affinity for CB1 based on the screening 
data. The decreased affinity and selectivity of 3.24 as compared to 3.23 suggests the CB2 receptor 
may prefer more hydrophobic substitutions in this position, and the addition of the carbonyl may 
generate favorable interactions with CB1. Hydroxy containing compound 3.25 possesses poor 
affinity for both receptors, reinforcing the importance of larger groups in this position of the 
scaffold for receptor binding. Naphthyl containing 3.36 was designed to mimic the known CB2 
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selective compound RS-028 by the inclusion of an additional phenyl ring to occupy the same 
volume as RS-028. This hypothesis, however, does not seem to be supported by the biological 
data. Compound 3.36 and its homolog 3.23 possess virtually identical affinities for CB2, and very 
similar radioligand displacement at CB1 at all three concentrations tested. The additional ring on 
3.6 does not seem to enhance either CB2 receptor affinity or selectivity, indicating our compounds 
are not likely adopting the same binding mode RS-028. Surprisingly, compound 3.38 displayed 
remarkably improved CB2 affinity with a ki of 78.36 nM, and 28-fold selectivity for CB2 over 
CB1. Compound 3.38 is the most potent compound discovered in this dissertation research. The 
utilization of a naphthyl group does have precedent in compound 70 (Chapter 1), however this 
compound did not exhibit any selectivity for either receptor (CB1 = 11.7±1.6 nM, CB2 = 9.4±1.5 
nM). The dramatically different affinities of 3.38 compared to 3.36 alleviate the concern that the 
symmetry of these molecules may cause multiple binding modes, and suggest a more specific 
binding mode in the CB2 receptor.  
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3.3 Conclusions and Future Directions 
Cannabinoid receptor targeted therapeutics have been an area of great focus for several 
decades now, and with the exception of the Δ9-THC analog Nabilone, no synthetic compound has 
successfully been brought to market. Compounds targeting the CB2 receptor may have utility in 
the treatment of inflammation, diabetes, cancer, pain, and numerous other ailments, and significant 
effort has been devoted to the development of CB2 selective compounds.191 CB2 selective 
candidates thus far, however, have all failed in clinical trials due to a lack of efficacy and/or 
eliciting CB1 mediated side effects, even with many showing several hundred-fold selectivity for 
CB2 over CB1. These clinical failures were indicative that new approaches were needed for 
targeting CB2 utilizing novel scaffolds with significantly greater selectivity. 
This project constitutes such an approach; to develop a novel scaffold targeting the 
cannabinoid receptors, based on the pharmacophoric features of the phytocannabinoids 10a-OH 
THC. While the original scaffold design proposed was found to bind to the cannabinoid receptors, 
another benzofuran scaffold with a substituted exo-methylene group was found to have 
significantly higher affinities for the CB2 receptor, with one compound possessing 78.36 nM 
affinity at CB2. This compound was found to be 28-fold selective for CB2 over CB1. While this 
is certainly interesting biological activity, these compounds leave much to be desired in their lack 
of “drug-likeness.” Compound 3.38 for example, has a cLogP of 7.94, which far above the 
recommendation of 5 or less based on Lipinski’s Rule of 5.192 However, this compound provides 
an interesting starting point for further work to explore the structure activity relationship of this 
scaffold. This compound, and the others presented in this work represent new additions to CB2 
targeting small molecules, utilizing a novel scaffold previously unknown to the cannabinoid 
receptors. 
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3.3.1 Structure Activity Relationship Elucidation 
 
Figure 3.8. Proposed SAR elements of the benzofuran scaffolds. Regions of the scaffold 
significantly affect receptor binding are highlighted. Alternative substitutions on the alkyl side 
chain, such as those highlighted in Chapter 1, may be employed to increase receptor affinity. The 
benzylic substitutions examined thus far are hydroxy, methyl, ethyl and acetate groups; the use of 
larger non-polar and polar groups may enhance receptor selectivity. The coupled side chain may 
also play a significant role in both receptor affinity and selectivity. The use of a naphthyl group 
greater enhance CB2 affinity and selectivity, and analogs with other groups in this region need to 
be explored. 
 
The final assay results of this project suggest numerous possibilities for improving the 
affinity and selectivity of this scaffold. Surprisingly, it is not the originally proposed  
3-hydroxybenzofuran scaffold with the best receptor activity, but the rearranged benzofuran 
compounds with benzylic substitutions. Thus far, the largest groups tested here have been ethyl 
and acetate functionalities. The relatively low affinity of the acetate group suggests more lipophilic 
groups here may be better tolerated by the CB2 receptor, however this needs to be further explored 
with larger groups such as phenyl rings and heterocycles. There remains much potential in this 
new scaffold for exploration and optimization of CB2 receptor affinity (Figure 3.8). Given that 
these products are essentially obtained a side products of a reduction step, a synthetic route 
providing direct access to these compounds would be prudent.  
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3.3.2 Alternate Strategy for Analog Synthesis 
 
Scheme 3.18. Proposed synthesis of exo-methylene substituted benzofurans. Reagents and 
conditions: (a) NaBH4, then HCl, 1,4-dioxane, 25ºC, 2 hours; (b) n-BuLi, aldehyde, -78ºC, 4 
hours; (c) trimethylamine, 4-toluenesulfonyl chloride, 25ºC, 1 hour; (d) nucleophile, DMF or 
acetone, 25-60ºC, 6 hours.  
 
The most expeditious route to these compounds, illustrated in Scheme 3.18, utilizes 2.22 as 
a starting material to synthesize 6-pentylbenzofuran 3.39 via reduction and elimination. Synthesis 
of the organolithium base of 3.39 using n-butyllithium allows for nucleophilic addition to a 
substituted benzaldehyde or naphthaldehyde to give 3.40 To probe the SAR of the benzylic 
position, SN2 chemistry provides the most efficient route to analog synthesis. However, earlier 
work has shown this hydroxy group to be a poor leaving group, requiring harsh conditions to 
facilitate substitution at this position. Tosylation of 3.40 provides an excellent leaving group that 
should allow for the addition of a variety of nucleophiles to 3.41. An immediate focus of future 
work will be decreasing the lipophilicity of these compounds, while simultaneously further SAR 
elucidation.  
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Scheme 3.19. Proposed synthesis of quinoline analogs. 2-quinoline analog is displayed as a 
representative example. Compounds can be synthesized using chemistry depicted in Scheme 3.17, 
using commercially available quinolinecarboxaldehydes; all isomers of this quinoline are readily 
available. 
 
 Given the selective and potent activity of 3.38 for the CB2 receptor, it would be sensible 
to explore the SAR of the naphthyl ring. An expedient strategy to accomplish this would be the 
use of quinolines in place of the naphthyl ring, probing the receptor binding site while 
simultaneously providing a much welcomed decrease in lipophilicity (Scheme 3.19). All 
carboxaldehydequinoline isomers (2-8 substituted) are commercially available from Sigma-
Aldrich and other vendors. Optimization of this ring system in conjunction with optimizing the 
benzylic substitution may provide highly selective and potent leads that may be more suitable for 
further biological analysis.  
Other strategies to increase polarity would be the incorporation of heteroatoms in the alkyl 
chain, similar to the strategy used in compounds 3.21a and 3.21b. If these compounds bind to the 
CB receptors in a similar fashion to that of the classical cannabinoids, the alkyl chain can be 
extensively functionalized with a number of different heteroatom containing groups such as esters, 
carboxylic acids, ethers, heterocycles and others. The C3 alkyl analogs presented in Chapter 1 may 
be instructive in achieving increased polarity and receptor affinity.  
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CHAPTER 4  
EXPERIMENTAL PROCEDURES AND COMPOUND DATA 
General Methods 
All reagents and starting materials were purchased from Sigma-Aldrich (St. Louis, MO), 
Acros Organics/Thermo Fisher Scientific (Waltham, MA) or Accela ChemBio Inc. (San Diego, 
CA). All anhydrous solvents were purchased in bottles with molecular sieves (4Å). Air-free and 
moisture sensitive reactions were carried out using standard air-free techniques in flame dried 
glassware under an argon atmosphere. Thin-layer chromatography was utilized to monitor 
reactions with 225 μm aluminum backed TLC plates coated with silica gel 60 F254 (EMD Millipore, 
Billerica, MA). TLC plates were visualized with UV light (254 nm) and staining with ethanolic p-
anisaldehyde, potassium permanganate, or phosphomolybdic acid. Mass spectrometry (low 
resolution) experiments were performed on a Waters Micromass ZQ single quadrupole mass 
spectrometer using either ESI positive (ESI+) or ESI negative (ESI-) electrospray ionization. 
Proton (1H) and carbon (13C) NMR spectra were recorded on Bruker 400 MHz Avance NMR 
spectrometers and processed using MNova NMR (Mestrelab Research).  
Cannabinoid receptor binding assays 
Cannabinoid receptor assay were conducted by COBRE Core C at The University of 
Mississippi. Assays were conducted in accordance with the method republished below in 
Tarawneh et al.193 "Reprinted with permission from Tarawneh, A. et al., Flavonoids from 
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Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for 
Human Opioid and Cannabinoid Receptors. Journal of Natural Products, 2015. 78(6): p. 1461. 
Copyright (2015) American Chemical Society." 
Cell Culture and Membrane Preparation. 
 HEK293 cells (ATCC) were stably transfected with plasmids containing cloned human 
cannabinoid receptor subtypes 1 and 2 (obtained from Origene, Rockville, MD, USA). These cells 
were maintained in a humidified incubator at 37°C and 5% CO2 in a Dulbecco’s modified Eagle’s 
medium (DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum, 1000 IU/mL penicillin, and 1000 μg/mL of streptomycin, and 0.5 mg/mL G418 
antibiotic solution. Membranes for the radioligand binding assays were prepared by scraping the 
cells in cold Tris-HCl, pH 7.4, and then centrifuged at 5200 g for 10 min at 4°C. The supernatant 
was discarded, and the pellet was resuspended in the same buffer, homogenized using a sonic 
dismembrator model 100 (Fisher Scientific, Pittsburgh, PA, USA) for 30 seconds, and then 
centrifuged at 1000g for 10 min at 4°C. The supernatant was saved, and the pellet underwent the 
suspension and sonication process two additional times under the same conditions. The 
supernatants were combined and centrifuged at 23300g for 40 minutes at 4°C. The pellet was 
resuspended and aliquoted into 2 mL vials and stored at −80 °C. The total protein concentration 
was determined using a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) 
according to the manufacturer’s instructions. The optimal membrane and radioligand 
concentrations for each receptor batch were established through membrane evaluation and 
saturation binding experiments.  
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Radioligand Displacement for Cannabinoid Receptor Subtypes.  
Compounds evaluated in this assay were run in competition binding with both cannabinoid 
receptor subtypes, CB1 and CB2. CB receptor binding screening was performed under the 
following conditions: 10 μM of each compound from independent triplicate dilutions was 
incubated with 1.6975 nM (CB1) or 1.959 nM (CB2). [3H]-CP 55,940, and 5 μg of CB1 or 1 μg 
of CB2 membrane were incubated for 90 min at 37°C with gentle agitation in a 96-well plate in a 
0.2 mL final volume of 50 mM Tris-HCl, 20 mM EDTA, 154 mM NaCl, and 0.2% 
radioimmunoassay grade BSA, pH 7.4. The reaction was terminated via rapid vacuum filtration 
through a UniFilter 96 GF/C filter (PerkinElmer Life Sciences Inc., Boston, MA, USA), presoaked 
with 0.3% polyethylenimine, followed by 10 washes with 50 mM Tris-HCl, pH 7.4, buffer 
containing 0.2% BSA. Filters were dried, 25 μL of MicroScint20 was added, and the plates were 
read using a TopCount NXT microplate scintillation counter (PerkinElmer Life Sciences Inc., 
Boston, MA, USA). Total binding was defined as binding in the presence of vehicle (1.0% 
DMSO). Nonspecific binding was the binding observed in the presence of 10.0 μM CP-55,940. 
Specific binding was defined as the difference between total and nonspecific binding. Percent 
displacement was calculated using the following formula: 100-(binding of compound - nonspecific 
binding) x (100/specific binding). 
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(2.2)  5-Chloro-2-(1-hydroxy-3-phenylprop-2-yn-1-yl)phenol 
Phenylacetylene (3.09 mL, 28.10 mmol) was dissolved in 25 mL anhydrous THF under argon, to 
which a 3.0M solution of methylmagnesium chloride in THF (9.37 mL, 28.10 mmol) was added 
dropwise. The reaction was stirred for 1 hour, or until expulsion of methane from the solution 
ceased. A solution of 4-chlorosalicyladehyde (2.1, 2.00 g, 12.77 mmol) in 25 mL anhydrous THF 
was then added, and the reaction stirred for 2 hours. The reaction was diluted with sat. NH4Cl and 
extracted with ethyl acetate (EtOAc). Organic extracts were combined, dried with MgSO4, filtered 
and concentrated in vacuo to afford crude 2.2 as a yellow oil. Purification via column 
chromatography (20% EtOAc/Hexanes) afforded 2.76 g (83.4%) of pure 2.2 as a white powder. 
MS (ESI+) m/z = 241.18 [M-OH]+, 283.17 [M+Na]+. 1H NMR  (400 MHz, Acetone-D6) δ 7.60 
(d, J = 8.8 Hz, 1H), 7.45 (dd, J = 6.6, 3.1 Hz, 2H), 7.41 – 7.32 (m, 3H), 6.99 – 6.90 (m, 2H), 5.98 
(s, 1H). 13C NMR (101 MHz, CDCl3) δ 156.07, 135.43, 131.84, 129.09, 128.62, 128.42, 123.01, 
121.67, 120.38, 117.53, 88.61, 85.96, 64.07. 
 
(2.3)  (Z)-2-benzylidene-6-chloro-2,3-dihydrobenzofuran-3-ol 
Using a procedure adapted from Harkat et al.,145 To solution of 2.2 (400.0 mg, 1.55 mmol) and 
K2CO3 (21.4 mg, 0.16 mmol) in 10 mL anhydrous acetonitrile, was added AuCl (35.9 mg, 0.16 
mmol), and stirred under argon for 16 hours. The reaction was diluted with H2O and extracted with 
EtOAc. Organic extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to 
afford crude 2.3 as a yellow oil. Purification via column chromatography (20% EtOAc/Hexanes) 
afforded 372.2 mg (93%) of yellow solid. MS (ESI+) m/z = 241.19 [M-OH]+, 283.21 [M+Na]+. 
1H NMR  (400 MHz, Acetone-D6) δ 7.73 (d, J = 7.4 Hz, 2H), 7.50 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 
97 
7.7 Hz, 2H), 7.28 – 7.17 (m, 2H), 7.13 (dd, J = 8.0, 1.8 Hz, 1H), 6.04 (d, J = 1.2 Hz, 1H), 5.80 (s, 
1H), 5.31 – 5.10 (m, 1H). 13C NMR (101 MHz, Acetone-D6)  δ 158.31, 157.94, 134.81, 134.75, 
128.52, 128.35, 126.80, 126.60, 122.78, 110.73, 105.55, 70.95.  
 
(2.7)    (Z)-((2-benzylidene-6-chloro-2,3-dihydrobenzofuran-3-yl)oxy)(tert-butyl)dimethylsilane 
Using a procedure adapted from Corey et al.,194 2.6 (308.0 mg, 1.19 mmol) was dissolved in 5 mL 
anhydrous DCM and stirred under argon at room temperature. Imidazole (243.1 mg, 3.57 mmol) 
and TBSCl (197.4 mg, 1.31 mmol) were added, and the reaction stirred for 3 hours. The reaction 
was poured into sat. NH4Cl and extracted with DCM. The combined organic fractions were dried 
with MgSO4, filtered and concentrated in vacuo, affording a crude yellow oil. Purification via 
column chromatography (20% EtOAc/hexanes) gave 2.7 as a clear oil. 250.3 mg (56.4%). MS 
(ESI+) m/z = 395.82 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.92 (d, J = 6.9 Hz, 2H), 7.77 (d, 
J = 8.2 Hz, 1H), 7.51 – 7.43 (m, 4H), 7.40 (d, J = 1.6 Hz, 1H), 7.24 (dd, J = 8.2, 1.6 Hz, 1H), 6.94 
(s, 1H), 1.28 (s, 9H), 0.89 (s, 6H). 
 
(2.10)  4-Formyl-3-hydroxyphenyl trifluoromethanesulfonate:  
2,4-dihydroxybenzaldehyde (2.9, 1.00 g, 7.24 mmol) was dissolved in 25 mL anhydrous DCM, 
and stirred under argon. 2,6-Lutidine (0.92 mL, 7.96 mmol) was added, and the reaction cooled to 
0ºC, followed by dropwise addition over 1 hour of triflic anhydride (1.34 mL, 7.96 mmol). Upon 
complete addition of triflic anhydride the reaction turned dark pink; TLC (20% EtOAc/Hexanes) 
at this time indicated complete conversion of the starting material. The reaction was poured into 
50 mL 1.0 N HCl and extracted with DCM. Organic extracts were combined, dried with MgSO4, 
98 
filtered and concentrated in vacuo to afford crude 2.10 as a red oil. Purification via column 
chromatography (20% EtOAc/Hexanes) afforded 1.02 g pure 2.10 as a clear oil (52.1%). MS (ES-
) m/z = 269.061 [M-H]- 1H NMR  (400 MHz, CDCl3) δ 11.28 (s, 1H), 9.92 (s, 1H), 7.69 (d, J = 
8.5 Hz, 1H), 6.99 – 6.85 (m, 2H). 
 
(2.11) 3-Hydroxy-4-(1-hydroxy-3-phenylprop-2-yn-1-yl)phenyl trifluoromethanesulfonate 
Same procedure used for 2.2. Phenylacetylene (2.03 mL, 18.50 mmol) was dissolved in 20 mL 
anhydrous THF under argon, to which a 3.0M solution of methylmagnesium chloride in THF (5.42 
mL, 16.29 mmol) was added dropwise. The reaction was stirred for 1 hour, or until expulsion of 
methane from the solution ceased. A solution of 2.10, (2.0 g, 7.40 mmol) in 20 mL anhydrous THF 
was then added, and the reaction stirred for 2 hours. The reaction was diluted with sat. NH4Cl and 
extracted with ethyl acetate (EtOAc). Organic extracts were combined, dried with MgSO4, filtered 
and concentrated in vacuo to afford crude 2.11 as a yellow oil. Purification via column 
chromatography (20% EtOAc/Hexanes) afforded 2.03 g (73.6%) of pure 2.11 as a white powder. 
MS (ESI+) m/z = 395.08 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.53 (d, J = 8.5 Hz, 1H), 7.48 
(dd, J = 7.7, 1.7 Hz, 3H), 7.34 (q, J = 6.4 Hz, 4H), 6.90 – 6.76 (m, 2H), 5.93 (s, 1H). 13C NMR 
(101 MHz, CDCl3) δ 156.65, 150.03, 131.77, 129.04, 128.99, 128.39, 125.56, 121.81, 112.49, 
110.01, 88.13, 86.20, 63.10. 
 
(2.12) (Z)-2-benzylidene-3-hydroxy-2,3-dihydrobenzofuran-6-yl trifluoromethanesulfonate 
Using a procedure adapted from Harkat et al.,145 to solution of 2.11 (1.87 g, 5.03 mmol) and K2CO3 
(69.5 mg, 0.50 mmol) in 20 mL anhydrous acetonitrile was added AuCl (116.9 mg, 0.50 mmol), 
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and stirred under argon for 16 hours. The reaction was diluted with H2O and extracted with EtOAc. 
Organic extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to afford 
crude 2.12 as a yellow oil. Purification via column chromatography (20% EtOAc/Hexanes) 
afforded 1.177 g (62.8%) of yellow solid. MS (ESI+) m/z = 395.08 [M+Na]+. 1H NMR  (400 
MHz, CDCl3) δ 7.67 (d, J = 7.5 Hz, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.32 – 
7.26 (m, 1H), 7.04 – 6.95 (m, 2H), 6.02 (s, 1H), 5.72 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 
158.37, 156.31, 150.57, 133.73, 128.80, 128.55, 127.44, 127.36, 126.79, 120.31, 117.12, 115.82, 
107.34, 104.85, 71.46. 
 
(2.13)  (Z)-2-benzylidene-3-((tert-butyldimethylsilyl)oxy)-2,3-dihydrobenzofuran-6-yl 
trifluoromethanesulfonate 
Using a procedure adapted from Corey et al.,194 to a solution of 2.12 (1.18 g, 3.16 mmol) in 
anhydrous DCM was added imidazole (1.94 g, 28.44 mmol) and TBSCl (1.67 g, 11.06 mmol). The 
reaction was stirred under argon for 2 hours, poured into sat. NH4Cl and extracted with DCM. 
Organic extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to afford 
crude 2.13 as a clear oil. Purification via column chromatography (10% EtOAc/Hexanes) afforded 
1.433 g (93.2%) of clear oil. MS (ESI+) m/z = 509.22 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 
7.71 (d, J = 7.6 Hz, 2H), 7.50 – 7.37 (m, 3H), 7.29 (t, J = 7.9 Hz, 1H), 7.08 – 6.97 (m, 2H), 5.92 
(d, J = 3.7 Hz, 2H), 0.98 (s, 9H), 0.22 (s, 3H), 0.17 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 158.39, 
156.50, 150.38, 134.08, 128.72, 128.50, 128.13, 127.09, 126.56, 115.48, 107.12, 104.75, 72.07, 
25.72, 18.02, -3.76, -3.97.  
100 
(2.8)  (Z)-((2-benzylidene-6-pentyl-2,3-dihydrobenzofuran-3-yl)oxy)(tert-
butyl)dimethylsilane 
Using a procedure adapted from Fürstner et al.,169 a solution of 2.13 (165.3 mg, 0.34 mmol) and 
Fe(acac)3 (6 mg, 0.02 mmol) in 0.200 mL anhydrous N-methyl-2-pyrrolidone (NMP) and 2 mL 
anhydrous THF, was cooled to 0ºC and stirred under argon for 5 minutes. A solution of 
pentylmagnesium bromide (2.0 M in ether; 0.203 mL, 0.41 mmol) was added dropwise over 1 
minute. Immediately upon adding the Grignard reagent, the reaction turned from a dark red color 
to a very dark purple. TLC (10% EtOAc/Hexanes) showed no remaining starting material within 
5 minutes of adding Grignard reagent. The reaction was quenched with sat. NH4Cl and extracted 
EtOAc. Organic extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to 
afford crude 2.8 as a yellow oil. Purification via column chromatography (20% EtOAc/Hexanes) 
afforded 27.9 mg (20.1%) of pure 2.8 as a yellow oil. MS (ESI+) m/z = 277.19 [M-OTBS] +, 
408.93 [M+H]+, 431.32 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 7.6 Hz, 2H), 7.44 (t, 
J = 7.7 Hz, 3H), 7.35 (d, J = 7.6 Hz, 1H), 6.99 – 6.91 (m, 2H), 5.93 (d, J = 8.0 Hz, 2H), 2.75 – 2.66 
(m, 2H), 1.71 (p, J = 7.5 Hz, 2H), 1.48 – 1.39 (m, 5H), 1.03 (s, 11H), 0.23 (s, 3H), 0.18 (s, 3H).  
(2.16)  Methyl 4-chloro-2-hydroxybenzoate  
Following Sigma Aldrich Technical Bulletin 180. CAUTION: Diazomethane is extremely 
explosive and toxic with improper use. Sigma Aldrich Diazald Kit P/N# Z100250 with polished 
Clear-Seal® Joints. 
5.00 g potassium hydroxide was dissolved in 10 mL 95% ethanol in a 50 mL round bottom flask 
fitted with a condenser and heated to 65ºC. The receiving flask was charged with a solution of  
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4-chlorosalicylic acid (2.76 g, 16.00 mmol). A solution of Diazald (5 g, 23.00 mmmol) in 30 mL 
diethyl ether was added dropwise via addition funnel to the potassium hydroxide solution. A 
solution of diazomethane in ether will distill into the receiving flask at approximately the rate of 
Diazald addition. Once Diazald solution was completely added, another 10 mL diethyl ether was 
added to rinse the distillation apparatus, and the receiving flask disconnected. The reaction was 
allowed to stir open to the atmosphere to evaporate remaining unreacted diazomethane, observable 
by a yellow color. Once the reaction turned clear, the solution was concentrated in vacuo, yielding 
2.98 g (99.7%) pure 2.16 as a clear oil. MS (ESI-) m/z = 185.03 [M-H]-. 1H NMR (400 MHz, 
CDCl3) δ 10.83 (s, 1H), 7.71 (d, J = 8.6 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 6.82 (dd, J = 8.6, 2.0 
Hz, 1H), 3.93 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.91, 162.08, 141.34, 130.83, 119.76, 
117.65, 110.95, 52.38. 
(2.17)  Methyl 2-((tert-butyldimethylsilyl)oxy)-4-chlorobenzoate 
Using a procedure adapted from Corey et al.,194 to a solution of 2.16 (2.98 g, 15.96 mmol) in 30 
mL anhydrous DMF was added imidazole (1.09 g, 15.96 mmol) and TBSCl (2.41 g, 15.96 mmol). 
The reaction was stirred under argon for 2 hours. The reaction was poured in sat. NH4Cl and 
extracted with EtOAc. The combined organic extracts were washed with 10 x 30 mL H2O, dried 
with MgSO4, filtered and concentrated in vacuo to afford a crude clear oil. Purification via column 
chromatography (20% EtOAc/Hexanes) afforded 4.63 g (96.4%) of 2.17 as a clear oil. MS (ESI+) 
m/z = [323.72]+. 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.4 Hz, 1H), 6.98 (dd, J = 8.4, 1.9 Hz, 
1H), 6.88 (d, J = 1.9 Hz, 1H), 3.86 (s, 3H), 1.03 (s, 9H), 0.25 (s, 6H). 13C NMR (101 MHz, CDCl3) 
δ 166.27, 155.96, 138.50, 132.69, 121.37, 121.32, 121.26, 51.86, 25.57, 18.25, -4.44. 
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(2.18)  Methyl 2-((tert-butyldimethylsilyl)oxy)-4-pentylbenzoate 
Using a procedure adapted from Fürstner et al.,169 a solution of 2.17 (4.63 g, 15.39 mmol) and 
Fe(acac)3 (271.6 mg, 0.77 mmol) in 10 mL anhydrous N-methyl-2-pyrrolidone (NMP) and 100 
mL anhydrous THF, was cooled to 0ºC and stirred under argon for 5 minutes. A solution of 
pentylmagnesium bromide (2.0 M in ether; 8.0 mL, 16.00 mmol) was added dropwise over 5 
minutes. Immediately upon adding the Grignard reagent, the reaction turned from a dark red color 
to yellow, and eventuall to a very dark purple. TLC (20% EtOAc/Hexanes) showed no remaining 
starting material within 5 minutes of finishing the Grignard addition. The reaction was quenched 
with sat. NH4Cl and extracted EtOAc. Organic extracts were combined, dried with MgSO4, filtered 
and concentrated in vacuo to afford a crude yellow oil. Purification via column chromatography 
(20% EtOAc/Hexanes) afforded 4.94 g (95.5%) of pure 2.18 as a yellow oil. MS (ESI+) m/z = 
337.37 [M+H] +, 360.43 [M+Na] +. 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.66 (m, 1H), 6.80 (d, J 
= 8.0 Hz, 1H), 6.69 (s, 1H), 3.84 (s, 4H), 2.57 (t, J = 7.6 Hz, 2H), 1.60 (p, J = 7.3 Hz, 2H), 1.31 
(h, J = 6.6 Hz, 5H), 1.03 (s, 10H), 0.89 (t, J = 6.9 Hz, 3H), 0.22 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 167.09, 155.20, 148.86, 132.68, 131.65, 121.36, 121.28, 121.22, 119.93, 51.53, 35.69, 
31.26, 30.56, 25.68, 25.56, 22.47, 18.27, 13.96, -4.39. 
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(2.19)  Methyl 2-(2-(tert-butoxy)-2-oxoethoxy)-4-pentylbenzoate 
Using a procedure adapted from Sinhababu et al.,174 To a stirred solution of 2.18 (4.94 g, 14.69 
mmol) and potassium fluoride (1.71 g, 29.38 mmol) in 30 mL anhydrous DMF, was added tert-
butyl bromoacetate (2.60 mL, 17.63 mmol). The reaction was stirred under argon for 6 hours at 
25ºC, then poured into H2O and extracted with diethyl ether. The combined organic fractions were 
washed with 10 x 30 mL H2O, dried with MgSO4, filtered and concentrated in vacuo, affording a 
crude yellow oil. Purification via column chromatography, (20% EtOAc/Hexanes) gave 3.74 g of 
2.19 as a colorless oil. MS (ESI+) m/z = 360.03 [M+Na]+, 696.11 [2M+Na]+. 1H NMR (400 MHz, 
CDCl3) δ 7.73 (d, J = 7.9 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.64 (s, 1H), 4.58 (s, 2H), 3.85 (s, 3H), 
2.62 – 2.50 (m, 2H), 1.57 (p, J = 7.0 Hz, 2H), 1.45 (s, 9H), 1.27 (dd, J = 6.9, 3.0 Hz, 4H), 0.85 (t, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 167.58, 166.31, 157.70, 149.23, 131.95, 121.37, 
118.05, 113.85, 82.17, 77.42, 77.10, 76.79, 66.68, 51.82, 36.09, 31.32, 30.59, 27.97, 25.63, 22.42, 
13.91. 
(2.20)  tert-Butyl 3-oxo-6-pentyl-2,3-dihydrobenzofuran-2-carboxylate 
To a solution of 2.19 (3.36 g, 10.00 mmol) in anhydrous THF, was added potassium tert-butoxide 
(1.0 M in THF, 10.0 mL, 10.00 mmol) at 0ºC. The reaction was stirred for 2 hours, poured into 
NH4Cl and extracted with EtOAc. The combined organic fractions were dried with MgSO4, filtered 
and concentrated in vacuo to give a crude off-white solid. Purification via column chromatography 
(20% EtOAc/hexanes) gave 2.28 g of pure 2.20 as a white solid (75.3%). 1H NMR (400 MHz, 
DMSO-D6) δ 7.60 (d, J = 8.1 Hz, 1H), 7.15 (s, 2H), 7.01 (d, J = 8.1 Hz, 1H), 3.83 (s, 1H), 2.63 (t, 
J = 7.6 Hz, 3H), 1.55 (s, 15H), 1.29 – 1.20 (m, 6H), 0.81 (t, J = 6.7 Hz, 5H). 13C NMR (101 MHz, 
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DMSO) δ 160.38, 153.28, 148.42, 144.27, 127.22, 123.80, 123.50, 121.95, 120.40, 119.37, 112.56, 
111.54, 81.58, 36.09, 31.26, 31.23, 31.12, 31.10, 28.50, 22.40, 14.11. 
(2.25)  3-Oxo-2,3-dihydrobenzofuran-6-yl trifluoromethanesulfonate  
Using a procedure adapted from Frantz et al.,172 6-hydroxy-3-coumaranone (2.24, 1.00 g, 6.66 
mmol) was dissolved in a bisphasic mixture of 12 mL toluene and 12 mL 30% K3PO4 in H2O. The 
reaction was cooled to 0ºC, and triflic anhydride (1.34 mL, 7.99 mmol) was added dropwise over 
15 minutes, and the reaction stirred for an additional 15 minutes. The reaction was diluted with 
EtOAc and H2O, the layers separated and the water layer further extracted with EtOAc. Organic 
extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to afford 1.57 g 
(83.3%) of 2.25 as an off white powder. MS (ESI-) m/z = 281.08 [M-H]-. 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 1.8 Hz, 1H), 7.01 (dd, J = 8.5, 2.0 Hz, 1H), 4.72 (s, 
2H). 13C NMR (101 MHz, CDCl3) δ 197.53, 174.19, 155.56, 125.92, 121.08, 117.02, 115.64, 
107.40, 75.74. 
(2.30)  3-(1-Hydroxypentyl)phenol 
Using a procedure adapted from Ujváry et al.,195 to a solution of 3-hydroxybenzaldehyde (2.29, 
2.50 g, 20.47 mmol) in 100 mL anhydrous THF at 0ºC under argon, was added n-butyllithium (2.5 
M in hexanes, 16.40 mL, 40.94 mmol) slowly over 15 minutes. The reaction was stirred for an 
additional 2 hours, after which isopropanol was added to quench the reaction. The reaction was 
poured into 1N HCl and extracted with EtOAc. Organic extracts were combined, dried with 
MgSO4, filtered and concentrated in vacuo to afford a crude off white powder. Recrystallization 
from diethyl ether afforded 3.34 g (90.4%)  pure 2.30. MS (ESI+) m/z = 203.17 [M+Na]+. 1H 
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NMR (400 MHz, Acetone-D6) δ 8.21 (s, 1H), 7.12 (t, J = 7.8 Hz, 1H), 6.88 (s, 1H), 6.81 (d, J = 
7.6 Hz, 1H), 6.73 – 6.66 (m, 1H), 4.57 (t, J = 4.2 Hz, 1H), 4.06 (s, 1H), 1.67 (ddd, J = 15.0, 12.3, 
7.4 Hz, 2H), 1.50 – 1.20 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, Acetone-D6) δ 
157.22, 148.14, 128.87, 116.99, 113.53, 112.72, 73.27, 39.29, 27.90, 22.44, 13.49. 
(2.31)  3-Pentylphenol 
Using a procedure adapted from Ujváry et al.,195 To a solution of 2.30 (3.34 g, 18.53 mmol) in 
methanol was added 5 drops of 70% perchloric acid followed by 100 mg 10% Pd/C. The reaction 
was run under 1 atm H2 for 3 hours, until TLC (20% EtOAc/hexanes) showed complete conversion 
of the starting material. The reaction was filtered over celite and concentrated in vacuo. The residue 
was run through a plug of silica (20% EtOAc/hexanes) to remove any remaining perchloric acid, 
yielding 2.60 g (85.6%) pure 2.31 as a clear oil.  
(2.32)  2-Chloro-1-(2-hydroxy-4-pentylphenyl)ethan-1-one 
Using a procedure adapted from Toyoda et al.,179 to a solution of BCl3 (1.0 M in DCM, 19.0 mL 
19.00 mmol) cooled to 0ºC was added a solution of 2.31 (2.60 g, 15.84 mmol) in 20 mL DCM. 
Chloroacetonitrile (1.0 mL, 15.84 mmol) was added slowly over 2 minutes, followed by AlCl3 
(1.06 g, 7.92 mmol). The reaction was allowed to warm to room temperature and stir overnight for 
16 hours under argon. 40 mL 2N HCl was then added very slowly, and the reaction stirred for an 
additional 2 hours. The reaction was diluted with H2O and extracted with DCM. Organic extracts 
were combined, dried with MgSO4, filtered and concentrated in vacuo to afford a crude green oil. 
Purification via column chromatography (20% EtOAc/hexanes) gave 3.40 g (89.1%) of pure 2.32 
as oil an initially yellow oil, which later turned green within an hour of isolation (no change in 
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purity via NMR or MS was observed after this color change). MS (ESI+) m/z = 263.7 [M+Na]+. 
1H NMR (400 MHz, CDCl3) δ 11.70 (s, 1H), 7.58 (d, J = 8.3 Hz, 1H), 6.91 – 6.81 (m, 1H), 6.76 
(dd, J = 8.2, 1.5 Hz, 1H), 4.68 (s, 2H), 2.70 – 2.53 (m, 2H), 1.62 (p, J = 7.5 Hz, 2H), 1.32 (dd, J = 
6.6, 2.8 Hz, 4H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 195.79, 163.01, 154.18, 
129.45, 120.04, 118.15, 115.21, 45.11, 36.23, 31.37, 30.17, 22.45, 13.95. 
(2.22)  6-Pentylbenzofuran-3(2H)-one 
To a solution of 2.32 (3.40 g, 14.15 mmol) in 15 mL anhydrous DMF was added K2CO3  
(3.91 g, 28.30 mmol). The reaction was stirred under argon for 1 hour, then diluted with H2O and 
extracted with EtOAc. The combined organic fractions were washed with 10 x 15 mL H2O, dried 
with MgSO4, filtered and concentrated in vacuo to give 2.80 g (98.0%) 2.22 as a yellow solid. MS 
(ESI+) m/z = 227.60 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 7.9 Hz, 1H), 7.00 – 
6.89 (m, 2H), 4.61 (s, 2H), 2.74 – 2.63 (m, 2H), 1.65 (p, J = 7.5 Hz, 2H), 1.33 (dd, J = 8.0, 4.2 Hz, 
5H), 0.90 (t, J = 6.8 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 199.29, 174.60, 154.98, 123.67, 
123.03, 118.98, 112.92, 74.97, 36.67, 31.35, 30.58, 22.45, 13.94. 
(3.1)  (Z)-2-benzylidene-6-pentylbenzofuran-3(2H)-one 
Using a procedure adapted from Shin et al.,153 to a solution of 2.2 (204.0 mg, 1.00 mmol) in 5 mL 
glacial acetic acid was added benzaldehyde (0.10 mL, 1.00 mmol) and 2 drops conc. HCl. The 
reaction was stirred for 1 hour in an open 20 mL vial. The reaction was poured into H2O, 
neutralized with sat. NaHCO3, and extracted with EtOAc. Organic extracts were combined, dried 
with MgSO4, filtered and concentrated in vacuo to afford a crude yellow solid. Purification via 
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column chromatography (20% EtOAc/hexanes) gave 245.6 mg (84.0%) pure 3.1 as a yellow solid. 
MS (ESI+) m/z = 315.41 [M+Na]+.  
(2.6)  (Z)-2-benzylidene-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Using a procedure adapted from Luche et al.,180 To a solution of 3.1 (240.0 mg, 0.82 mmol) and 
CeCl3-7H2O (305.8 mg, 0.82 mmol) in methanol was added NaBH4 (31.1 mg, 0.82 mmol) in small 
portions over 1 minute. The reaction was stirred for 20 minutes, then poured into 1N HCl and 
extracted EtOAc. The combined organic fractions were washed with 10 x 15 mL H2O, dried with 
MgSO4, filtered and concentrated in vacuo to give a crude yellow solid. Purification via column 
chromatography (20%EtOAc/hexanes) gave 210.9 mg (87.3%) of 2.6 as a white solid. MS (ESI+) 
m/z = 277.32 [M-OH]+, 317.41 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 6.9 Hz, 2H), 
7.39 (s, 3H), 7.26 (d, J = 8.8 Hz, 1H), 7.02 – 6.84 (m, 2H), 6.01 (s, 1H), 5.73 (d, J = 8.7 Hz, 1H), 
2.66 (dd, J = 9.8, 4.7 Hz, 2H), 2.22 – 2.06 (m, 1H), 1.65 (s, 2H), 1.35 (s, 4H), 1.06 – 0.82 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 158.05, 146.45, 128.64, 128.42, 126.73, 125.18, 123.13, 110.50, 
105.79, 99.99, 72.48, 36.13, 31.37, 31.10, 22.52, 14.01. 
General Procedure A for Aldol Condensation 
Using an adapted procedure from Manjulatha et al.,154 chromanone 2.22 or 3.7 (0.12 mmol) was 
dissolved in 1 mL acetonitrile in a 4 mL glass vial. Ethylenediamine diacetic acid (EDDA) (0.12 
mmol) was added, followed by the appropriately substituted benzaldehyde (0.12 mmol). The vial 
placed in a microwave run at 60% power for 2 minute intervals until the reaction was complete 
via TLC. The reactions were redissolved in EtOAc and purified via column chromatography.   
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General procedure B for Luche Reductions 
Using a procedure adapted from Luche et al.,180 aldol products were dissolved in methanol or 95% 
ethanol, followed by addition of CeCl3-7H2O (100 mol %). The reaction was cooled to 0ºC and 
stirred for 5 minutes, and NaBH4 (100 mol%) added in small portions over 1 minute. After stirring 
for 10 minutes, the reaction was poured into sat. NH4Cl and extracted with EtOAc. The combined 
organic fractions were dried with MgSO4, filtered, and concentrated in vacuo to afford a crude 
product. Purification via column chromatography (20% EtOAc/hexanes) afforded pure product. 
(3.8a)   (Z)-2-benzylidenebenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. White solid. Yield: 
74.9%. MS (ESI+) m/z = 245.88 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.65 (m, 4H), 
7.51 (s, 1H), 7.41 (dd, J = 14.5, 7.0 Hz, 2H), 7.05 – 6.96 (m, 1H), 5.91 (s, 1H). 13C NMR (101 
MHz, CDCl3) δ 128.54, 128.46, 128.27, 127.87, 127.77, 127.44, 127.33, 124.21, 122.74, 121.05, 
111.47, 105.04, 70.87. 
(3.8b)   (Z)-2-(4-fluorobenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Pink needles. Yield: 
73.7%. MS (ESI+) m/z = 263.98 [M+Na]+, 502.44 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.10 
(s, 1H), 7.81 (t, J = 6.5 Hz, 2H), 7.68 (t, J = 7.8 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.34 (dd, J = 
19.0, 8.1 Hz, 2H), 7.25 (t, J = 7.5 Hz, 1H), 6.79 (s, 1H). 
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(3.8c)   (Z)-2-(4-methylbenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow powder. 
Yield: 77.9%. MS (ESI+) m/z = 275.98 [M+K]+, 511.67 [2M+K]+. 1H NMR (400 MHz, Acetone-
D6) δ 7.93 (d, J = 8.0 Hz, 2H), 7.80 (t, J = 7.9 Hz, 2H), 7.51 (d, J = 8.9 Hz, 1H), 7.35 (d, J = 7.9 
Hz, 3H), 6.85 (s, 1H), 2.41 (s, 3H). 
(3.8d)   (Z)-2-(4-methoxybenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Red solid. Yield: 
84.5%. %. MS (ESI+) m/z = 275.29 [M+Na]+, 527.54 [2M+Na]+. 1H NMR (400 MHz, Acetone-
D6) δ 8.00 (d, J = 8.9 Hz, 2H), 7.79 (t, J = 8.1 Hz, 2H), 7.50 (d, J = 8.5 Hz, 1H), 7.32 (t, J = 7.6 
Hz, 1H), 7.09 (d, J = 8.9 Hz, 2H), 6.85 (s, 1H), 3.90 (s, 3H). 13C NMR (101 MHz, Acetone-D6)  δ 
183.32, 165.72, 161.29, 145.67, 136.83, 133.33, 124.93, 123.97, 123.57, 121.69, 114.52, 112.97, 
112.19, 54.92. 
(3.8e)   (Z)-2-(3-methoxybenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield 
95.5%. MS (ESI+) m/z = 253.22 [M+H]+, 275.19 [M+Na]+, 528.28 [2M+Na]+. 1H NMR (400 
MHz, CDCl3) δ 7.81 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 5.5 Hz, 2H), 7.42 – 
7.30 (m, 2H), 7.22 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.86 (s, 1H), 3.88 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 184.76, 166.13, 159.75, 146.95, 136.92, 133.48, 129.82, 124.66, 
124.29, 123.49, 121.59, 116.50, 115.73, 112.95, 55.32. 
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(3.8f)   (Z)-2-(4-nitrobenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield: 
63.2%. MS (ESI+) m/z = 290.12 [M+Na]+. 1H NMR (400 MHz, DMSO-D6) δ 8.17 (d, J = 8.6 Hz, 
1H), 7.75 (s, 2H), 7.53 (d, J = 3.9 Hz, 1H), 7.42 – 7.22 (m, 2H), 7.16 (s, 1H), 6.70 (d, J = 20.6 Hz, 
3H). 
(3.8g)   (Z)-2-(pyridin-3-ylmethylene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Orange solid. Yield: 
63.2%. MS (ESI+) m/z = 246.33 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.40 – 
8.36 (m, 2H), 8.04 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 7.45 (t, J = 7.2 Hz, 1H), 7.18 (dd, 
J = 7.9, 4.8 Hz, 2H), 7.09 (d, J = 8.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 183.87, 165.82, 151.88, 149.75, 147.75, 137.50, 137.12, 128.38, 124.54, 123.68, 123.62, 
121.02, 112.79, 108.48. 
(3.9b)   (Z)-2-(4-fluorobenzylidene)-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. White powder. Yield: 
96.9%. MS (ESI+) m/z = 225.31 [M-OH]+, 265.33 [M+Na]+. 1H NMR (400 MHz, Acetone-D6) δ 
7.68 (dd, J = 8.8, 5.6 Hz, 2H), 7.45 (d, J = 7.5 Hz, 1H), 7.28 (t, J = 7.3 Hz, 1H), 7.03 (td, J = 8.8, 
7.8, 3.8 Hz, 4H), 5.94 (d, J = 1.5 Hz, 1H), 5.75 (s, 1H), 4.98 (s, 1H). 13C NMR (101 MHz, Acetone-
D6)  δ 162.42, 159.98, 157.51, 131.37, 130.15, 130.07, 130.00, 127.79, 125.65, 122.66, 115.13, 
114.92, 110.11, 103.86, 71.72. 
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(3.9c)   (Z)-2-(4-methylbenzylidene)-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Pink powder. Yield: 
95.4%. MS (ESI+) m/z = 221.27 [M-OH]+, 261.32 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.63 
(d, J = 8.0 Hz, 2H), 7.50 (d, J = 7.7 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.9 Hz, 2H), 7.15 
– 7.05 (m, 2H), 5.99 (s, 1H), 5.75 (s, 1H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 157.77, 
156.26, 136.63, 131.65, 130.56, 129.16, 128.59, 127.01, 125.63, 122.74, 110.61, 105.96, 77.35, 
77.03, 76.71, 72.47, 21.29. 
(3.9d)   (Z)-2-(4-methoxybenzylidene)-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Yellow powder. Yield: 
94.7%. MS (ESI+) m/z = 277.29 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.55 (m, 2H), 
7.44 – 7.36 (m, 1H), 7.25 (qd, J = 7.8, 1.3 Hz, 1H), 7.00 (qd, J = 5.2, 4.4, 2.6 Hz, 2H), 6.89 – 6.80 
(m, 2H), 5.86 (s, 1H), 5.61 (s, 1H), 3.75 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 158.28, 157.72, 
155.44, 130.35, 129.93, 127.48, 127.27, 125.67, 122.62, 113.87, 110.45, 105.43, 77.47, 77.15, 
76.83, 72.17, 67.78, 55.21, 25.51. 
(3.10a) (Z)-2-benzylidene-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield: 
83.2%. MS (ESI+) m/z = 315.41 [M+Na]+.  
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(3.10b) (Z)-2-(4-fluorobenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Orange oil. Yield: 
87.7%. MS (ESI+) m/z = 333.28 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 8.7, 5.5 
Hz, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.18 – 7.09 (m, 3H), 7.04 (d, J = 7.9 Hz, 1H), 6.81 (s, 1H), 2.80 
– 2.69 (m, 2H), 1.69 (p, J = 7.5 Hz, 3H), 1.42 – 1.30 (m, 6H), 0.91 (td, J = 6.8, 4.6 Hz, 5H). 13C 
NMR (101 MHz, CDCl3) δ 184.23, 166.65, 154.21, 147.04, 133.40, 133.32, 128.74, 128.71, 
124.36, 119.40, 116.15, 115.93, 112.33, 111.26, 111.24, 77.35, 77.04, 76.72, 36.81, 31.35, 30.64, 
22.47, 13.96. 
(3.10c)  (Z)-2-(4-chlorobenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow oil. Yield: 
43.9%. MS (ESI+) m/z = 349.47 [M+Na]+, 676.09 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.98 
(d, J = 8.3 Hz, 2H), 7.77 – 7.59 (m, 3H), 7.15 (s, 1H), 7.05 (d, J = 7.9 Hz, 1H), 6.81 (s, 1H), 2.82 
– 2.66 (m, 2H), 1.77 – 1.63 (m, 2H), 1.36 (dt, J = 7.4, 3.8 Hz, 5H), 0.92 (t, J = 6.9 Hz, 4H). 13C 
NMR (101 MHz, CDCl3) δ 184.14, 166.84, 154.69, 148.31, 131.26, 125.64, 125.60, 124.63, 
124.49, 119.08, 112.40, 110.04, 36.83, 31.35, 30.62, 22.46, 13.93. 
(3.10d) (Z)-2-(3-methoxybenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield: 
62.9%. MS (ESI+) m/z = 345.41 [M+Na]+, 667.74 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.69 
(d, J = 7.8 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.13 (s, 1H), 7.03 (d, J = 7.9 
Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.82 (s, 1H), 3.88 (s, 3H), 2.81 – 2.66 (m, 2H), 1.68 (p, J = 7.4 
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Hz, 2H), 1.35 (dt, J = 7.4, 3.6 Hz, 5H), 0.92 (t, J = 6.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 
184.32, 166.71, 159.74, 154.16, 147.47, 133.64, 129.75, 124.31, 124.17, 119.40, 116.36, 115.56, 
112.38, 112.33, 77.37, 77.06, 76.74, 55.29, 36.81, 31.37, 30.65, 22.48, 13.97. 
(3.10e)  (Z)-2-(2,3-dimethoxybenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Orange oil. Yield: 
77.2%. MS (ESI+) m/z = 375.17 [M+Na]+, 728.04 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.92 
(d, J = 8.0 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.33 (s, 1H), 7.19 – 7.09 (m, 3H), 7.02 (d, J = 7.9 Hz, 
1H), 6.96 (d, J = 9.3 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 3H), 2.77 – 2.63 (m, 2H), 1.67 (p, J = 7.5 Hz, 
2H), 1.34 (dd, J = 7.1, 3.6 Hz, 5H), 0.90 (t, J = 6.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 190.12, 
184.31, 166.60, 154.00, 152.76, 147.99, 126.68, 124.30, 124.21, 124.15, 123.36, 119.53, 119.16, 
118.09, 113.89, 112.33, 106.43, 77.39, 77.07, 76.75, 61.65, 55.84, 36.79, 31.34, 30.64, 22.47, 
13.95. 
(3.10f)  (Z)-2-(3-bromobenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield: 
72.4%. MS (ESI+) m/z = 393.59 [M+Na]+, 766.01 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.09 
(s, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 7.9 
Hz, 1H), 7.17 (s, 1H), 7.05 (d, J = 7.7 Hz, 1H), 6.74 (s, 1H), 2.74 (t, J = 7.7 Hz, 2H), 1.69 (p, J = 
7.3 Hz, 3H), 1.36 (dd, J = 7.0, 3.6 Hz, 7H), 0.92 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ 184.17, 166.77, 154.53, 147.85, 134.50, 133.68, 132.42, 130.59, 130.25, 129.89, 124.54, 124.43, 
122.92, 119.19, 112.48, 110.45, 77.35, 77.03, 76.71, 36.85, 31.37, 30.65, 22.48, 13.97.  
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(3.10g) (Z)-4-((3-oxo-6-pentylbenzofuran-2(3H)-ylidene)methyl)benzonitrile 
Synthesized using the general procedure A described for aldol condensations. Orange solid. Yield: 
70.5%. MS (ESI+) m/z = 340.29 [M+Na]+, 657.87 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.95 
(d, J = 8.3 Hz, 2H), 7.68 (dd, J = 8.1, 4.1 Hz, 3H), 7.14 (s, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.74 (s, 
1H), 2.82 – 2.66 (m, 2H), 1.68 (p, J = 7.3 Hz, 2H), 1.34 (dt, J = 7.3, 3.8 Hz, 6H), 0.91 (t, J = 6.9 
Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 183.95, 166.79, 154.93, 148.67, 136.89, 132.37, 131.36, 
124.83, 124.56, 118.90, 118.55, 112.41, 112.34, 109.37, 77.41, 77.09, 76.77, 36.84, 31.34, 30.60, 
22.46, 13.96. 
(3.10h) (Z)-6-pentyl-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow Oil. Yield: 
37.0%. MS (ESI+) m/z = 293.67 [M+H]+, 609.88 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.69 
(s, 2H), 7.70 (dd, J = 12.2, 6.7 Hz, 3H), 7.15 (s, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.69 (s, 1H), 2.81 – 
2.65 (m, 2H), 1.67 (p, J = 7.5 Hz, 2H), 1.34 (dt, J = 7.4, 3.7 Hz, 4H), 0.90 (t, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 183.99, 166.92, 155.08, 150.20, 149.63, 139.72, 124.85, 124.61, 
118.82, 112.45, 108.49, 77.37, 77.05, 76.73, 36.85, 31.32, 30.58, 22.45, 13.94. 
(3.10i)  (Z)-2-((4-methylthiazol-5-yl)methylene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Red solid. Yield: 
52.9%. MS (ESI+) m/z = 336.22 [M+Na]+, 649.74 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.87 
(s, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.12 (s, 2H), 7.03 (d, J = 7.8 Hz, 1H), 2.71 (t, J = 7.6 Hz, 2H), 
2.63 (s, 3H), 1.75 – 1.58 (m, 2H), 1.33 (s, 4H), 0.90 (t, J = 6.2 Hz, 3H). 13C NMR (101 MHz, 
115 
CDCl3) δ 182.97, 166.10, 157.03, 155.51, 154.27, 146.31, 124.52, 124.36, 124.34, 119.96, 112.45, 
103.03, 77.38, 77.06, 76.75, 36.82, 31.36, 30.66, 22.45, 15.82, 13.95. 
(3.10j)  (Z)-N-(4-((3-oxo-6-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using the general procedure A described for aldol condensations. Yellow solid. Yield: 
58.2%. MS (ESI+) m/z = 372.39 [M+Na]+, 721.79 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.15 
(s, 1H), 7.86 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 7.9 Hz, 3H), 7.12 (s, 1H), 7.02 (d, J = 7.9 Hz, 1H), 
6.81 (s, 1H), 2.78 – 2.65 (m, 2H), 2.22 (s, 3H), 1.67 (p, J = 7.4 Hz, 2H), 1.34 (dt, J = 7.3, 3.7 Hz, 
4H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 184.37, 168.84, 166.55, 154.16, 
146.92, 139.55, 132.47, 131.12, 128.11, 124.29, 124.19, 119.73, 119.47, 112.43, 112.39, 99.99, 
77.36, 77.05, 76.73, 36.80, 31.35, 30.64, 24.67, 22.46, 13.96. 
(3.11a) (Z)-2-benzylidene-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. White solid. Yield: 
82.3%. MS (ESI+) m/z = 317.31 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 5.6 Hz, 
2H), 7.40 (d, J = 7.0 Hz, 3H), 7.26 (d, J = 8.2 Hz, 1H), 7.04 – 6.81 (m, 2H), 6.01 (s, 1H), 5.73 (d, 
J = 9.6 Hz, 1H), 2.79 – 2.56 (m, 2H), 1.78 – 1.53 (m, 3H), 1.46 – 1.25 (m, 4H), 1.03 – 0.85 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 158.05, 157.51, 146.45, 128.64, 128.42, 126.73, 125.18, 
124.18, 123.13, 110.50, 105.79, 99.99, 72.48, 36.13, 31.37, 31.10, 22.52, 14.01. 
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(3.11b) (Z)-2-(4-fluorobenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. White solid. Yield: 
25.6%. MS (ESI+) m/z = 295.14 [M-OH]+. 1H NMR (400 MHz, Acetone-D6) δ 7.86 – 7.73 (m, 
2H), 7.39 (d, J = 7.6 Hz, 1H), 7.14 (t, J = 8.9 Hz, 2H), 7.03 – 6.90 (m, 2H), 5.99 (s, 1H), 5.76 (d, 
J = 7.3 Hz, 1H), 5.02 (d, J = 7.8 Hz, 1H), 2.73 – 2.59 (m, 2H), 1.66 (p, J = 7.5 Hz, 2H), 1.35 (q, J 
= 5.4, 3.8 Hz, 5H), 0.90 (t, J = 6.9 Hz, 4H). 13C NMR (101 MHz, Acetone-D6)  δ 205.23, 162.39, 
158.38, 157.80, 145.56, 131.75, 130.17, 130.09, 125.50, 125.31, 122.94, 115.10, 114.89, 109.91, 
103.41, 71.46, 35.69, 31.22, 31.07, 29.52, 29.33, 29.14, 28.94, 28.75, 28.56, 28.37, 22.27, 13.40. 
(3.11c)  (Z)-2-(4-chlorobenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Off-white solid. Yield: 
80.9%. MS (ESI+) m/z = 311.81 [M-OH]+, 341.78 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.49 
– 7.34 (m, 5H), 7.27 (d, J = 4.2 Hz, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.47 (s, 1H), 5.91 (s, 1H), 2.77 
– 2.67 (m, 2H), 1.65 (dt, J = 13.9, 6.9 Hz, 3H), 1.34 (dt, J = 8.9, 4.3 Hz, 5H), 0.90 (t, J = 6.9 Hz, 
4H). 13C NMR (101 MHz, CDCl3) δ 157.35, 155.52, 140.12, 138.80, 134.05, 128.69, 128.14, 
125.49, 123.82, 120.66, 110.88, 104.09, 69.95, 36.10, 31.50, 31.41, 22.55, 14.02. 
(3.11d) (Z)-2-(3-methoxybenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. White solid. Yield: 
99.4%. MS (ESI+) m/z = 307.19 [M-OH]+, 347.21 [M+Na]+, 671.72 [2M+Na]+. 1H NMR (400 
MHz, Acetone-D6) δ 7.39 (d, J = 7.4 Hz, 2H), 7.29 (d, J = 6.3 Hz, 2H), 6.99 (s, 1H), 6.95 (d, J = 
7.6 Hz, 1H), 6.85 – 6.78 (m, 1H), 5.97 (d, J = 1.4 Hz, 1H), 5.76 (d, J = 7.6 Hz, 1H), 5.03 (d, J = 
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7.8 Hz, 1H), 3.84 (s, 3H), 2.70 – 2.59 (m, 2H), 1.65 (q, J = 7.3 Hz, 2H), 1.42 – 1.29 (m, 5H), 0.91 
(t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, Acetone-D6)  δ 159.82, 158.82, 157.87, 145.56, 136.56, 
129.19, 125.47, 125.30, 122.91, 120.99, 113.84, 111.88, 109.96, 104.61, 71.56, 54.53, 35.73, 
31.25, 31.10, 22.30, 13.45. 
(3.11e)  (Z)-2-(2,3-dimethoxybenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Clear oil. Yield: 40.6%. 
MS (ESI+) m/z = 337.38 [M-OH]+, 377.29 [M+Na]+, 732.37 [2M+Na]+. 1H NMR (400 MHz, 
Acetone-D6) δ 7.79 (dd, J = 8.0, 1.5 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 7.09 (t, J = 8.1 Hz, 1H), 
7.01 – 6.87 (m, 3H), 6.37 (s, 1H), 5.79 (d, J = 7.1 Hz, 1H), 5.05 (d, J = 7.6 Hz, 1H), 3.86 (s, 3H), 
3.80 (s, 3H), 2.71 – 2.60 (m, 2H), 1.66 (p, J = 7.5 Hz, 2H), 1.43 – 1.28 (m, 5H), 0.90 (t, J = 6.9 
Hz, 3H). 13C NMR (101 MHz, Acetone-D6)  δ 205.22, 159.26, 157.89, 152.82, 146.17, 145.49, 
129.04, 125.55, 125.32, 123.63, 122.84, 121.40, 110.96, 109.88, 97.96, 71.65, 59.94, 55.18, 35.69, 
31.22, 31.07, 29.52, 29.33, 29.13, 28.94, 28.75, 28.56, 28.36, 22.27, 13.40. 
(3.11f)  (Z)-2-(3-bromobenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Clear oil. Yield: 30.8%. 
MS (ESI+) m/z = 355.32 [M-OH]+, 393.56 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.96 – 7.80 
(m, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 7.6 Hz, 2H), 7.23 (t, J = 7.9 Hz, 1H), 7.02 – 6.87 
(m, 2H), 5.89 (s, 1H), 5.69 (s, 1H), 2.64 (t, J = 7.6 Hz, 2H), 1.64 (p, J = 7.5 Hz, 2H), 1.42 – 1.30 
(m, 5H), 0.92 (t, J = 6.7 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 158.60, 157.83, 146.59, 136.73, 
131.26, 129.86, 129.54, 127.15, 125.17, 123.94, 123.37, 122.57, 110.59, 104.32, 77.36, 77.04, 
76.72, 72.43, 36.14, 31.40, 31.11, 22.53, 14.03.  
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(3.11g) (Z)-4-((3-hydroxy-6-pentylbenzofuran-2(3H)-ylidene)methyl)benzonitrile 
Synthesized using the general procedure B described for Luche reductions. Yellow powder. Yield: 
21.8%. MS (ESI+) m/z = 302.39 [M-OH]+, 342.42 [M+Na]+, 662.08 [2M+Na]+. 1H NMR (400 
MHz, Acetone-D6) δ 7.92 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 7.6 Hz, 1H), 
7.11 – 6.91 (m, 2H), 6.09 (s, 1H), 5.81 (s, 1H), 2.75 – 2.61 (m, 2H), 2.17 – 2.03 (m, 2H), 1.66 (p, 
J = 7.5 Hz, 2H), 1.45 – 1.26 (m, 5H), 0.90 (t, J = 6.8 Hz, 4H). 13C NMR (101 MHz, Acetone-D6)  
δ 205.25, 161.89, 157.59, 145.75, 140.08, 132.09, 128.79, 125.35, 125.21, 123.38, 118.75, 110.06, 
109.07, 102.99, 71.63, 35.67, 31.21, 31.05, 29.53, 29.34, 29.18, 29.15, 29.00, 28.95, 28.81, 28.76, 
28.57, 28.37, 22.26, 13.40. 
(3.11h) (Z)-6-pentyl-2-(pyridin-4-ylmethylene)-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Orange oil. Yield: 
75.4%. MS (ESI+) m/z = 297.07 [M+H]+, 318.38 [M+Na]+, 591.73 [2M+H]+. 1H NMR (400 MHz, 
Acetone-D6) δ 8.47 (d, J = 27.2 Hz, 2H), 7.81 (d, J = 8.4 Hz, 1H), 7.45 – 7.26 (m, 4H), 6.99 (dd, J 
= 12.9, 4.9 Hz, 1H), 6.90 (s, 1H), 6.78 (d, J = 4.8 Hz, 1H), 2.08 – 2.01 (m, 3H), 1.64 (p, J = 8.0 
Hz, 4H), 1.38 – 1.25 (m, 9H), 0.89 (td, J = 7.6, 7.0, 3.6 Hz, 6H). 
(3.11i)  (Z)-2-((4-methylthiazol-5-yl)methylene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions. Off white powder. 
Yield: 72.9%. MS (ESI+) m/z = 298.23 [M-OH]+, 316.20 [M+H]+. 1H NMR (400 MHz, CDCl3) 
δ 8.44 (s, 1H), 7.36 (d, J = 7.5 Hz, 1H), 6.89 (d, J = 8.0 Hz, 2H), 6.19 (s, 1H), 5.71 (s, 1H), 2.67 – 
2.58 (m, 2H), 2.42 (s, 3H), 1.62 (p, J = 7.5 Hz, 2H), 1.40 – 1.29 (m, 5H), 0.90 (t, J = 6.9 Hz, 4H). 
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13C NMR (101 MHz, CDCl3) δ 157.39, 157.20, 151.01, 149.17, 146.31, 125.26, 124.90, 123.36, 
110.44, 96.05, 77.36, 77.04, 76.72, 71.38, 36.09, 31.38, 31.10, 22.50, 15.10, 14.00. 
(3.11j)     (Z)-N-(4-((3-hydroxy-6-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions. White powder. Yield: 
5.6%. MS (ESI+) m/z = 333.59 [M-OH]+, 374.22 [M+Na]+. 1H NMR (400 MHz, Acetone-D6) δ 
7.66 (s, 4H), 7.38 (d, J = 7.5 Hz, 1H), 6.98 (s, 1H), 6.94 (d, J = 7.6 Hz, 1H), 5.93 (d, J = 1.6 Hz, 
1H), 5.75 (d, J = 7.3 Hz, 1H), 4.95 (d, J = 7.8 Hz, 1H), 2.83 (s, 3H), 2.73 – 2.60 (m, 2H), 1.66 (p, 
J = 7.5 Hz, 2H), 1.35 (dq, J = 9.7, 5.7 Hz, 5H), 0.90 (t, J = 6.9 Hz, 3H). 
(3.12j)  N-(4-(ethoxy(6-pentylbenzofuran-2-yl)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions. Yellow oil. Yield: 
37.3%. MS (ESI+) m/z = 334.31 [M-CH3CH2OH]
+, 402.28 [M+Na]+. 1H NMR (400 MHz, 
CDCl3) δ 7.51 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 7.9 Hz, 1H), 7.32 (s, 1H), 
7.26 (s, 1H), 7.02 (d, J = 7.6 Hz, 1H), 6.49 (s, 1H), 5.46 (s, 1H), 3.73 – 3.50 (m, 2H), 2.74 – 2.61 
(m, 2H), 2.18 (s, 3H), 1.74 – 1.55 (m, 3H), 1.40 – 1.21 (m, 8H), 0.89 (t, J = 6.8 Hz, 3H). 
(3.14)  2-(1-Hydroxypentyl)phenol 
Using a procedure adapted from Ujváry et al.,195 To a solution of salicylaldehyde (3.13, 2.50 g, 
20.47 mmol) in 100 mL anhydrous THF at 0ºC under argon, was added n-butyllithium (2.5 M in 
hexanes, 16.4 mL, 40.94 mmol) slowly over 15 minutes. The reaction was stirred for an additional 
2 hours, after which isopropanol was added to quench the reaction. The reaction was poured into 
1N HCl and extracted with EtOAc. Organic extracts were combined, dried with MgSO4, filtered 
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and concentrated in vacuo to afford a crude off white powder. Recrystallization from diethyl ether 
afforded 3.02 g (81.9%) pure 3.14. MS (ESI+) m/z = 203.27 [M+Na]+. 1H NMR (400 MHz, 
CDCl3) δ 8.12 (s, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 7.5 Hz, 1H), 6.84 (q, J = 7.1 Hz, 2H), 
4.80 (t, J = 6.6 Hz, 1H), 3.16 (s, 1H), 1.97 – 1.72 (m, 2H), 1.31 (ddd, J = 34.3, 11.4, 4.4 Hz, 4H), 
0.91 (t, J = 6.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 155.37, 128.72, 127.70, 127.20, 119.68, 
117.01, 76.00, 36.90, 27.88, 22.48, 13.98. 
(3.15)  2-Pentylphenol 
Using a procedure adapted from Ujváry et al.,195 To a solution of 3.14 (3.00 g, 16.64 mmol) in 
methanol was added 5 drops of 70% perchloric acid followed by 100 mg 10% Pd/C. The reaction 
was conducted under 1 atm H2 for 3 hours, until TLC (20% EtOAc/hexanes) showed complete 
conversion of the starting material. The reaction was filtered over celite and concentrated in vacuo. 
The residue was run through a plug of silica (20% EtOAc/hexanes) to remove any remaining 
perchloric acid, yielding 2.52 g (92.1%) pure 3.15 as a clear oil.  1H NMR (400 MHz, CDCl3) δ 
7.19 (d, J = 7.4 Hz, 1H), 7.13 (t, J = 7.7 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.9 Hz, 1H), 
5.78 (s, 1H), 2.75 – 2.61 (m, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.47 – 1.37 (m, 4H), 0.98 (t, J = 6.4 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.37, 153.68, 130.18, 128.98, 126.92, 120.60, 115.27, 
77.46, 77.14, 76.82, 60.97, 31.81, 29.99, 29.56, 22.65, 21.09, 14.13, 14.08. 
(3.16)  2-Chloro-1-(2-hydroxy-3-pentylphenyl)ethan-1-one 
Using a procedure adapted from Toyoda et al.,179 to a solution of BCl3 (1.0 M in DCM, 18.3 mL, 
18.26 mmol) cooled to 0ºC was added a solution of 3.15 (2.50 g, 15.22 mmol) in 20 mL DCM. 
Chloroacetonitrile (1.2 mL, 18.26 mmol) was added slowly over 2 minutes, followed by AlCl3 
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(1.02 g, 7.61 mmol). The reaction was allowed to warm to room temperature and stir overnight for 
16 hours under argon. 40 mL 2N HCl was then added very slowly, and the reaction stirred for an 
additional 2 hours. The reaction was diluted with H2O and extracted with DCM. Organic extracts 
were combined, dried with MgSO4, filtered and concentrated in vacuo to afford a crude green oil. 
Purification via column chromatography (20% EtOAc/hexanes) gave 3.39 g (92.5%) of pure 3.16 
as oil an initially yellow oil, which later turned green within an hour of isolation (no change in 
purity via NMR or MS was observed after this color change). MS (ESI+) m/z = 242.8 [M+H]+. 1H 
NMR  (400 MHz, CDCl3) δ 12.01 (s, 1H), 7.55 (dd, J = 8.1, 1.5 Hz, 1H), 7.46 – 7.35 (m, 1H), 
6.92 – 6.82 (m, 1H), 4.74 (s, 2H), 2.73 – 2.62 (m, 2H), 1.69 – 1.59 (m, 2H), 1.35 (dt, J = 7.3, 3.8 
Hz, 4H), 0.96 – 0.83 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 137.30, 136.39, 132.76, 127.08, 
118.72, 63.59, 45.43, 31.67, 29.47, 28.97, 22.53, 14.03. 
(3.17)  7-Pentylbenzofuran-3(2H)-one 
To a solution of 2.32 (3.39 g, 14.15 mmol) in 15 mL anhydrous DMF was added K2CO3  
(3.912 g, 28.31 mmol). The reaction was stirred under argon for 1 hour, then diluted with H2O and 
extracted with EtOAc. The combined organic fractions were washed with 10 x 15 mL H2O, dried 
with MgSO4, filtered and concentrated in vacuo to give 2.80 g (98.0%) 3.17 as a yellow solid. MS 
(ESI+) m/z = 227.60 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.50 (d, J = 7.7 Hz, 1H), 7.42 (d, 
J = 7.2 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 4.62 (s, 2H), 2.72 – 2.62 (m, 2H), 1.66 (dt, J = 13.7, 8.3 
Hz, 3H), 1.36 (dt, J = 7.0, 4.3 Hz, 5H), 0.91 (t, J = 5.6 Hz, 4H). 13C NMR  (101 MHz, CDCl3) δ 
200.56, 172.61, 137.38, 128.72, 121.92, 121.30, 120.67, 74.60, 31.52, 29.06, 28.68, 22.46, 14.01. 
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(3.19)  6-Butoxybenzofuran-3(2H)-one 
6-Hydroxy-2-coumaranone (3.18, 150.1 mg, 1.00 mmol) was dissolved in 10 mL anhydrous DMF 
and stirred under argon. Sodium hydride, (60% dispersion in mineral oil, 40.0 mg, 1.00 mmol) 
was added slowly to the reaction over 1 minute, and the reaction stirred at room tempurature for 8 
hours. The reaction was then poured into H2O and extracted with EtOAc. The combined organic 
fractions were washed with 10 x 15 mL H2O, dried with MgSO4, filtered and concentrated in vacuo 
to give 125.8 mg 3.19 as a yellow solid. MS ES+ m/z = 206.57 [M+H]+. 1H NMR  (400 MHz, 
CDCl3) δ 7.32 (d, J = 8.6 Hz, 1H), 6.44 (dd, J = 8.6, 2.0 Hz, 1H), 6.35 (d, J = 1.9 Hz, 1H), 4.41 (s, 
2H), 3.85 (t, J = 6.4 Hz, 2H), 1.60 (dt, J = 14.4, 6.6 Hz, 2H), 1.30 (dq, J = 14.8, 7.4 Hz, 2H), 0.78 
(t, J = 7.4 Hz, 3H). 
(3.20a) (Z)-6-butoxy-2-(4-fluorobenzylidene)benzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow powder. 
Yield: 51.18%. MS ES+ m/z = 313.47 [M+H]+, 335.78 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 
7.88 (dd, J = 8.8, 5.5 Hz, 2H), 7.69 (d, J = 9.1 Hz, 1H), 7.13 (t, J = 8.7 Hz, 2H), 6.79 – 6.72 (m, 
3H), 4.08 (t, J = 6.5 Hz, 2H), 1.83 (dt, J = 14.5, 6.5 Hz, 3H), 1.53 (dq, J = 14.7, 7.4 Hz, 3H), 1.01 
(t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 182.86, 168.54, 167.11, 147.52, 133.24, 133.16, 
128.77, 125.79, 116.11, 115.89, 114.53, 112.67, 110.48, 96.98, 68.71, 30.94, 19.14, 13.76. 
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(3.20b)           (Z)-N-(4-((6-butoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using the general procedure A described for aldol condensations. Yellow powder. 
Yield: 22.75%. MS ES+ m/z = 352.71 [M+H]+, 374.73 [M+Na]+. 1H NMR  (400 MHz, DMSO-
D6) δ 7.91 (d, J = 8.7 Hz, 2H), 7.71 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.6 Hz, 1H), 7.14 (d, J = 2.0 
Hz, 1H), 6.83 (dd, J = 8.6, 2.1 Hz, 1H), 6.78 (s, 1H), 4.15 (t, J = 6.5 Hz, 2H), 2.07 (s, 3H), 1.75 
(dt, J = 14.3, 6.6 Hz, 2H), 1.45 (dq, J = 14.7, 7.4 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
(3.20c)  (Z)-N-(4-((3-oxo-6-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Yellow oil. Yield: 45.1%. Data were in accordance with 3.10j. 
(3.20 d/e) (Z)-2-(4-methoxybenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow oil. Yield: 
35.7%. MS ES+ m/z = 345.51 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.87 (d, J = 8.9 Hz, 2H), 
7.69 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 7.02 (d, J = 8.9 Hz, 1H), 6.97 (d, J = 8.9 Hz, 2H), 6.84 (s, 
1H), 3.86 (s, 3H), 2.79 – 2.67 (m, 2H), 1.67 (t, J = 11.2 Hz, 2H), 1.35 (dt, J = 7.6, 3.8 Hz, 5H), 
0.94 – 0.87 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 184.15, 166.40, 160.89, 153.68, 146.36, 
133.26, 125.18, 124.18, 124.09, 119.72, 114.43, 112.79, 112.29, 55.35, 36.79, 31.37, 30.67, 22.48, 
14.19, 13.97. 
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(3.20 f/g) (Z)-N-(4-((3-oxo-7-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using the general procedure A described for aldol condensations. Yellow oil. Yield: 
69.5%. MS ES+ m/z = 372.41 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 2H), 
7.57 (d, J = 7.8 Hz, 2H), 7.43 (d, J = 7.4 Hz, 1H), 7.30 (d, J = 7.0 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 
6.67 (s, 1H), 5.18 (s, 2H), 2.67 (t, J = 7.4 Hz, 2H), 2.05 (s, 3H), 1.61 (s, 2H), 1.25 (s, 4H), 0.76 (t, 
J = 5.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 207.07, 164.23, 146.22, 140.18, 136.58, 132.25, 
127.66, 123.22, 121.58, 121.11, 119.49, 112.46, 53.41, 31.34, 28.95, 28.72, 24.23, 22.24, 13.80. 
(3.20h) (Z)-2-(4-fluorobenzylidene)-7-pentylbenzofuran-3(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Yellow oil. Yield: 
73.6%. MS ES+ m/z = 323.42 [M+Na]+. 1H NMR  (400 MHz, Acetonitrile-d3) δ 8.06 – 7.91 (m, 
2H), 7.57 (d, J = 7.4 Hz, 2H), 7.22 (dt, J = 15.2, 8.2 Hz, 3H), 6.82 (s, 1H), 2.90 – 2.80 (m, 2H), 
1.81 – 1.69 (m, 2H), 1.45 – 1.34 (m, 5H), 0.93 (t, J = 7.0 Hz, 4H). 13C NMR (101 MHz, CD3CN) 
δ 184.50, 164.45, 146.66, 137.13, 133.54, 133.46, 128.03, 123.70, 121.45, 116.09, 115.87, 110.36, 
31.20, 29.03, 28.34, 22.14, 13.32. 
(3.21a) 6-Butoxy-2-(ethoxy(4-fluorophenyl)methyl)benzofuran 
Synthesized using the general procedure B described for Luche reductions. Yellow oil. Yield: 
65.6% MS ES+ m/z = 365.36 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.47 (dd, J = 8.6, 5.4 Hz, 
3H), 7.36 (dd, J = 8.5, 3.0 Hz, 2H), 7.08 (t, J = 7.8 Hz, 3H), 7.00 (s, 2H), 6.91 – 6.81 (m, 2H), 6.46 
(s, 1H), 5.47 (s, 1H), 3.98 (t, J = 6.5 Hz, 4H), 3.71 – 3.53 (m, 2H), 1.80 (p, J = 7.5, 7.0 Hz, 4H), 
1.53 (dt, J = 15.0, 7.4 Hz, 4H), 1.30 (t, J = 7.0 Hz, 7H), 0.99 (t, J = 7.4 Hz, 6H).  
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(3.21b) N-(4-((6-butoxybenzofuran-2-yl)(ethoxy)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions. Yellow oil. Yield: 
26.6%. MS ES+ m/z = 404.19 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 2H), 
7.44 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.28 (s, 2H), 6.44 (s, 1H), 5.45 (s, 1H), 3.98 (t, 
J = 6.5 Hz, 3H), 3.71 – 3.52 (m, 2H), 2.19 (s, 4H), 1.79 (dt, J = 14.3, 6.5 Hz, 3H), 1.51 (dq, J = 
14.7, 7.3 Hz, 3H), 1.29 (t, J = 7.0 Hz, 4H), 0.99 (t, J = 7.4 Hz, 5H). 
(3.21c)  N-(4-(methoxy(6-pentylbenzofuran-2-yl)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions.. Yellow oil. Yield: 
20.3%. MS ES+ m/z = 388.51 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.53 (d, J = 8.3 Hz, 3H), 
7.47 – 7.37 (m, 5H), 7.27 (d, J = 4.8 Hz, 3H), 7.03 (d, J = 7.6 Hz, 2H), 6.49 (s, 1H), 5.35 (s, 1H), 
3.44 (s, 3H), 2.69 (t, J = 7.7 Hz, 3H), 2.18 (s, 4H), 1.64 (dt, J = 14.9, 7.3 Hz, 5H), 0.89 (t, J = 6.8 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 128.01, 123.60, 120.48, 119.79, 110.96, 104.90, 57.13, 
36.08, 31.49, 31.38, 24.60, 22.54, 14.02. 
(3.21d) 2-(Ethoxy(4-methoxyphenyl)methyl)-6-pentylbenzofuran 
Synthesized using the general procedure B described for Luche reductions.. Yellow oil. Yield: 
17.1% MS ES+ m/z = 375.42 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.45 – 7.36 (m, 3H), 7.03 
(dd, J = 7.9, 1.3 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 6.50 (s, 1H), 5.46 (s, 1H), 3.83 (s, 3H), 3.70 – 
3.54 (m, 2H), 2.74 – 2.63 (m, 2H), 1.65 (dt, J = 15.0, 7.5 Hz, 2H), 1.38 – 1.32 (m, 3H), 1.30 (t, J 
= 7.0 Hz, 5H), 0.90 (t, J = 6.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 159.43, 157.14, 155.58, 
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139.54, 131.38, 128.54, 125.72, 123.48, 120.39, 113.82, 110.97, 104.41, 77.26, 64.76, 55.28, 
36.08, 31.52, 31.40, 22.55, 15.29, 14.02. 
(3.21e)  (Z)-2-(4-methoxybenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure A described for aldol condensations. White solid. Yield: 
5.3%. MS ES+ m/z = 307.39 [M-OH]+, 347.43 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.42 (dd, 
J = 8.2, 4.5 Hz, 3H), 7.28 (s, 1H), 7.05 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.6 Hz, 2H), 6.49 (s, 1H), 
5.91 (s, 1H), 3.84 (s, 3H), 2.76 – 2.67 (m, 2H), 1.66 (dt, J = 15.1, 7.5 Hz, 3H), 1.43 – 1.31 (m, 5H), 
0.91 (t, J = 6.8 Hz, 4H). 
(3.21f)  N-(4-(ethoxy(7-pentylbenzofuran-2-yl)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions.. Yellow oil. Yield: 
40.6%. MS ES+ m/z = 402.71 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.52 (d, J = 
8.5 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.12 (d, J = 7.4 Hz, 1H), 7.06 (d, J = 
7.2 Hz, 1H), 6.53 (s, 1H), 5.49 (s, 1H), 3.72 – 3.56 (m, 2H), 3.49 (s, 1H), 2.87 (t, J = 7.4 Hz, 2H), 
2.16 (s, 3H), 1.72 (p, J = 7.3 Hz, 3H), 1.34 (dt, J = 7.0, 3.8 Hz, 5H), 1.32 – 1.25 (m, 4H), 0.90 (t, 
J = 5.6 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 168.54, 156.95, 153.87, 137.75, 135.20, 127.93, 
127.65, 126.51, 124.07, 122.72, 119.79, 118.45, 104.85, 77.37, 77.06, 76.74, 64.97, 31.59, 29.62, 
29.38, 24.51, 22.49, 15.30, 14.01. 
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(3.21g)    (Z)-N-(4-((3-hydroxy-7-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using the general procedure B described for Luche reductions.. Off-white solid. Yield: 
8.4%. MS ES+ m/z = 374.73 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.54 (d, J = 3.3 Hz, 4H), 
7.33 (d, J = 7.4 Hz, 1H), 7.08 (dd, J = 17.2, 7.4 Hz, 2H), 6.52 (s, 1H), 5.66 (s, 1H), 2.86 (t, J = 6.8 
Hz, 2H), 2.18 (s, 4H), 1.78 – 1.70 (m, 2H), 1.40 – 1.32 (m, 5H), 0.89 (t, J = 6.7 Hz, 4H). 
(3.21h) (Z)-2-(4-fluorobenzylidene)-7-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using the general procedure B described for Luche reductions.. Clear oil. Yield: 46.8% 
MS ES+ m/z = 335.29 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.71 (dd, J = 8.5, 5.7 Hz, 2H), 
7.34 (d, J = 7.3 Hz, 1H), 7.18 (d, J = 7.5 Hz, 1H), 7.06 (dt, J = 18.8, 8.1 Hz, 4H), 5.98 (s, 1H), 5.76 
(s, 1H), 2.78 – 2.71 (m, 2H), 1.73 (q, J = 7.1 Hz, 3H), 1.45 – 1.39 (m, 4H), 0.95 (t, J = 6.8 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 162.68, 156.67, 155.81, 130.91, 130.17, 130.09, 126.35, 125.71, 
122.92, 122.90, 115.44, 115.23, 104.60, 72.83, 31.66, 29.76, 29.28, 22.46, 14.06. 
(3.22)  2-((4-Fluorophenyl)(methoxy)methyl)-6-pentylbenzofuran 
Synthesized using Luche reduction general method, solvent: methanol. Green oil. Yield: 69.9%. 
MS ES+ m/z = 295.17 [M-CH3OH]
+, 335.61 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.48 (dd, 
J = 8.2, 5.6 Hz, 2H), 7.43 (d, J = 7.9 Hz, 1H), 7.30 (s, 1H), 7.13 – 7.04 (m, 4H), 6.53 (s, 1H), 5.39 
(s, 1H), 3.48 (s, 3H), 2.72 (t, J = 7.7 Hz, 2H), 1.67 (p, J = 7.2 Hz, 3H), 1.40 – 1.31 (m, 6H), 0.92 
(t, J = 6.6 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 156.00, 155.65, 139.93, 129.02, 128.94, 125.52, 
123.69, 120.54, 115.48, 115.27, 110.99, 104.98, 78.79, 57.18, 36.11, 31.51, 31.42, 22.56, 14.03.  
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(3.23)  2-(ethoxy(4-fluorophenyl)methyl)-6-pentylbenzofuran 
Synthesized using the general procedure B described for Luche reductions., solvent: ethanol. 
Yellow oil. Yield: 74.5%. MS ES+ m/z = 295.17 [M-CH3CH2OH]
+, 364.14 [M+Na]+. 1H NMR  
(400 MHz, CDCl3) δ 7.50 (dd, J = 8.3, 5.5 Hz, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.32 (s, 1H), 7.16 – 
7.06 (m, 3H), 6.55 (s, 1H), 5.52 (s, 1H), 3.75 – 3.56 (m, 2H), 2.80 – 2.70 (m, 2H), 1.69 (p, J = 7.4 
Hz, 2H), 1.41 – 1.30 (m, 7H), 0.94 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 156.55, 
155.65, 139.81, 135.16, 128.96, 128.88, 125.63, 123.66, 120.52, 115.43, 115.22, 111.01, 104.72, 
77.01, 64.99, 36.13, 31.54, 31.44, 22.59, 15.29, 14.06. 
(3.24)  (4-Fluorophenyl)(6-pentylbenzofuran-2-yl)methyl acetate 
3.23 (10 mg, 0.0293 mmol) was dissolved 5 mL glacial acetic acid. A solution of bromine (1.5 μL, 
0.0293 mmol) in 1 mL glacial acetic acid was added slowly over 1 minute. The reaction was stirred 
for 1 hour, and poured in sat. NaHCO3 and extracted with EtOAc. The combined organic fractions 
were dried with MgSO4, filtered and concentrated in vacuo, giving a crude yellow oil. Purification 
via column chromatography (20% EtOAc/hexanes) afforded 7.9 mg pure 3.24 as a yellow solid. 
Yield: 76.9%. MS ES+ m/z = 295.17 [M-CH3COOH]
+, 377.15 [M+Na]+. 732.23 [2M+Na]+. 1H 
NMR  (400 MHz, CDCl3) δ 7.52 (dd, J = 8.6, 5.4 Hz, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.31 (s, 1H), 
7.11 (q, J = 8.0, 7.4 Hz, 3H), 7.01 (s, 1H), 6.57 (s, 1H), 2.77 – 2.68 (m, 2H), 2.20 (s, 3H), 1.67 (p, 
J = 7.6 Hz, 3H), 1.43 – 1.29 (m, 5H), 0.93 (t, J = 6.7 Hz, 3H). 
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(3.25)  (4-Fluorophenyl)(6-pentylbenzofuran-2-yl)methanol 
3.22 (25 mg, 0.0766 mmol) was dissolved in 2 mL 1,4-dioxane and 1 mL 6N HCl and stirred for 
2 hours. The reaction was poured in NaHCO3 and extracted with EtOAc. . The combined organic 
fractions were dried with MgSO4, filtered and concentrated in vacuo, giving a crude yellow solid. 
Purification via column chromatography (20% EtOAc/hexanes) afforded 13.1 mg pure 3.25 as a 
white solid. Yield 54.5% MS ES+ m/z = 295.17 [M-OH]+, 336.84 [M+Na]+. 649.54 [2M+Na]+. 
1H NMR  (400 MHz, CDCl3) δ 7.47 (dd, J = 8.1, 5.7 Hz, 2H), 7.42 (s, 1H), 7.12 – 7.04 (m, 3H), 
6.47 (s, 1H), 5.91 (s, 1H), 2.72 (t, J = 7.7 Hz, 2H), 1.67 (p, J = 7.3 Hz, 2H), 1.44 – 1.29 (m, 5H), 
0.92 (t, J = 6.6 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 163.84, 161.39, 157.67, 155.53, 140.05, 
136.15, 128.60, 128.52, 125.56, 123.79, 120.65, 115.52, 115.31, 110.88, 103.96, 69.99, 67.04, 
36.11, 31.52, 31.43, 22.56, 14.04. 
(3.27)  2,4-Dibromonaphthalen-1-amine 
Using an adapted procedure from MacLean et al.,188 1-naphthylamine (3.26, 1 g, 6.98 mmol) was 
dissolved in 30 mL glacial acetic acid and cooled to 0ºC. Bromine (0.80 mL, 15.67 mmol), 
dissolved in 10 mL glacial acetic acid, was added over 5 minutes. The reaction was stirred for 10 
minutes at 0ºC, then diluted with 30 mL glacial acetic acid and heated to 60ºC for 30 minutes. The 
reaction was cooled and filtered, collecting a purple solid. The purple solid was suspended in H2O 
and basified using NaOH until the pH was >10. The solid was collected by filtration and washed 
with copious amounts of water. The product was used without further purification. A small sample 
of the product was collected and dried under high vacuum for 3 days to provide NMR spectra. MS 
ES+ m/z = 299.88 [M-H]-. 1H NMR  (400 MHz, CDCl3) δ 8.18 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 
8.5 Hz, 2H), 7.63 – 7.51 (m, 2H), 4.66 (s, 2H).  
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(3.28)  4-Bromonaphtho[1,2-d][1,2,3]oxadiazole 
Using an adapted procedure from MacLean et al.,188 3.27 (2.10 g, 6.98 mmol) was dissolved in a 
mixture of 40 mL glacial acetic acid and 7.5 mL propionic acid and cooled to 0ºC. Sodium nitrite 
(482.9 mg, 7.00 mmol) was added in small portions over 1 minute, and the reaction was stirred for 
10 minutes. 40 mL H2O was added and the reaction mixture filtered quickly. The filtrate was 
poured into 250 mL H2O giving a dark brown precipitate which was collected by filtration. The 
precipitate was redissolved in hot H2O, giving a yellow solution with brown precipitate, which 
was rapidly filtered to remove the brown solid. The filtrate was cooled with ice and allowed to 
precipitate out over 1 hour in the dark, affording a yellow solid which was used without further 
purification or characterization. 
(3.29)  4-Bromonaphthalen-2-ol 
Using an adapted procedure from MacLean et al.,188 3.28 (1.73 g, 6.98 mmol) was dissolved in 
ethanol and cooled to 0ºC. Sodium borohydride (260.0 mg, 6.98 mmol) was added slowly, and the 
reaction stirred for 3 hours. The reaction was then poured into 1N HCl and extracted with DCM. 
The combined organic fractions were dried with MgSO4, filtered and concentrated in vacuo. 
Purification via column chromatography (10% EtOAc/hexanes) afforded 288.2 mg (18.7%) of 
pure 3.29 as a yellow oil. MS ES- m/z = 222.91 [M-H]-. 1H NMR  (400 MHz, CDCl3) δ 8.15 (d, J 
= 8.3 Hz, 1H), 7.75 – 7.61 (m, 1H), 7.47 (qd, J = 7.9, 1.3 Hz, 3H), 7.15 (d, J = 1.7 Hz, 1H), 5.23 
(s, 1H). 13C NMR (101 MHz, CDCl3) δ 152.88, 135.11, 127.59, 127.32, 126.99, 126.83, 125.01, 
123.66, 121.88, 109.76. 
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(3.32)  4-Pentylnaphthalen-2-ol 
Using a procedure adapted from Kim et al.,190 aluminum chloride (800 mg, 6.00 mmol) was placed 
in a flame dried round bottom flask charged with argon. Anhydrous DCM (6 mL) was added, 
followed by dropwise addition of 1-heptyne (1.18 mL, 9.00 mmol) and phenylacetyl chloride 
(1.190 mL, 9.0 mmol) at 0ºC. The reaction was stirred at this temperature for 15 minutes and 
warmed to room temperature. The reaction was stirred for 3 hours, quenched with H2O and 
extracted with DCM. The combined organic fractions were dried with MgSO4, filtered and 
concentrated in vacuo. Purification via column chromatography (10% EtOAc/hexanes) afforded 
1.157 g (90%) pure 3.32 as a yellow oil. MS ES- m/z = 213.17 [M-H]-. 1H NMR  (400 MHz, 
CDCl3) δ 7.98 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 8.1 Hz, 1H), 7.48 – 7.32 (m, 2H), 7.05 (d, J = 6.2 
Hz, 2H), 3.10 – 2.92 (m, 2H), 1.77 (dt, J = 15.4, 7.6 Hz, 2H), 1.50 – 1.35 (m, 5H), 0.95 (t, J = 7.0 
Hz, 5H). 13C NMR (101 MHz, CDCl3) δ 153.38, 141.41, 135.37, 127.40, 127.25, 125.98, 123.87, 
123.15, 117.93, 107.87, 32.94, 32.01, 30.36, 22.62, 14.11. 
(3.33)  2-Chloro-1-(2-hydroxy-4-pentylnaphthalen-1-yl)ethan-1-one 
Using a procedure adapted from Toyoda et al.,179 to a solution of BCl3 (1.0 M in DCM, 6.4 mL 
6.46 mmol) cooled to 0ºC was added a solution of 3.32 (1.16 g, 5.40 mmol) in 20 mL DCM. 
Chloroacetonitrile (0.34 mL, 5.40 mmol) was added slowly over 2 minutes, followed by AlCl3 
(359.9 mg, 2.70 mmol). The reaction was allowed to warm to room temperature and stir overnight 
for 16 hours under argon. 20 mL 2N HCl was then added very slowly, and the reaction stirred for 
an additional 2 hours. The reaction was diluted with H2O and extracted with DCM. Organic 
extracts were combined, dried with MgSO4, filtered and concentrated in vacuo to afford a crude 
green oil. Purification via column chromatography (20% EtOAc/hexanes) gave 1.15 g (73.0%) of 
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pure 3.16 as oil an initially yellow oil, which later turned green within an hour of isolation (no 
change in purity via NMR or MS was observed after this color change). MS ES+ m/z = 313.81 
[M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 8.01 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.57 
(t, J = 7.7 Hz, 1H), 7.48 – 7.39 (m, 1H), 7.07 (s, 1H), 4.74 (s, 2H), 3.05 – 2.95 (m, 2H), 1.74 (dt, J 
= 15.4, 7.5 Hz, 2H), 1.40 (dt, J = 17.5, 7.9 Hz, 5H), 0.92 (t, J = 6.9 Hz, 4H). 13C NMR (101 MHz, 
CDCl3) δ 196.90, 162.82, 150.32, 131.82, 128.25, 127.44, 125.12, 124.67, 124.19, 119.08, 113.22, 
48.25, 33.41, 31.89, 29.80, 22.51, 14.02. 
(3.34)  5-Pentylnaphtho[2,1-b]furan-1(2H)-one 
To a solution of 3.33 (1.15 g, 3.94 mmol) in 10 mL anhydrous DMF was added 1.09 g K2CO3. 
The reaction was stirred for 2 hours, poured in H2O and extracted with EtOAc. The combined 
organic fractions were dried with MgSO4, filtered and concentrated in vacuo to afford a crude red 
oil. Purification via column chromatography (5% EtOAc/hexanes) afforded 872.1 mg (87.1%) 
pure 3.34 as a red solid. MS ES+ m/z = 277.39 [M+Na]+, 531.19 [2M+Na]+. 1H NMR  (400 MHz, 
CDCl3) δ 8.81 (d, J = 8.8 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 7.4 Hz, 1H), 7.56 – 7.43 
(m, 1H), 7.12 (s, 1H), 4.71 (s, 2H), 3.17 – 2.98 (m, 2H), 1.78 (dt, J = 15.3, 7.6 Hz, 3H), 1.52 – 1.32 
(m, 5H), 0.94 (t, J = 7.0 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 198.76, 176.55, 153.17, 129.61, 
129.35, 127.96, 125.19, 124.43, 123.82, 113.44, 111.66, 75.36, 34.07, 31.87, 30.04, 22.51, 14.01. 
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(3.35)  (Z)-2-(4-fluorobenzylidene)-5-pentylnaphtho[2,1-b]furan-1(2H)-one 
Synthesized using the general procedure A described for aldol condensations. Orange oil. Yield: 
36.0% MS ES+ m/z = 383.51 [M+Na]+, 744.53 [2M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 8.90 
(d, J = 8.7 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 8.3, 5.9 Hz, 2H), 7.68 (t, J = 7.6 Hz, 
1H), 7.52 (dd, J = 8.4, 7.0 Hz, 1H), 7.30 (s, 1H), 7.15 (t, J = 8.7 Hz, 2H), 6.87 (s, 1H), 3.20 – 3.08 
(m, 2H), 1.81 (p, J = 7.3 Hz, 2H), 1.44 (tt, J = 14.8, 7.7 Hz, 5H), 1.01 – 0.92 (m, 3H). 13C NMR 
(101 MHz, CDCl3) δ 183.89, 167.89, 162.07, 152.55, 147.26, 133.44, 133.36, 129.73, 129.41, 
128.74, 128.74, 125.57, 124.56, 124.41, 116.16, 115.94, 112.58, 112.46, 111.31, 34.21, 31.89, 
30.11, 22.54, 14.02. 
(3.36)  2-(Ethoxy(4-fluorophenyl)methyl)-5-pentylnaphtho[2,1-b]furan 
Synthesized using the general procedure B described for Luche reductionss. Yellow oil. Yield: 
30.5%. MS ES+ m/z = 413.31 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 8.10 (t, J = 8.3 Hz, 3H), 
7.57 – 7.46 (m, 5H), 7.10 (t, J = 8.7 Hz, 2H), 7.00 (s, 1H), 5.59 (s, 1H), 3.76 – 3.57 (m, 2H), 3.15 
– 3.09 (m, 2H), 1.79 (dq, J = 15.4, 7.5 Hz, 3H), 1.51 – 1.38 (m, 6H), 1.33 (t, J = 7.0 Hz, 3H), 0.93 
(t, J = 7.0 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 155.58, 152.64, 136.70, 129.46, 128.96, 128.88, 
128.11, 125.85, 124.88, 124.25, 124.01, 121.49, 115.47, 115.26, 112.21, 103.96, 64.96, 33.52, 
31.91, 30.44, 22.60, 15.29, 14.07. 
(3.37)  (2-Methoxynaphthalen-1-yl)(6-pentylbenzofuran-2-yl)methanone 
Synthesized using the general procedure A described for aldol condensations. Yellow oil. Yield: 
61.6% MS ES+ m/z = 395.55 [M+Na]+, 767.96 [2M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 7.94 
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(d, J = 9.0 Hz, 1H), 7.86 (dd, J = 12.9, 8.4 Hz, 2H), 7.74 (d, J = 7.9 Hz, 1H), 7.54 – 7.47 (m, 1H), 
7.45 (s, 1H), 7.43 – 7.38 (m, 1H), 7.34 (d, J = 9.1 Hz, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.94 (s, 1H), 
4.01 (s, 3H), 2.71 – 2.64 (m, 2H), 1.64 (dt, J = 14.2, 7.1 Hz, 3H), 1.40 – 1.28 (m, 6H), 0.89 (t, J = 
6.7 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 183.84, 166.67, 156.26, 154.20, 148.50, 131.95, 
131.47, 128.91, 128.31, 126.93, 125.21, 124.36, 124.01, 123.90, 119.92, 114.85, 112.76, 112.34, 
107.85, 56.43, 36.78, 31.34, 30.58, 22.44, 13.95. 
(3.38)  (Z)-2-((2-methoxynaphthalen-1-yl)methylene)-6-pentylbenzofuran-3(2H)-one 
2-(ethoxy(2-methoxynaphthalen-1-yl)methyl)-6-pentylbenzofuran 
Synthesized using the general procedure B described for Luche reductionss. Yellow oil. Yield: 
26.8%. MS ES+ m/z = 426.19 [M+Na]+. 1H NMR  (400 MHz, CDCl3) δ 8.66 (d, J = 8.4 Hz, 1H), 
7.88 (d, J = 9.1 Hz, 1H), 7.40 – 7.21 (m, 7H), 6.98 (d, J = 7.8 Hz, 2H), 6.72 (s, 1H), 6.32 (s, 1H), 
3.98 (s, 3H), 3.75 – 3.63 (m, 1H), 3.52 (ddd, J = 14.1, 7.0, 2.3 Hz, 1H), 2.74 – 2.59 (m, 3H), 1.63 
(dt, J = 13.2, 5.8 Hz, 3H), 1.38 – 1.28 (m, 7H), 1.25 (t, J = 7.0 Hz, 4H), 0.89 (t, J = 6.7 Hz, 6H). 
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